<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

    <title>Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine</title>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <link rel="stylesheet" type="text/css" href="../stylesheet.css"/>
<link rel="stylesheet" type="text/css" href="../page_styles.css"/>

  


<link href="../calibreHtmlOutBasicCss.css" type="text/css" rel="stylesheet" />

</head>
<body>

<div class="calibreMeta">
  <div class="calibreMetaTitle">
  
  
    
    <h1>
      <a href="../../k34gmbu8.html">Pocket Medicine
</a>
    </h1>
    
    
  
  </div>
  <div class="calibreMetaAuthor">
    Marc Sabatine

  </div>
</div>

<div class="calibreMain">

  <div class="calibreEbookContent">
    
      <div class="calibreEbNavTop">
        
          <a href="part0005.html" class="calibreAPrev">previous page
</a>
        

        
          <a href="part0007.html" class="calibreANext">next page
</a>
        
      </div>
    

    
<h2 class="ct"><a id="h1" class="calibre7"></a><a id="page_1-1" class="calibre7"></a><a href="part0002.html#rh5" class="calibre7">ELECTROCARDIOGRAPHY</a></h2>
<p class="h2a"><b class="calibre4">Approach</b> <span class="s">(a systematic approach is vital)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Rate</b> (? tachy or brady) and <b class="calibre4">rhythm</b> (? P waves, regularity, P &amp; QRS relationship)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Intervals</b> (PR, QRS, QT) and <b class="calibre4">axis</b> (? LAD or RAD)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Chamber abnormality</b> (? LAA and/or RAA, ? LVH and/or RVH)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">QRST changes</b> (? Q waves, poor R-wave progression V<sub class="calibre8">1</sub>–V<sub class="calibre8">6</sub>, ST ↑/↓ or T-wave ∆s)</p>
<p class="capf"><b class="calibre4">Figure 1-1</b> QRS axis</p>
<p class="image"><img src="../images/00002.jpeg" alt="" class="calibre2"/></p>
<p class="h2a"><b class="calibre4">Left axis deviation (LAD)</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Definition:</b> axis beyond –30° (S &gt; R in lead II)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Etiologies:</b> LVH, LBBB, inferior MI, WPW</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Left anterior fascicular block (LAFB):</b> LAD (–45 to –90°) <i class="calibre3">and</i> qR in aVL <i class="calibre3">and</i> QRS &lt;120 msec <i class="calibre3">and</i> no other cause of LAD (eg, IMI)</p>
<p class="h2a"><b class="calibre4">Right axis deviation (RAD)</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Definition:</b> axis beyond +90° (S &gt; R in lead I)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Etiologies:</b> RVH, PE, COPD (usually not &gt; +110°), septal defects, lateral MI, WPW</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Left posterior fascicular block (LPFB):</b> RAD (90–180°) <i class="calibre3">and</i> rS in I &amp; aVL <i class="calibre3">and</i> qR in III &amp; aVF <i class="calibre3">and</i> QRS &lt;120 msec <i class="calibre3">and</i> no other cause of RAD</p>
<p class="imagef"><img src="../images/00003.jpeg" alt="" class="calibre2"/></p>
<p class="fn">Bifascicular block: RBBB + LAFB/LPFB. “Trifascicular block”: bifascicular block + 1° AVB.</p>
<p class="h2a"><b class="calibre4">Prolonged QT interval</b> <span class="s">(<i class="calibre3">NEJM</i> 2008;358:169; <a href="http://www.torsades.org" class="calibre1">www.torsades.org</a>)</span></p>
<p class="bl"><span class="sbl">•</span> Measure QT from start of QRS to end of Tw (use longest QT, often V2-V3, omit U wave)</p>
<p class="bl"><span class="sbl">•</span> QT varies w/ HR → corrected w/ Bazett formula: QTc = QT/<img class="mid" src="../images/00004.jpeg" alt=""/> (RR in sec), overcorrects at high HR, undercorrects at low HR (nl QTc &lt;450 msec ♂, &lt;460 msec ♀)</p>
<p class="bl"><span class="sbl">•</span> Fridericia’s formula preferred at very high or low HR: QTc = QT/<img class="mid" src="../images/00005.jpeg" alt=""/></p>
<p class="bl"><span class="sbl">•</span> QT prolongation a/w ↑ risk TdP (espec &gt;500 msec); establish baseline QT and monitor if using QT prolonging meds, no estab guidelines for stopping Rx if QT prolongs</p>
<p class="bl"><span class="sbl">•</span> Etiologies:</p>
<p class="bl1"><b class="calibre4">Antiarrhythmics:</b> class Ia (procainamide, disopyramide), class III (amio, sotalol, dofet)</p>
<p class="bl1"><b class="calibre4">Psych drugs:</b> antipsychotics (phenothiazines, haloperidol, atypicals), Li, ? SSRI, TCA</p>
<p class="bl1"><b class="calibre4">Antimicrobials:</b> macrolides, quinolones, azoles, pentamidine, atazanavir</p>
<p class="bl1"><b class="calibre4">Other:</b> antiemetics (droperidol, 5-HT<sub class="calibre8">3</sub> antagonists), alfuzosin, methadone, ranolazine</p>
<p class="bl1"><b class="calibre4">Electrolyte disturbances:</b> hypoCa (nb, hyperCa a/w ↓ QT), ± hypoK, ? hypoMg</p>
<p class="bl1"><b class="calibre4">Autonomic dysfxn:</b> ICH (deep TWI), Takotsubo, stroke, CEA, neck dissection</p>
<p class="bl1"><b class="calibre4">Congenital</b> (long QT syndrome): K, Na, &amp; Ca channelopathies <span class="s">(<i class="calibre3">Circ</i> 2013;127:126)</span></p>
<p class="bl1"><b class="calibre4">Misc:</b> CAD, CMP, bradycardia, high-grade AVB, hypothyroidism, hypothermia, BBB</p>
<p class="image1"><img src="../images/00006.jpeg" alt="" class="calibre2"/></p>
<p class="h2a">Left ventricular hypertrophy (LVH) <span class="s">(<i class="calibre3">Circ</i> 2009;119:e251)</span></p>
<p class="bl"><span class="sbl">•</span> Etiologies: HTN, AS/AI, HCM, coarctation of aorta</p>
<p class="bl"><span class="sbl">•</span> Criteria (all w/ Se &lt;50%, Sp &gt;85%; accuracy affected by age, sex, race, BMI)</p>
<p class="bl1"><b class="calibre4">Sokolow-Lyon:</b> S in V<sub class="calibre8">1</sub> + R in V<sub class="calibre8">5</sub> or V<sub class="calibre8">6</sub> ≥35 mm or R in aVL ≥11 mm (↓ Se w/ ↑ BMI)</p>
<p class="bl1"><b class="calibre4">Cornell:</b> R in aVL + S in V<sub class="calibre8">3</sub> &gt;28 mm in men or &gt;20 mm in women</p>
<p class="bl1"><a id="page_1-2" class="calibre1"></a><b class="calibre4">Romhilt-Estes point-score system</b> (4 points = probable; 5 points = diagnostic): ↑ volt: limb lead R or S ≥20 mm <i class="calibre3">or</i> S in V<sub class="calibre8">1</sub> or V<sub class="calibre8">2</sub> ≥30 mm <i class="calibre3">or</i> R in V<sub class="calibre8">5</sub> or V<sub class="calibre8">6</sub> ≥30 mm (3 pts)</p>
<p class="bl1">ST displacement opposite to QRS deflection: w/o dig (3 pts); w/ dig (1 pt)</p>
<p class="bl2">LAA (3 pts); LAD (2 pts); QRS duration ≥90 msec (1 pt)</p>
<p class="bl2">Intrinsicoid deflection (QRS onset to peak of R) in V<sub class="calibre8">5</sub> or V<sub class="calibre8">6</sub> ≥50 msec (1 pt)</p>
<p class="bl1"><b class="calibre4">If LAFB present:</b> S in III + max (R+S) in any lead ≥30 mm in men or ≥28 mm in women</p>
<p class="h2a"><b class="calibre4">Right ventricular hypertrophy (RVH)</b> <span class="s">(<i class="calibre3">Circ</i> 2009;119:e251; <i class="calibre3">JACC</i> 2014;63:672)</span></p>
<p class="bl"><span class="sbl">•</span> Etiologies: cor pulmonale, congenital (tetralogy of Fallot, TGA, PS, ASD, VSD), MS, TR</p>
<p class="bl"><span class="sbl">•</span> Criteria [all insensitive, but specific (except in COPD); all w/ poor PPV in general population]</p>
<p class="bl1">R &gt; S in V<sub class="calibre8">1</sub>, R in V<sub class="calibre8">1</sub> ≥6 mm, S in V<sub class="calibre8">5</sub> ≥10 mm, S in V<sub class="calibre8">6</sub> ≥3 mm, R in aVR ≥4 mm</p>
<p class="bl1">RAD ≥110° (LVH + RAD <i class="calibre3">or</i> prominent S in V<sub class="calibre8">5</sub> or V<sub class="calibre8">6</sub> → consider <i class="calibre3">biventricular</i> hypertrophy)</p>
<p class="h2a"><b class="calibre4">Ddx of dominant R wave in V<sub class="calibre8">1</sub> or V<sub class="calibre8">2</sub></b></p>
<p class="bl"><span class="sbl">•</span> Ventricular abnl: RVH (RAD, RAA, deep S waves in I, V<sub class="calibre8">5</sub>, V<sub class="calibre8">6</sub>); HCM; Duchenne’s</p>
<p class="bl"><span class="sbl">•</span> Myocardial injury: posterior MI (anterior R wave = posterior Q wave; often with IMI)</p>
<p class="bl"><span class="sbl">•</span> Abnormal depolarization: RBBB (QRS &gt;120 msec, rSR′); WPW (↓ PR, δ wave, ↑ QRS)</p>
<p class="bl"><span class="sbl">•</span> Other: dextroversion; counterclockwise rotation; lead misplacement; nl variant</p>
<p class="h2a"><b class="calibre4">Poor R wave progression (PRWP)</b> <span class="s">(<i class="calibre3">Am Heart J</i> 2004;148:80)</span></p>
<p class="bl"><span class="sbl">•</span> Definition: loss of anterior forces w/o frank Q waves (V<sub class="calibre8">1</sub>–V<sub class="calibre8">3</sub>); R wave in V<sub class="calibre8">3</sub> ≤3 mm</p>
<p class="bl"><span class="sbl">•</span> Possible etiologies (nonspecific):</p>
<p class="bl1">old anteroseptal MI (usually w/ R wave V<sub class="calibre8">3</sub> ≤1.5 mm, ± persistent ST ↑ or TWI V<sub class="calibre8">2</sub> &amp; V<sub class="calibre8">3</sub>)</p>
<p class="bl1">LVH (delayed RWP w/ ↑ left precordial voltage), RVH, COPD (may also have RAA, RAD, limb lead QRS amplitude ≤5 mm, S<sub class="calibre8">I</sub>S<sub class="calibre8">II</sub>S<sub class="calibre8">III</sub> w/ R/S ratio &lt;1 in those leads)</p>
<p class="bl1">LBBB; WPW; clockwise rotation of the heart; lead misplacement; CMP; PTX</p>
<p class="h2a"><b class="calibre4">Pathologic Q waves</b></p>
<p class="bl"><span class="sbl">•</span> Definition: ≥30 msec (≥20 msec V<sub class="calibre8">2</sub>–V<sub class="calibre8">3</sub>) or &gt;25% height of R wave in that QRS complex</p>
<p class="bl"><span class="sbl">•</span> Small (septal) q waves in I, aVL, V<sub class="calibre8">5</sub> &amp; V<sub class="calibre8">6</sub> are nl, as can be isolated Qw in III, aVR, V<sub class="calibre8">1</sub></p>
<p class="bl"><span class="sbl">•</span> “Pseudoinfarct” pattern may be seen in LBBB, infiltrative dis., HCM, COPD, PTX, WPW</p>
<p class="h2a"><b class="calibre4">ST elevation (STE)</b> <span class="s">(<i class="calibre3">NEJM</i> 2003;349:2128; <i class="calibre3">Circ</i> 2009;119:e241 &amp; e262)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Acute MI:</b> upward convexity STE (ie, a “frown”) ± TWI (or prior MI w/ persistent STE)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Coronary spasm:</b> Prinzmetal’s angina; transient STE in a coronary distribution</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pericarditis:</b> diffuse, upward concavity STE (ie, a “smile”); a/w PR ↓; Tw usually upright</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">HCM, Takotsubo CMP, ventricular aneurysm</b>, cardiac contusion</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pulmonary embolism:</b> occ. STE V<sub class="calibre8">1</sub>–V<sub class="calibre8">3</sub>; classically a/w TWI V<sub class="calibre8">1</sub>–V<sub class="calibre8">4</sub>, RAD, RBBB, S<sub class="calibre8">1</sub>Q<sub class="calibre8">3</sub>T<sub class="calibre8">3</sub></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Repolarization abnormalities:</b></p>
<p class="bl1">LBBB (↑ QRS duration, STE discordant from QRS complex; see “ACS” for dx MI in LBBB)</p>
<p class="bl1">LVH (↑ QRS amplitude); Brugada syndrome (rSR′, downsloping STE V<sub class="calibre8">1</sub>–V<sub class="calibre8">2</sub>); pacing</p>
<p class="bl1">Hyperkalemia (↑ QRS duration, tall Ts, no P’s); epsilon waves (late afterdepol.) in ARVC</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">aVR:</b> STE &gt;1 mm a/w ↑ mortality in STEMI; STE aVR &gt; V<sub class="calibre8">1</sub> a/w left main disease</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Early repolarization:</b> most often seen in V<sub class="calibre8">2</sub>–V<sub class="calibre8">5</sub> in young adults <span class="s">(<i class="calibre3">Circ</i> 2016;133:1520)</span></p>
<p class="bl1">1–4 mm elev of peak of notch or start of slurred downstroke of R wave (ie, J point); ± up concavity of ST &amp; large Tw (∴ ratio of STE/T wave &lt;25%; may disappear w/ exercise)</p>
<p class="bl1">? early repol in inf leads may be a/w ↑ risk of VF <span class="s1r">(<i class="calibre3">NEJM</i> 2009;361:2529; <i class="calibre3">Circ</i> 2011;124:2208)</span></p>
<p class="h2a"><b class="calibre4">ST depression (STD)</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Myocardial ischemia</b> (± Tw abnl)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Acute true posterior MI:</b> posterior STE appearing as anterior STD (± ↑ R wave) in V<sub class="calibre8">1</sub>–V<sub class="calibre8">3</sub> ✔ posterior ECG leads; manage as a STEMI with rapid reperfusion (see “ACS”)</p>
<p class="bl"><span class="sbl">•</span> Digitalis effect (downsloping ST ± Tw abnl; does <i class="calibre3">not</i> correlate w/ dig levels)</p>
<p class="bl"><span class="sbl">•</span> Hypokalemia (± U wave)</p>
<p class="bl"><span class="sbl">•</span> Repolarization abnl a/w LBBB or LVH (usually in leads V<sub class="calibre8">5</sub>, V<sub class="calibre8">6</sub>, I, aVL)</p>
<p class="h2a"><b class="calibre4">T wave inversion (TWI; generally ≥1 mm; deep if ≥5 mm)</b> <span class="s">(<i class="calibre3">Circ</i> 2009;119:e241)</span></p>
<p class="bl"><span class="sbl">•</span> Ischemia or infarct; <i class="calibre3">Wellens’ sign</i> (deep, symm precordial TWI) → critical prox LAD lesion</p>
<p class="bl"><span class="sbl">•</span> Myopericarditis; CMP (Takotsubo, ARVC, apical HCM); MVP; PE (espec if TWI V<sub class="calibre8">1</sub>–V<sub class="calibre8">4</sub>)</p>
<p class="bl"><span class="sbl">•</span> Repolarization abnl in a/w LVH/RVH (“strain pattern”); BBB; nl variant if QRS predom. ⊖</p>
<p class="bl"><span class="sbl">•</span> Posttachycardia or postpacing (“memory” T waves)</p>
<p class="bl"><span class="sbl">•</span> Electrolyte, digoxin, PaO<sub class="calibre8">2</sub>, PaCO<sub class="calibre8">2</sub>, pH/core temp ∆’s, intracranial bleed (“cerebral Tw”)</p>
<p class="h2a"><b class="calibre4">Low voltage</b></p>
<p class="bl"><span class="sbl">•</span> QRS amplitude (R + S) &lt;5 mm in all limb leads &amp; &lt;10 mm in all precordial leads</p>
<p class="bl"><span class="sbl">•</span> Etiol: COPD, pericard./pleural effusion, myxedema, ↑ BMI, amyloid, diffuse CAD</p>
<p class="h2a"><b class="calibre4">Electrolyte abnormalities</b></p>
<p class="bl"><span class="sbl">•</span> ↑ <b class="calibre4">K:</b> tented Tw, ↓ QT, ↑ PR, AVB, wide QRS, STE; ↓ <b class="calibre4">K:</b> flattened Tw, U waves, ↑ QT</p>
<p class="bl"><span class="sbl">•</span> ↑ <b class="calibre4">Ca:</b> ↓ QT, flattened Tw &amp; Pw, J point elevation; ↓ <b class="calibre4">Ca:</b> ↑ QT; Tw ∆s</p>
<p class="h2a"><b class="calibre4">ECG in young athletes</b> <span class="s">(<i class="calibre3">JACC</i> 2017;69:805)</span></p>
<p class="bl"><span class="sbl">•</span> Normal patterns may incl. LVH, RVH, early repol</p>
<p class="bl"><span class="sbl">•</span> Evaluate if: arrhythmias, HR &lt;30, prolonged QT, ε/δ waves, LBBB, Brugada pattern, QRS &gt;140 ms, PR &gt;400 ms, Mobitz II, 3˚ AVB, ST depression, TWI</p>
<h2 class="ct"><a id="h2" class="calibre7"></a><a id="page_1-3" class="calibre7"></a><a href="part0002.html#rh6" class="calibre7">CHEST PAIN</a></h2>
<table class="t-topbot">
<colgroup class="calibre9">
<col class="calibre10"/>
<col class="calibre11"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-br"><p class="tabheadc"><b class="calibre4">Disorder</b></p></td>
<td class="bg1-b"><p class="tabhead"><b class="calibre4">Typical Characteristics &amp; Diagnostic Studies</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg2-b" colspan="2"><p class="tabheadc"><b class="calibre4"><i class="calibre3">Cardiac Causes</i></b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">ACS</b></p>
<p class="tab">(15–25% of chest pain in ED)</p></td>
<td class="bg0-b"><p class="tab">Substernal “pressure” (! LR 1.3) → neck, jaw, arm (! LR 1.3–1.5)</p>
<p class="tab">Sharp, pleuritic, positional, or reprod. w/ palp all w/ ⊕ LR ≤0.35</p>
<p class="tab">Diaphoresis (⊕ LR 1.4), dyspnea (⊕ LR 1.2), a/w exertion (⊕ LR 1.5–1.8)</p>
<p class="tab">≈ prior MI (⊕ LR 2.2); ↓ w/ NTG/rest (but not reliable; <i class="calibre3">Annals EM</i> 2005;45:581)</p>
<p class="tab">± ECG ∆s: STE, STD, TWI, Qw. ± ↑ Troponin.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Pericarditis &amp; myo- pericarditis</b></p></td>
<td class="bg0-b"><p class="tab">Sharp pain → trapezius, ↑ w/ respiration, ↓ w/ sitting forward. ± Pericardial friction rub. ECG ∆s (diffuse STE &amp; PR ↓, opposite in aVR) ± pericardial effusion. If myocarditis, same as above + ↑ Tn and ± s/s HF and ↓ EF.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Aortic dissection</b></p></td>
<td class="bg0-b"><p class="tab">Sudden severe tearing pain (absence ⊖ LR 0.3). ± Asymm (&gt;20 mmHg) BP or pulse (⊕ LR 5.7), focal neuro deficit (⊕ LR &gt;6), AI, widened mediast. on CXR (absence ⊖ LR 0.3); false lumen on imaging. (<i class="calibre3">JAMA</i> 2002;287:2262)</p></td>
</tr>
<tr class="calibre12">
<td class="bg2-b" colspan="2"><p class="tabheadc"><b class="calibre4"><i class="calibre3">Pulmonary Causes</i></b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Pneumonia</b></p></td>
<td class="bg0-b"><p class="tab">Pleuritic; dyspnea, fever, cough, sputum. ↑ RR, crackles. CXR infiltrate.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Pleuritis</b></p></td>
<td class="bg0-b"><p class="tab">Sharp, pleuritic pain. ± Pleuritic friction rub.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">PTX</b></p></td>
<td class="bg0-b"><p class="tab">Sudden onset, sharp pleuritic pain. Hyperresonance, ↓ BS. PTX on CXR.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">PE</b></p></td>
<td class="bg0-b"><p class="tab">Sudden onset pleuritic pain. ↑ RR &amp; HR, ↓ S<sub class="calibre13">a</sub>O<sub class="calibre13">2</sub>, ECG ∆s (sinus tach, RAD, RBBB, S<sub class="calibre13">I</sub>Q<sub class="calibre13">III</sub>T<sub class="calibre13">III</sub>, TWI V<sub class="calibre13">1</sub>–V<sub class="calibre13">4</sub>, occ STE V<sub class="calibre13">1</sub>–V<sub class="calibre13">3</sub>), + CTA or V/Q, ± ↑ Tn.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Pulm HTN</b></p></td>
<td class="bg0-b"><p class="tab">Exertional pressure, DOE. ↓ S<sub class="calibre13">a</sub>O<sub class="calibre13">2</sub>, loud P<sub class="calibre13">2</sub>, RV heave, right S<sub class="calibre13">3</sub> and/or S<sub class="calibre13">4</sub>.</p></td>
</tr>
<tr class="calibre12">
<td class="bg2-b" colspan="2"><p class="tabheadc"><b class="calibre4"><i class="calibre3">GI Causes</i></b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Esophageal reflux</b></p></td>
<td class="bg0-b"><p class="tab">Substernal burning, acid taste in mouth, water brash. ↑ by meals, recumbency; ↓ by antacids. EGD, manometry, pH monitoring.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Esoph spasm</b></p></td>
<td class="bg0-b"><p class="tab">Intense substernal pain. ↑ by swallowing, ↓ by NTG/CCB. Manometry.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Mallory-Weiss</b></p></td>
<td class="bg0-b"><p class="tab">Esoph tear precipitated by vomiting. ± Hematemesis. Dx w/ EGD.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Boerhaave</b></p></td>
<td class="bg0-b"><p class="tab">Esoph rupture. Severe pain, ↑ w/ swallow. Mediastinal air palpable &amp; on CT.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">PUD</b></p></td>
<td class="bg0-b"><p class="tab">Epigastric pain, relieved by antacids. ± GIB. EGD, ± <i class="calibre3">H. pylori</i> test.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Biliary dis.</b></p></td>
<td class="bg0-b"><p class="tab">RUQ pain, N/V. ↑ by fatty foods. RUQ U/S; ↑ LFTs.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Pancreatitis</b></p></td>
<td class="bg0-b"><p class="tab">Epigastric/back discomfort. ↑ amylase &amp; lipase; abd CT.</p></td>
</tr>
<tr class="calibre12">
<td class="bg2-b" colspan="2"><p class="tabheadc"><b class="calibre4"><i class="calibre3">Musculoskeletal and Miscellaneous Causes</i></b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Costochond</b></p></td>
<td class="bg0-b"><p class="tab">Localized sharp pain. ↑ w/ movement. Reproduced by palpation.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Zoster</b></p></td>
<td class="bg0-b"><p class="tab">Intense unilateral pain. Pain may precede dermatomal rash.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br1"><p class="tab"><b class="calibre4">Anxiety</b></p></td>
<td class="bg0-b1"><p class="tab">“Tightness,” dyspnea, palpitations, other somatic symptoms</p></td>
</tr>
</table>
<p class="tsr">(<i class="calibre3">Braunwald’s Heart Disease</i>, 11<sup class="calibre14">th</sup> ed, 2018; <i class="calibre3">JAMA</i> 2015;314:1955)</p>
<p class="h2a"><b class="calibre4">Initial approach</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Focused history:</b> quality, severity, location, radiation; provoking/palliating factors; intensity at onset; duration, freq, &amp; pattern; setting; assoc sx; cardiac hx &amp; risk factors</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Targeted exam:</b> VS (incl. BP in both arms); gallops, murmurs, rubs; signs of vascular dis. (carotid/femoral bruits, ↓ pulses) or CHF; lung &amp; abd. exam; chest wall for reproducibility</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">12-lead ECG:</b> obtain w/in 10 min; comp to priors &amp; obtain serial ECGs; consider <i class="calibre3">posterior leads</i> (V<sub class="calibre8">7</sub>–V<sub class="calibre8">9</sub>) to ✔ for posterior STEMI if: hx c/w ACS but stnd ECG unrevealing; ST ↓ V<sub class="calibre8">1</sub>–V<sub class="calibre8">3</sub> (ant ischemia vs. post STEMI) w/ refractory angina; or R/S &gt;1 in V<sub class="calibre8">1</sub>–V<sub class="calibre8">2</sub></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">CXR;</b> other imaging (echo, PE CTA, etc.) as indicated based on H&amp;P and initial testing</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Troponin:</b> &gt;<i class="calibre3">99th %ile w/ rise and/or fall in approp. setting is dx of AMI</i> <span class="s1r">(<i class="calibre3">Circ</i> 2018;138:e618)</span></p>
<p class="bl1">Detectable 1–6 h after injury, peaks 24 h, may be elevated for 7–14 d in STEMI ✔ at presentation &amp; 3–6 h later; repeat if clinical or ECG ∆s; ? sex-specific cutpoints If high-sens Tn (hsTn) assay, can ✔ at presentation &amp; 1 h later; assess level &amp; Δ</p>
<p class="bl"><span class="sbl">•</span> Causes for ↑ Tn other than plaque rupture (= “type 1 MI”): (1) Supply-demand mismatch not due to ∆ in CAD (= “type 2 MI”; eg, ↑↑ HR, shock, HTN crisis, spasm, severe AS), (2) non-ischemic injury (myocarditis/toxic CMP, cardioversion, cardiac contusion) or (3) multifactorial (PE, sepsis, severe HF, renal failure, Takotsubo, infilt dis.)</p>
<p class="bl"><span class="sbl">•</span> CK-MB: less Se &amp; Sp than Tn (other sources: skel. muscle, intestine, etc.); CK-MB/CK ratio &gt;2.5 → cardiac source. Limited utility: ? higher bar for post-revasc MI; early reMI.</p>
<p class="h2a"><b class="calibre4">Early noninvasive imaging</b></p>
<p class="bl"><span class="sbl">•</span> Low prob of ACS (eg, ⊖ ECG &amp; Tn) &amp; stable → outPt or inPt noninv. fxnal or imaging test (qv)</p>
<p class="bl"><span class="sbl">•</span> CCTA w/ high NPV, low PPV. ↓ LOS c/w fxnal testing <span class="s1r">(<i class="calibre3">NEJM</i> 2012;366:1393)</span>. In stable outPt w/ CP, CCTA added to standard of care ↑ early but not overall angiography/revasc; ↑ use of preventive med Rx, and ↓ coronary death/MI at 5 y <span class="s1r">(<i class="calibre3">NEJM</i> 2018;379:924)</span>.</p>
<p class="bl"><span class="sbl">•</span> “Triple r/o” CT angiogram sometimes performed to r/o CAD, PE, AoD if dx unclear</p>
<h2 class="ct"><a id="h3" class="calibre7"></a><a id="page_1-4" class="calibre7"></a><a href="part0002.html#rh7" class="calibre7">NONINVASIVE EVALUATION OF CAD</a></h2>
<p class="h2a"><b class="calibre4">Stress testing</b> <span class="s">(<i class="calibre3">JACC</i> 2012;60:1828; <i class="calibre3">J Nucl Cardiol</i> 2016; 23:606)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Indications:</b> dx obstructive CAD, evaluate ∆ in clinical status in Pt w/ known CAD, risk stratify after ACS, evaluate exercise tolerance, localize ischemia (imaging required)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Contraindications</b> <span class="s1r">(<i class="calibre3">Circ</i> 2002;106:1883; &amp; 2012;126:2465)</span></p>
<p class="bl1"><b class="calibre4">Absolute:</b> AMI w/in 48 h, high-risk UA, acute PE, severe sx AS, uncontrolled HF, uncontrolled arrhythmias, myopericarditis, acute aortic dissection</p>
<p class="bl1"><b class="calibre4">Relative</b> (discuss with stress lab): left main CAD, mod symptomatic valvular stenosis, severe HTN, HCMP, high-degree AVB, severe electrolyte abnl</p>
<p class="h2a"><b class="calibre4">Exercise tolerance test (w/ ECG alone)</b></p>
<p class="bl"><span class="sbl">•</span> Generally preferred if Pt can meaningfully exercise; ECG ∆s w/ Se ~65%, Sp ~80%</p>
<p class="bl"><span class="sbl">•</span> Typically via treadmill w/ Bruce protocol (modified Bruce or submax if decond. or recent MI)</p>
<p class="bl"><span class="sbl">•</span> Hold anti-isch. meds (eg, nitrates, βB) if dx’ing CAD but give to assess adequacy of meds</p>
<p class="h2a"><b class="calibre4">Pharmacologic stress test</b> <span class="s">(nb, requires imaging because ECG not interpretable)</span></p>
<p class="bl"><span class="sbl">•</span> Use if unable to exercise, low exercise tolerance, or recent MI. Se &amp; Sp ≈ exercise.</p>
<p class="bl"><span class="sbl">•</span> Preferred if LBBB, WPW or V-paced, because higher prob of false ⊕ imaging with exercise</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Coronary vasodilator:</i> diffuse vasodilation → relative “coronary steal” from vessels w/ fixed epicardial dis. Reveals CAD, but <i class="calibre3">not</i> if Pt <i class="calibre3">ischemic w/ exercise.</i> Regadenoson (↓ side effects), dipyridamole, adenosine. Side effects: flushing, ↓ HR, AVB, SOB, bronchospasm.</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Chronotropes/inotropes</i> (dobuta): more physiologic, but longer test; may precip arrhythmia</p>
<p class="h2a"><b class="calibre4">Imaging for stress test</b></p>
<p class="bl"><span class="sbl">•</span> Use if uninterpretable ECG (V-paced, LBBB, resting ST ↓ &gt;1 mm, digoxin, LVH, WPW), after indeterminate ECG test, or if pharmacologic test</p>
<p class="bl"><span class="sbl">•</span> Use when need to localize ischemia (often used if prior coronary revasc)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Radionuclide myocardial perfusion imaging</b> w/ images obtained at rest &amp; w/ stress</p>
<p class="bl1"><b class="calibre4">SPECT</b> (eg, <sup class="calibre15">99m</sup>Tc-sestamibi): Se ~85%, Sp ~80%</p>
<p class="bl1"><b class="calibre4">PET</b> (rubidium-82): Se ~90%, Sp ~85%; requires pharmacologic stress, not exercise</p>
<p class="bl1">ECG-gated imaging allows assessment of regional LV fxn (sign of ischemia/infarction)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Echo</b> (exercise or dobuta): Se ~85%, Sp ~85%; no radiation; operator dependent</p>
<p class="bl"><span class="sbl">•</span> Cardiac MRI (w/ pharmacologic stress) another option with excellent Se &amp; Sp</p>
<p class="h2a"><b class="calibre4">Test results</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">HR</b> (must achieve ≥85% of max pred HR [220-age] for <i class="calibre3">exer.</i> test to be dx), <b class="calibre4">BP</b> response, peak <b class="calibre4">double product</b> (HR × BP; nl &gt;20k), HR recovery (HR<sub class="calibre8">peak</sub> – HR<sub class="calibre8">1 min later</sub>; nl &gt;12)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Max exercise capacity</b> achieved (METS or min); <b class="calibre4">occurrence of symptoms</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">ECG</b> ∆<b class="calibre4">s:</b> <i class="calibre3">downsloping</i> or <i class="calibre3">horizontal</i> ST ↓ (≥1 mm) 60–80 ms after QRS predictive of CAD (but does <i class="calibre3">not</i> localize ischemic territory); however, STE highly predictive &amp; localizes</p>
<p class="bl"><span class="sbl">•</span> Duke treadmill score = exercise min – (5 × max ST dev) – (4 × angina index) [0 none, 1 nonlimiting, 2 limiting]; score ≥5 → &lt;1% 1-y mort; –10 to + 4 → 2–3%; ≤–11 → ≥5%</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Imaging:</b> radionuclide defects or echocardiographic regional wall motion abnormalities</p>
<p class="bl1">reversible defect = ischemia; fixed defect = infarct; transient isch dilation → ? severe 3VD</p>
<p class="bl1">false ⊕: breast → ant defect; diaphragm → inf defect. False ⊖: balanced (3VD) ischemia.</p>
<p class="h2a"><b class="calibre4">High-risk test results</b> <span class="s">(PPV ~50% for LM or 3VD, ∴ consider coronary angio)</span></p>
<p class="bl"><span class="sbl">•</span> ECG: ST ↓ ≥2 mm <i class="calibre3">or</i> ≥1 mm in stage 1 <i class="calibre3">or</i> in ≥5 leads <i class="calibre3">or</i> ≥5 min in recovery; ST ↑; VT</p>
<p class="bl"><span class="sbl">•</span> Physiologic: ↓ or fail to ↑ BP, &lt;4 METS, angina during exercise, Duke score ≤–11; ↓ EF</p>
<p class="bl"><span class="sbl">•</span> Radionuclide: ≥1 lg or ≥2 mod. reversible defects, transient LV cavity dilation, ↑ lung uptake</p>
<p class="h2a"><b class="calibre4">Myocardial viability</b> <span class="s">(<i class="calibre3">Circ</i> 2008;117:103; <i class="calibre3">Eur Heart J</i> 2011;31:2984 &amp; 2011;32:810)</span></p>
<p class="bl"><span class="sbl">•</span> Goal: identify hibernating myocardium that could regain fxn after revascularization</p>
<p class="bl"><span class="sbl">•</span> Options: <b class="calibre4">MRI</b> (Se ~85%, Sp ~75%), <b class="calibre4">PET</b> (Se ~90%, Sp ~65%), <b class="calibre4">dobutamine stress</b></p>
<p class="bl1"><b class="calibre4">echo</b> (Se ~80%, Sp ~80%); <b class="calibre4">SPECT/rest-redistribution</b> (Se ~85%, Sp ~60%)</p>
<p class="bl1">In Pts w/ LV dysfxn, viabil. doesn’t predict ↑ CABG benefit vs. med Rx <span class="s1r">(<i class="calibre3">NEJM</i> 2011;364:1617)</span></p>
<p class="h2a"><b class="calibre4">Coronary CT/MR angio</b> <span class="s">(<i class="calibre3">NEJM</i> 2008;359:2324; <i class="calibre3">Circ</i> 2010;121:2509; <i class="calibre3">Lancet</i> 2012;379:453)</span></p>
<p class="bl"><span class="sbl">•</span> Pts w/ CP: CCTA 100% Se, 54% Sp for ACS, ∴ NPV 100%, PPV 17% <span class="s1r">(<i class="calibre3">JACC</i> 2009;53:1642)</span>. ↓ LOS, but ↑ cath/PCI, radiation vs. fxnal study <span class="s1r">(<i class="calibre3">NEJM</i> 2012;367:299; <i class="calibre3">JACC</i> 2013;61:880)</span>.</p>
<p class="bl"><span class="sbl">•</span> Sx outPt: CCTA vs. fxnal testing → ↑ radiation, cath/PCI early; by 5 y, ↓ CHD death/MI w/ similar rates of cath/PCI <span class="s1r">(<i class="calibre3">NEJM</i> 2018;379:924)</span></p>
<p class="bl"><span class="sbl">•</span> Unlike CCTA, MR does not require iodinated contrast or radiation, and can assess LV fxn</p>
<p class="h2a"><b class="calibre4">Coronary artery calcium score</b> <span class="s">(<i class="calibre3">NEJM</i> 2012;366:294; <i class="calibre3">JAMA</i> 2012;308:788)</span></p>
<p class="bl"><span class="sbl">•</span> Quantifies extent of calcium; thus, <i class="calibre3">estimates</i> plaque burden (but <i class="calibre3">not</i> % coronary stenosis)</p>
<p class="bl"><span class="sbl">•</span> CAC sensitive (91%) but not specific (49%) for presence of CAD; high NPV to r/o CAD</p>
<p class="bl"><span class="sbl">•</span> May provide incremental value to clinical scores for risk stratification <span class="s1r">(<i class="calibre3">JAMA</i> 2004;291:210)</span>. ACC/AHA guidelines note CAC assessment is reasonable in asx Pts w/ intermed risk (7.5– &lt;20% 10-y risk) and selected borderline risk (5– &lt;7.5% 10-y risk) <span class="s1r">(<i class="calibre3">Circ</i> 2019;139:e1082)</span>.</p>
<h2 class="ct"><a id="h4" class="calibre7"></a><a id="page_1-5" class="calibre7"></a><a href="part0002.html#rh8" class="calibre7">CORONARY ANGIOGRAPHY AND REVASCULARIZATION</a></h2>
<p class="h2a"><b class="calibre4">Indications for coronary angiography in stable CAD, asx Pts, and others</b></p>
<p class="bl"><span class="sbl">•</span> CCS class III–IV angina despite med Rx, angina + systolic dysfxn, or unexplained low EF</p>
<p class="bl"><span class="sbl">•</span> High-risk stress test findings (qv) or uncertain dx after noninv testing (&amp; info will ∆ mgmt)</p>
<p class="bl"><span class="sbl">•</span> Occupational need for definitive dx (eg, pilot) or inability to undergo noninvasive testing</p>
<p class="bl"><span class="sbl">•</span> Survivor of SCD, polymorphic VT, sustained monomorphic VT</p>
<p class="bl"><span class="sbl">•</span> Suspected spasm; nonathero cause of ischemia (eg, anomalous coronary; CCTA preferred)</p>
<p class="bl"><span class="sbl">•</span> Preop workup in select Pts undergoing organ transplant eval (CCTA reasonable)</p>
<p class="h2a"><b class="calibre4">Precath checklist &amp; periprocedural pharmacotherapy</b></p>
<p class="bl"><span class="sbl">•</span> Peripheral arterial exam (radial, femoral, DP, PT pulses; bruits); ✔ palmar arch intact (eg, w/ pulse oximetry &amp; plethysmography). ✔ can lie flat, NPO &gt;6 h.</p>
<p class="bl"><span class="sbl">•</span> ✔CBC, PT, Cr; hold ACEI/ARB if renal dysfxn (see “CIAKI”). Blood bank sample.</p>
<p class="bl"><span class="sbl">•</span> ASA 325 mg × 1. Timing of P2Y<sub class="calibre8">12</sub> inhib debated. ASAP for STEMI. ? preRx NSTEACS if clopi <span class="s1r">(<i class="calibre3">JAMA</i> 2012;308:2507)</span> or ticagrelor, not prasugrel. Cangrelor (IV P2Y<sub class="calibre8">12</sub> inhib) ↓ peri-</p>
<p class="bl1">PCI events vs. clopi w/o PreRx <span class="s1r">(<i class="calibre3">NEJM</i> 2013;368:1303)</span>. ? statin preRx <span class="s1r">(<i class="calibre3">Circ</i> 2011;123:1622)</span>.</p>
<p class="h2a"><b class="calibre4">Coronary revascularization in stable CAD</b> <span class="s">(<i class="calibre3">NEJM</i> 2016;374:1167; <i class="calibre3">JACC</i> 2017;69:2212)</span></p>
<p class="bl"><span class="sbl">•</span> Optimal med Rx (<b class="calibre4">OMT</b>): preferred 1<sup class="calibre15">st</sup> line if stable disease w/o critical anatomy &amp; w/ nl EF</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">PCI:</b> ↓ angina; no ∆ exercise time <span class="s1r">(<i class="calibre3">Lancet</i> 2018;391:31)</span> or D/MI <span class="s1r">(<i class="calibre3">NEJM</i> 2015;373:1204)</span>;</p>
<p class="bl1">if ≥1 stenosis w/ FFR (qv) ≤0.8, ↓ urg revasc &amp; MI c/w OMT <span class="s1r">(<i class="calibre3">NEJM</i> 2018;379:250)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">CABG</b> <span class="s1r">(<i class="calibre3">NEJM</i> 2016;374:1954)</span>: in older studies, ↓ mort. c/w OMT if 3VD, LM, 2VD w/ crit. prox LAD, esp. if ↓ EF; recently confirmed if multivessel dis. &amp; EF &lt;35% <span class="s1r">(<i class="calibre3">NEJM</i> 2016;374:1511)</span>; radial artery ↑ patency &amp; ↓ MACE vs. saphenous vein grafts <span class="s1r">(<i class="calibre3">NEJM</i> 2018;378:2069)</span>; less complete revasc &amp; possibly ↑ mort. w/ off vs. on-pump <span class="s1r">(<i class="calibre3">NEJM</i> 2016;375:2359 &amp; 377:623)</span></p>
<p class="bl"><span class="sbl">•</span> If revasc deemed necessary, <i class="calibre3">PCI</i> if limited # of discrete lesions, nl EF, no DM, poor operative candidate; <i class="calibre3">CABG</i> if extensive or diffuse disease, ↓ EF, DM or valvular disease; SYNTAX score II: ID Pts w/ ↑ benefit w/ CABG <span class="s1r">(<i class="calibre3">Lancet</i> 2013;381:639)</span>; if multivessel disease w/ high complexity or DM, CABG ↓ mortality <span class="s1r">(<i class="calibre3">Lancet</i> 2018;391:939)</span>; if LM disease, PCI ≈ CABG, but ↑ repeat revasc w/ PCI <span class="s1r">(<i class="calibre3">JAMA Cardiol.</i> 2017;2:1079)</span></p>
<p class="h2a"><b class="calibre4">PCI and peri-PCI interventions</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Access:</b> radial ↓ bleed/vasc comp (? ↓ death in ACS) vs. fem <span class="s1r">(<i class="calibre3">Circ CV Interv</i> 2018;11:e000035)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Fractional flow reserve</b> (FFR): ratio of max flow (induced by adenosine) distal vs. prox to stenosis to ID hemodyn. signif. lesions (≤0.80). Instantaneous wave-free ratio (iFR) similar to FFR, doesn’t require vasodilator; iFR threshold ≤0.89 <span class="s1r">(<i class="calibre3">NEJM</i> 2017;376:1813 &amp; 1824)</span>.</p>
<p class="bl"><span class="sbl">•</span> Balloon angioplasty by itself rare b/c elastic recoil; reserved for lesions too narrow to stent</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Bare metal stents (BMS):</b> ↓ restenosis &amp; repeat revasc c/w angioplasty alone</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Drug-eluting stents (DES):</b> latest DES ↓ cardiac death or MI, repeat revasc, and stent thrombosis vs. BMS <span class="s1r">(<i class="calibre3">Lancet</i> 2019;393:2503)</span></p>
<p class="bl"><span class="sbl">•</span> Antiplt Rx: DAPT (ASA 81 + P2Y<sub class="calibre8">12</sub> inhib) in SIHD for 4 wk (BMS) or ≥6 mo (DES); in <i class="calibre3">ACS</i> (qv) for 12 mo and possibly beyond <span class="s1r">(<i class="calibre3">JAMA Cards</i> 2016;1:627)</span>. Data emerging for DAPT for just 1 mo, followed by P2Y<sub class="calibre8">12</sub> inhib for 11 mo <span class="s1r">(<i class="calibre3">Lancet</i> 2018;392:940; <i class="calibre3">JAMA</i> 2019;321:2414 &amp; 2428)</span>.</p>
<p class="bl"><span class="sbl">•</span> If need long-term oral anticoag, consider clopi+DOAC and consider stopping ASA (? after ~1 wk) as ↓ bleed, but trend small ↑ ischemic risk <span class="s1r">(<i class="calibre3">Lancet</i> 2013;381:1107 &amp; <i class="calibre3">NEJM</i> 2019;380:1509)</span></p>
<p class="h2a"><b class="calibre4">Post-PCI complications</b> <span class="s">(<i class="calibre3">NEJM</i> 2017;377:1513)</span></p>
<p class="bl"><span class="sbl">•</span> Postprocedure ✔ vascular access site, distal pulses, ECG, CBC, Cr</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Bleeding:</b> if hematoma/overt bleeding → <b class="calibre4">manual compression</b>, reverse/stop anticoag.</p>
<p class="bl1"><i class="calibre3">Retroperitoneal bleed:</i> may p/w ↓ Hct ± back pain; ↑ HR &amp; ↓ BP late; Dx w/ abd/pelvic CT (I<sup class="calibre15">–</sup>); Rx: reverse/stop anticoag (d/w interventionalist), IVF/PRBC/plts as required.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Vascular damage</b> (~1% of dx angio, ~5% of transfemoral PCI; <i class="calibre3">Circ</i> 2007;115:2666)</p>
<p class="bl1">Pseudoaneurysm: triad of pain, expansile mass, systolic bruit; Dx: U/S; Rx (if pain or &gt;2 cm): manual or U/S-directed compression, thrombin injection, or surgical repair</p>
<p class="bl1">AV fistula: continuous bruit; Dx: U/S; Rx: surgical repair if large or sx</p>
<p class="bl1">LE ischemia (emboli, dissection, clot): cool, mottled extremity, ↓ distal pulses; Dx: pulse volume recording (PVR), angio; Rx: percutaneous or surgical repair</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Peri-PCI MI:</b> &gt;5× ULN of Tn/CK-MB + either sx or ECG/angio ∆s; Qw MI in &lt;1%</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Contrast-induced AKI:</b> w/in 48 h, peak 3–5 d; pre-hydration reasonable (see “CIAKI”)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cholesterol emboli syndrome</b> (typically in middle-aged &amp; elderly and w/ Ao atheroma)</p>
<p class="bl1">renal failure (late and progressive, ± eos in urine); mesenteric ischemia (abd pain, LGIB, pancreatitis); intact distal pulses but livedo pattern and toe necrosis</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Stent thrombosis:</b> mins-yrs after PCI, typically p/w AMI. Due to mech prob. (stent underexpansion or unrecognized dissection, typically presents early) or d/c of antiplt Rx; espec if d/c both ASA &amp; P2Y<sub class="calibre8">12</sub> inhib <span class="s1r">(<i class="calibre3">JAMA</i> 2005;293:2126)</span>.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">In-stent restenosis:</b> mos after PCI, typically p/w gradual ↑ angina (10% p/w ACS).</p>
<p class="bl1">Due to combination of elastic recoil and neointimal hyperplasia; ↓ w/ DES vs. BMS.</p>
<h2 class="ct"><a id="h5" class="calibre7"></a><a id="page_1-6" class="calibre7"></a><a href="part0002.html#rh9" class="calibre7">ACUTE CORONARY SYNDROMES</a></h2>
<p class="image1"><img src="../images/00007.jpeg" alt="" class="calibre2"/></p>
<p class="h2a"><b class="calibre4">Ddx</b> <span class="s">(causes of myocardial ischemia/infarction other than atherosclerotic plaque rupture)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Nonatherosclerotic coronary artery disease</b> <span class="s1r">(<i class="calibre3">JACC</i> 2018;72:2231)</span></p>
<p class="bl1">Spasm: Prinzmetal’s variant, cocaine-induced (6% of chest pain + cocaine use r/i for MI)</p>
<p class="bl1">Dissection: spontaneous (vasculitis, CTD, pregnancy), aortic dissection with retrograde extension (usually involving RCA → IMI) or mechanical (PCI, surgery, trauma)</p>
<p class="bl1">Embolism <span class="s1r">(<i class="calibre3">Circ</i> 2015;132:241)</span>: AF, thrombus/myxoma, endocard., prosth valve thrombosis</p>
<p class="bl1">Vasculitis: Kawasaki syndrome, Takayasu arteritis, PAN, Churg-Strauss, SLE, RA</p>
<p class="bl1">Congenital: anomalous origin from aorta or PA, myocardial bridge (intramural segment)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Ischemia w/o plaque rupture</b> (“type 2” MI): ↑ demand (eg, ↑ HR), ↓ supply (eg, HoTN)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Direct myocardial injury:</b> myocarditis; Takotsubo/stress CMP; toxic CMP; cardiac contusion</p>
<p class="h2a"><b class="calibre4">Clinical manifestations</b> <span class="s">(<i class="calibre3">JAMA</i> 2015;314:1955)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Typical angina:</b> retrosternal pressure/pain/tightness ± radiation to neck, jaw, arms; precip. by exertion, relieved by rest/ NTG. In ACS: new-onset, crescendo or at rest.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Associated symptoms:</b> dyspnea, diaphoresis, N/V, palpitations or light-headedness</p>
<p class="bl"><span class="sbl">•</span> Many MIs (~20% in older series) are initially unrecognized b/c silent or atypical sx</p>
<p class="bl"><span class="sbl">•</span> Atypical sxs (incl N/V &amp; epig pain) ? more common in ♀, elderly, diabetes, inferior ischemia</p>
<p class="h2a"><b class="calibre4">Physical exam</b></p>
<p class="bl"><span class="sbl">•</span> Signs of ischemia: S<sub class="calibre8">4</sub>, new MR murmur 2° pap. muscle dysfxn, paradoxical S<sub class="calibre8">2</sub>, diaphoresis</p>
<p class="bl"><span class="sbl">•</span> Signs of heart failure: ↑ JVP, crackles in lung fields, ⊕ S<sub class="calibre8">3</sub>, HoTN, cool extremities</p>
<p class="bl"><span class="sbl">•</span> Signs of other vascular disease: asymmetric BP, carotid or femoral bruits, ↓ distal pulses</p>
<p class="h2a"><b class="calibre4">Diagnostic studies</b> <span class="s1r">(<i class="calibre3">NEJM</i> 2017;376:2053)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">ECG:</b> ST ↓/↑, TWI, new LBBB, hyperacute Tw; Qw/PRWP may suggest prior MI &amp; ∴ CAD</p>
<p class="bl1">✔ ECG w/in 10 min of presentation, with any ∆ in sx &amp; at 6–12 h; compare w/ baseline</p>
<p class="bl1">STEMI dx w/ old LBBB: ≥1 mm STE <i class="calibre3">concordant</i> w/ QRS (Se 73%, Sp 92%), STD ≥1 mm V<sub class="calibre8">1</sub>–V<sub class="calibre8">3</sub> (Se 25%, Sp 96%), STE ≥5 mm <i class="calibre3">discordant</i> w/ QRS (Se 31%, Sp 92%)</p>
<table class="t-topbot1" border="1">
<colgroup class="calibre9">
<col class="calibre16"/>
<col class="calibre17"/>
<col class="calibre16"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><a id="page_1-7" class="calibre1"></a><p class="tabheadc"><b class="calibre4">Localization of MI</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc"><b class="calibre4">Anatomic Area</b></p></td>
<td class="bg0-br"><p class="tabc"><b class="calibre4">ECG Leads w/ STE</b></p></td>
<td class="bg0-b"><p class="tabc"><b class="calibre4">Coronary Artery</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">Septal</p></td>
<td class="bg0-br"><p class="tabc">V<sub class="calibre13">1</sub>–V<sub class="calibre13">2</sub> ± aVR</p></td>
<td class="bg0-b"><p class="tabc">Proximal LAD</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">Anterior</p></td>
<td class="bg0-br"><p class="tabc">V<sub class="calibre13">3</sub>–V<sub class="calibre13">4</sub></p></td>
<td class="bg0-b"><p class="tabc">LAD</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">Apical</p></td>
<td class="bg0-br"><p class="tabc">V<sub class="calibre13">5</sub>–V<sub class="calibre13">6</sub></p></td>
<td class="bg0-b"><p class="tabc">Distal LAD, LCx, or RCA</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">Lateral</p></td>
<td class="bg0-br"><p class="tabc">I, aVL</p></td>
<td class="bg0-b"><p class="tabc">LCx</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">Inferior</p></td>
<td class="bg0-br"><p class="tabc">II, III, aVF ± aVR</p></td>
<td class="bg0-b"><p class="tabc">RCA (~85%), LCx (~15%)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">RV</p></td>
<td class="bg0-br"><p class="tabc">V<sub class="calibre13">1</sub>–V<sub class="calibre13">2</sub> &amp; V<sub class="calibre13">4</sub>R (most Se)</p></td>
<td class="bg0-b"><p class="tabc">Proximal RCA</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br1"><p class="tabc">Posterior</p></td>
<td class="bg0-br1"><p class="tabc">ST <i class="calibre3">depression</i> V<sub class="calibre13">1</sub>–V<sub class="calibre13">3</sub> (= STE V<sub class="calibre13">7</sub>–V<sub class="calibre13">9</sub> posterior leads, ✔ if clinical suspicion)</p></td>
<td class="bg0-b1"><p class="tabc">RCA or LCx</p></td>
</tr>
</table>
<p class="tsr">If ECG non-dx &amp; suspicion high, ✔ leads V<sub class="calibre18">7</sub>–V<sub class="calibre18">9</sub> to assess distal LC<small class="calibre19">X</small>/RCA territory. ✔ R-sided precordial leads in IMI to help detect RV involvement (STE in V<sub class="calibre18">4</sub>R most Se). STE in III &gt; STE in II and lack of STE in I or aVL suggest RCA rather than LC<small class="calibre19">X</small> culprit in IMI. STE in aVR suggests LM or prox LAD occlusion or diffuse ischemia.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cardiac biomarkers:</b> ✔ Tn (pref. over CK-MB) at presentation &amp; 3–6 h (? 1hr if hsTn); repeat if clinical or ECG ∆s; &gt;99th %ile w/ rise and/or fall in appropriate clinical setting dx of AMI (see “Chest Pain”); in CKD, ↑ Tn still portends poor prognosis <span class="s1r">(<i class="calibre3">NEJM</i> 2002;346:2047)</span></p>
<p class="bl"><span class="sbl">•</span> If low prob, <b class="calibre4">stress test, CT angio</b> to r/o CAD; new wall motion abnl on TTE suggests ACS</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Coronary angio</b> gold standard for epicardial CAD</p>
<p class="h2a"><b class="calibre4">Prinzmetal’s (variant) angina</b></p>
<p class="bl"><span class="sbl">•</span> Coronary spasm → transient STE usually w/o MI <span class="s1r">(<i class="calibre3">but</i> MI, AVB, VT can occur)</span></p>
<p class="bl"><span class="sbl">•</span> Pts usually young, smokers, ± other vasospastic disorders (eg, migraines, Raynaud’s)</p>
<p class="bl"><span class="sbl">•</span> Angiography: nonobstructive CAD (spasm can be provoked during cath but rarely done)</p>
<p class="bl"><span class="sbl">•</span> Treatment: high-dose CCB &amp; standing nitrates (+SL prn), ? α-blockers/statins; d/c smoking; avoid high-dose ASA (can inhibit prostacyclin and worsen spasm), nonselect βB, triptans</p>
<p class="bl"><span class="sbl">•</span> Cocaine-induced vasospasm: CCB, nitrates, ASA; ? avoid βB, but labetalol appears safe</p>
<p class="image1"><img src="../images/00008.jpeg" alt="" class="calibre2"/></p>
<p class="h2a"><b class="calibre4">Approach to triage</b></p>
<p class="bl"><span class="sbl">•</span> If hx, initial ECG &amp; Tn non-dx, repeat ECG q15–30min × 1 h &amp; Tn 3–6 h (? 1hr if hs) later</p>
<p class="bl"><span class="sbl">•</span> If remain nl and low likelihood of ACS, search for alternative causes of chest pain</p>
<p class="bl"><span class="sbl">•</span> If remain nl, have ruled out MI, <i class="calibre3">but</i> if high suspicion for ACS based on hx, then still need to r/o UA w/ stress test to assess for inducible ischemia (or CTA to r/o epicardial CAD);</p>
<p class="bl1">if low risk (eg, age ≤70; ∅ prior CAD, CVD, PAD; ∅ rest angina) can do before d/c from ED or as outPt w/in 72 h (0% mortality, &lt;0.5% MI; <i class="calibre3">Ann Emerg Med</i> 2006;47:427)</p>
<p class="bl1">if not low risk, admit and initiate Rx for possible ACS and consider stress test or cath</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre16"/>
<col class="calibre20"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Acute Anti-Ischemic and Analgesic Treatment</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Nitrates</b> (SL or IV) 0.3–0.4 mg SL q5min × 3, then consider IV if still sx</p></td>
<td class="bg0-b"><p class="tab">Use for relief of sx, Rx for HTN or HF. No clear ↓ in mortality.</p>
<p class="tabh"><i class="calibre3">Caution</i> if preload-sensitive (eg, HoTN, AS, sx RV infarct); contraindicated if recent PDE5 inhibitor use.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">β<b class="calibre4">-blockers</b></p>
<p class="tab">eg, metop 25–50 mg PO q6h titrate slowly to HR 50–60 IV only if HTN and no HF</p></td>
<td class="bg0-b"><p class="tab">↓ ischemia &amp; progression of UA to MI (<span class="tfont"><i class="calibre3">JAMA</i> 1988;260:2259</span>)</p>
<p class="tabh">STEMI: ↓ arrhythmic death &amp; reMI, but ↑ cardiogenic shock early (espec if signs of HF) (<span class="tfont"><i class="calibre3">Lancet</i> 2005;366:1622</span>).</p>
<p class="tabh"><i class="calibre3">Contraindic.</i> PR &gt;0.24 sec, HR &lt;60, 2°/3° AVB, severe bron-chospasm, s/s HF or low output, risk factors for shock (eg, &gt;70 y, HR &gt;110, SBP &lt;120, late presentation STEMI)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">CCB</b> (nondihydropyridines)</p></td>
<td class="bg0-b"><p class="tab">If cannot tolerate βB b/c bronchospasm</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Morphine</b></p></td>
<td class="bg0-b"><p class="tab">Relieves pain/anxiety; venodilation ↓ preload. Do not mask refractory sx. May delay antiplt effects of P2Y<sub class="calibre13">1</sub><sub class="calibre13">2</sub> inhib.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br1"><p class="tab"><b class="calibre4">Oxygen</b></p></td>
<td class="bg0-b1"><p class="tab">Use prn for resp distress or to keep S<sub class="calibre13">a</sub>O<sub class="calibre13">2</sub> &gt;90%; no mortality benefit if S<sub class="calibre13">a</sub>O<sub class="calibre13">2</sub> ≥90% (<span class="tfont"><i class="calibre3">NEJM</i> 2017;377:1240</span>)</p></td>
</tr>
</table>
<p class="h2a"><b class="calibre4">Other early adjunctive therapy</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">High-intensity statin therapy</b> (eg, atorva 80 mg qd; PROVE-IT TIMI 22, <i class="calibre3">NEJM</i> 2004;350:1495); ↓ ischemic events w/ benefit emerging w/in wks <span class="s1r">(<i class="calibre3">JAMA</i> 2001;285:1711 &amp; <i class="calibre3">JACC</i> 2005;46:1405)</span>; ↓ peri-PCI MI <span class="s1r">(<i class="calibre3">JACC</i> 2010;56:1099)</span>; ? ↓ contrast-induced nephropathy <span class="s1r">(<i class="calibre3">NEJM</i> 2019;380:2156)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Ezetimibe:</b> ↓ CV events when added to statin (IMPROVE-IT, <i class="calibre3">NEJM</i> 2015;372:1500)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">ACEI/ARB:</b> start once hemodynamics and renal function stable</p>
<p class="bl1">Strong indication for ACEI if heart failure, EF &lt;40%, HTN, DM, CKD; ~10% ↓ mortality, greatest benefit in ant. STEMI or prior MI <span class="s1r">(<i class="calibre3">Lancet</i> 1994;343:1115 &amp; 1995;345:669)</span></p>
<p class="bl1">ARB appear ≈ ACEI <span class="s1r">(<i class="calibre3">NEJM</i> 2003;349:20)</span>; give if contraindic to ACEI</p>
<p class="bl"><span class="sbl">•</span> IABP: can be used for refractory angina when PCI not available</p>
<p class="h"><b class="calibre21">NSTE-ACS</b> <span class="s1">(<i class="calibre22">C<small class="calibre23">IRC</small></i> 2014;130:e344)</span></p>
<p class="cst"><i class="calibre3">Key issues are antithrombotic regimen and invasive vs. conservative strategy</i></p>
<table class="t-topbot" border="1">
<colgroup class="calibre9">
<col class="calibre17"/>
<col class="calibre24"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Antiplatelet Therapy</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Aspirin</b></p>
<p class="tab">162–325 mg × 1, then 81 mg qd</p>
<p class="tab">(non–enteric-coated, chewable)</p></td>
<td class="bg0-b"><p class="tab">50–70% ↓ D/MI (<span class="tfont"><i class="calibre3">NEJM</i> 1988;319:1105</span>)</p>
<p class="tab">Low dose (~81 mg) pref long term (<span class="tfont"><i class="calibre3">NEJM</i> 2010;363:930</span>)</p>
<p class="tab">If allergy, use clopi and/or desensitize to ASA</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b" colspan="2"><p class="tab"><b class="calibre4">P2Y<sub class="calibre13">1</sub><sub class="calibre13">2</sub> (ADP receptor) inhibitor</b> (choose one of the following in addition to ASA).</p>
<p class="tab">Timing (on presentation or at angiography) remains controversial. Some data for upstream clopidogrel (<span class="tfont"><i class="calibre3">JAMA</i> 2012;308:2507</span>). See below for specific recommendations.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br">
<p class="bull-t"><span class="sbull-t">•</span> <b class="calibre4">Ticagrelor</b> (preferred over clopi)</p>
<p class="tabh1">180 mg × 1 → 90 mg bid</p>
<p class="tabh1">Reversible, but wait 3–5 d prior to surg. Antidote being developed (<span class="tfont"><i class="calibre3">NEJM</i> 2019;380:1825</span>).</p>
<p class="tabh1">Use only with ASA &lt;100 mg qd</p></td>
<td class="bg0-b"><p class="tab">More rapid and potent plt inhib c/w clopi</p>
<p class="tabh">16% ↓ CVD/MI/stroke &amp; 21% ↓ CV death c/w clopi; ↑ non-CABG bleeding (<span class="tfont"><i class="calibre3">NEJM</i> 2009;361;1045</span>)</p>
<p class="tab">Given upstream or at time of PCI</p>
<p class="tab">Dyspnea (but S<sub class="calibre13">a</sub>O<sub class="calibre13">2</sub> &amp; PFTs nl) &amp; ventricular pauses</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br">
<p class="bull-t"><a id="page_1-8" class="calibre1"></a><span class="sbull-t">•</span> <b class="calibre4">Prasugrel</b> (preferred over clopi)</p>
<p class="tabh1">60 mg × 1 if undergoing PCI → 10 mg qd (consider 5 mg/d if &lt;60 kg)</p> 
<p class="tabh1">Wait 7 d prior to surgery</p></td>
<td class="bg0-b"><p class="tab">More rapid and potent plt inhib c/w clopi</p>
<p class="tabh">19% ↓ CVD/MI/stroke in ACS w/ planned PCI vs. clopi, but ↑ bleeding (<span class="tfont"><i class="calibre3">NEJM</i> 2007;359:2001</span>), incl fatal bleeds</p>
<p class="tabh">In NSTE-ACS, should be given at time of PCI and not upstream due to ↑ bleeding (<span class="tfont"><i class="calibre3">NEJM</i> 2013;369:999</span>)</p>
<p class="tab">Contraindic. if h/o TIA/CVA; ? avoid if &gt;75 y</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br">
<p class="bull-t"><span class="sbull-t">•</span> <b class="calibre4">Clopidogrel</b><a id="st1" class="calibre1"></a><a href="part0006.html#sst1" class="calibre1">*</a></p>
<p class="tabh">300–600 mg × 1 → 75 mg qd</p>
<p class="tabh">Requires ~6 h to steady state</p></td>
<td class="bg0-b">
<p class="tabh">ASA+clopi → 20% ↓ CVD/MI/stroke vs. ASA alone ↑ benefit if given hrs <i class="calibre3">prior</i> to PCI (<span class="tfont"><i class="calibre3">JAMA</i> 2012;308:2507</span>), but if require CABG, need to wait &gt;5 d after d/c clopi</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br">
<p class="bull-t"><span class="sbull-t">•</span> <b class="calibre4">Cangrelor</b></p>
<p class="tabh">Only IV P2Y<sub class="calibre13">1</sub><sub class="calibre13">2</sub> inhibitor</p>
<p class="tabh">Rapid onset/offset; t¹⁄² 3–5 min</p></td>
<td class="bg0-b">
<p class="tabh">22% ↓ CV events (mostly peri-PCI MI and stent thrombosis) vs. clopi 300 mg at time of PCI; no significant ↑ bleeding (<span class="tfont"><i class="calibre3">NEJM</i> 2013;368:1303</span>)</p>
<p class="tabh">Consider for rapidly reversible P2Y<sub class="calibre13">1</sub><sub class="calibre13">2</sub> inhibition during PCI or as bridge to surgery in high-risk Pts who need to stop P2Y<sub class="calibre13">1</sub><sub class="calibre13">2</sub></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br1"><p class="tab"><b class="calibre4">GP IIb/IIIa inhibitors (GPI)</b></p>
<p class="tab">abciximab; eptifibatide; tirofiban</p>
<p class="tabh">Infusions given ≤24 h peri &amp; post PCI; shorter (~2 h) as effective w/ ↓ bleeding (<span class="tfont"><i class="calibre3">JACC</i> 2009;53:837</span>)</p></td>
<td class="bg0-b1"><p class="tab">No clear benefit for routinely starting prior to PCI and ↑ bleeding (<span class="tfont"><i class="calibre3">NEJM</i> 2009;360:2176</span>)</p>
<p class="tabh">Consider if refractory ischemia despite optimal Rx while awaiting angio or in high-risk Pts (eg, large clot burden) at time of PCI, espec if using clopi and no preRx.</p></td>
</tr>
</table>
<p class="tsr"><a id="sst1" class="calibre1"></a><a href="part0006.html#st1" class="calibre1">*</a>~30% pop has ↓ fxn <i class="calibre3">CYP2C</i>1<i class="calibre3">9</i> → ↑ CV events if PCI on clopi (<i class="calibre3">NEJM</i> 2009;360:354)</p>
<table class="t-topbot2">
<colgroup class="calibre9">
<col class="calibre16"/>
<col class="calibre20"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Anticoagulant Therapy (choose one)</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">UFH:</b> 60 U/kg IVB (max 4000 U) then 12 U/kg/h (max 1000 U/h initially) × 48 h or until end of PCI</p></td>
<td class="bg0-b"><p class="tab">24% ↓ D/MI (<span class="tfont"><i class="calibre3">JAMA</i> 1996;276:811</span>)</p>
<p class="tab">Titrate to aPTT 1.5–2× control (~50–70 sec)</p>
<p class="tab">Hold until INR &lt;2 if already on warfarin</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Enoxaparin</b> (low-molec-wt heparin) 1 mg/kg SC bid (± 30 mg IVB) (qd if CrCl &lt;30) × 2–8 d or until PCI</p></td>
<td class="bg0-b"><p class="tab">~10% ↓ D/MI vs. UFH (<span class="tfont"><i class="calibre3">JAMA</i> 2004;292:45,89</span>). Can perform PCI on enox (<span class="tfont"><i class="calibre3">Circ</i> 2001;103:658</span>), but ↑ bleeding if switch b/w enox and UFH.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Bivalirudin</b> (direct thrombin inhibitor) 0.75 mg/kg IVB at PCI → 1.75 mg/kg/h</p></td>
<td class="bg0-b"><p class="tab">No diff in bleeding, MI, or death c/w UFH (<span class="tfont"><i class="calibre3">NEJM</i> 2017;377:1132</span>). Use instead of UFH if HIT.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br1"><p class="tab"><b class="calibre4">Fondaparinux</b> (Xa inh) 2.5 mg SC qd</p></td>
<td class="bg0-b1"><p class="tab">Rarely used; must supplement w/ UFH if PCI.</p></td>
</tr>
</table>
<p class="h2a"><b class="calibre4">Coronary angiography</b> <span class="s">(<i class="calibre3">Circ</i> 2014;130:e344)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Immediate/urgent coronary angiography</b> (w/in 2 h) if refractory/recurrent angina or hemodynamic or electrical instability</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Invasive (INV) strategy</b> = <span class="underline">routine angiography w/in 72 h</span></p>
<p class="bl1"><i class="calibre3"><span class="underline">Early</span> (w/in 24 h) if:</i> ⊕ Tn, ST ∆, GRACE risk score (<a href="http://www.outcomes-massmed.org/grace" class="calibre1">www.outcomes-massmed.org/grace</a>) &gt;140 <span class="s1r">(<i class="calibre3">NEJM</i> 2009;360:2165; <i class="calibre3">Circ</i> 2018;138:2741)</span></p>
<p class="bl1"><i class="calibre3"><span class="underline">Delayed</span> (ie, w/in 72 h) acceptable if w/o above features but w/:</i> diabetes, EF &lt;40%, GFR &lt;60, post-MI angina, TRS ≥3, GRACE score 109–140, PCI w/in 6 mo, prior CABG</p>
<p class="bl1">32% ↓ rehosp for ACS, nonsignif 16% ↓ MI, no ∆ in mortality c/w cons. <span class="s1r">(<i class="calibre3">JAMA</i> 2008;300:71)</span>.</p>
<p class="bl1">↑ peri-PCI MI counterbalanced by ↓↓ in spont. MI. Mortality benefit seen in some studies, likely only if cons. strategy w/ low rate of angio.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Conservative (CONS) strategy</b> = selective angio. Med Rx w/ pre-d/c stress test; angio only if recurrent ischemia or strongly ⊕ ETT. <i class="calibre3">Indicated for:</i> low TIMI Risk Score, Pt or physician pref in absence of high-risk features, or low-risk women <span class="s1r">(<i class="calibre3">JAMA</i> 2008;300:71)</span>.</p>
<p class="image1"><img src="../images/00009.jpeg" alt="" class="calibre2"/></p>
<p class="capf"><a id="page_1-9" class="calibre1"></a><b class="calibre4">Figure 1-2</b> Approach to UA/NSTEMI</p>
<p class="image"><img src="../images/00010.jpeg" alt="" class="calibre2"/></p>
<p class="h"><b class="calibre21">STEMI</b></p>
<p class="h2a"><b class="calibre4">Requisite STE (at J point)</b></p>
<p class="bl"><span class="sbl">•</span> ≥2 contiguous leads w/ ≥1 mm (except for V<sub class="calibre8">2</sub>–V<sub class="calibre8">3</sub>: ≥2 mm in ♂ and ≥1.5 mm in ♀), or</p>
<p class="bl"><span class="sbl">•</span> New or presumed new LBBB w/ compelling H&amp;P, or</p>
<p class="bl"><span class="sbl">•</span> True posterior MI: ST depression V<sub class="calibre8">1</sub>–V<sub class="calibre8">3</sub> ± tall Rw w/ STE on posterior leads (V<sub class="calibre8">7</sub>–V<sub class="calibre8">9</sub>)</p>
<p class="h2a"><b class="calibre4">Reperfusion (“time is muscle”)</b></p>
<p class="bl"><span class="sbl">•</span> In PCI-capable hospital, goal should be <b class="calibre4">primary PCI w/in 90 min</b> of 1<sup class="calibre15">st</sup> medical contact</p>
<p class="bl"><span class="sbl">•</span> In non–PCI-capable hospital, consider <i class="calibre3">transfer</i> to PCI-capable hospital (see below), o/w <b class="calibre4">fibrinolytic therapy</b> w/in 30 min of hospital presentation</p>
<p class="bl"><span class="sbl">•</span> Do not let decision regarding <i class="calibre3">method</i> of reperfusion delay <i class="calibre3">time</i> to reperfusion</p>
<p class="h2a"><b class="calibre4">Primary PCI</b> <span class="s">(<i class="calibre3">JACC</i> 2013;61:e78 &amp; 2016;67:1235)</span></p>
<p class="bl"><span class="sbl">•</span> Definition: immediate PCI upon arrival to hospital or transfer for immediate PCI</p>
<p class="bl"><span class="sbl">•</span> Indic: STE + sx onset w/in &lt;12 h; ongoing ischemia 12–24 h after sx onset; shock</p>
<p class="bl"><span class="sbl">•</span> Superior to lysis: 27% ↓ death, 65% ↓ reMI, 54% ↓ stroke, 95% ↓ ICH <span class="s1r">(<i class="calibre3">Lancet</i> 2003;361:13)</span></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Transfer</i> to center for 1° PCI superior to lysis <span class="s1r">(<i class="calibre3">NEJM</i> 2003;349:733)</span>, see below</p>
<p class="bl"><span class="sbl">•</span> Routine thrombus aspiration: no benefit, ↑ stroke <span class="s1r">(<i class="calibre3">Lancet</i> 2015;387:127; 2015;372:1389)</span></p>
<p class="bl"><span class="sbl">•</span> Consider PCI of non-culprit lesions at time of primary PCI or planned staged procedure because appears to ↓ MACE vs. culprit alone <span class="s1r">(<i class="calibre3">NEJM</i> 2013;369:1115; <i class="calibre3">JACC</i> 2015;65:963)</span>; but may harm if cardiogenic shock <span class="s1r">(<i class="calibre3">NEJM</i> 2018;379:1699)</span></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre25"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b"><p class="tabheadc"><b class="calibre4">Fibrinolysis vs. Hospital Transfer for Primary PCI: Assess Time and Risk</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b"><p class="bull-t"><span class="sbull-t">1.</span> <b class="calibre4">Time required for transport to skilled PCI lab:</b> door-to-balloon &lt;120 min &amp; [door- to-balloon]–[door-to-needle] &lt;1 h favors transfer for PCI</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b"><p class="bull-t"><span class="sbull-t">2.</span> high-risk Pts (eg, shock) fare better with mechanical reperfusion</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b"><p class="bull-t"><span class="sbull-t">3.</span> <b class="calibre4">Time to presentation:</b> efficacy of lytics ↓ w/ ↑ time from sx onset, espec &gt;3 h</p></td>
</tr>
<tr class="calibre12">
<td class="bg"><p class="bull-t"><span class="sbull-t">4.</span> <b class="calibre4">Risk of fibrinolysis:</b> if high risk of ICH or bleeding, PCI safer option</p></td>
</tr>
</table>
<p class="tsr">Adapted from ACC/AHA 2013 STEMI Guidelines (<i class="calibre3">Circ</i> 2013;127:529)</p>
<p class="h2a"><b class="calibre4">Fibrinolysis</b></p>
<p class="bl"><span class="sbl">•</span> Indic: STE/LBBB + sx &lt;12 h (&amp; &gt;120 min before PCI can be done); benefit if sx &gt;12 h less clear; reasonable if persist. sx &amp; STE, hemodynamic instability or large territory at risk</p>
<p class="bl"><span class="sbl">•</span> Mortality ↓ ~20% in anterior MI or LBBB and ~10% in IMI c/w ∅ reperfusion Rx</p>
<p class="bl"><span class="sbl">•</span> Prehospital lysis (ie, ambulance): further 17% ↓ in mortality <span class="s1r">(<i class="calibre3">JAMA</i> 2000;283:2686)</span></p>
<p class="bl"><span class="sbl">•</span> ~1% risk of ICH; high risk incl elderly (~2% if &gt;75 y), ♀, low wt. ∴ PCI more attractive</p>
<table class="t-topbot2">
<colgroup class="calibre9">
<col class="calibre26"/>
<col class="calibre26"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Contraindications to Fibrinolysis</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Absolute Contraindications</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Relative Contraindications</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="bull-t"><span class="sbull-t">•</span> Any prior ICH</p>
<p class="bull-t"><span class="sbull-t">•</span> Intracranial neoplasm, aneurysm, AVM</p>
<p class="bull-t"><span class="sbull-t">•</span> Ischemic stroke or closed head trauma w/in 3 mo; head/spinal surg. w/in 2 mo</p>
<p class="bull-t"><span class="sbull-t">•</span> Active internal bleeding or known bleeding diathesis</p>
<p class="bull-t"><span class="sbull-t">•</span> Suspected aortic dissection</p>
<p class="bull-t"><span class="sbull-t">•</span> Severe uncontrollable HTN</p>
<p class="bull-t"><span class="sbull-t">•</span> For SK, SK Rx w/in 6 mo</p>
</td>
<td class="bg"><p class="bull-t"><span class="sbull-t">•</span> H/o severe HTN, SBP &gt;180 or DBP &gt;110 on presentation (? absolute if low-risk MI)</p>
<p class="bull-t"><span class="sbull-t">•</span> Ischemic stroke &gt;3 mo prior</p>
<p class="bull-t"><span class="sbull-t">•</span> CPR &gt;10 min; trauma/major surg. w/in 3 wk</p>
<p class="bull-t"><span class="sbull-t">•</span> Internal bleed w/in 2–4 wk; active PUD</p>
<p class="bull-t"><span class="sbull-t">•</span> Noncompressible vascular punctures</p>
<p class="bull-t"><span class="sbull-t">•</span> Pregnancy</p>
<p class="bull-t"><span class="sbull-t">•</span> Current use of anticoagulants</p>
<p class="bull-t"><span class="sbull-t">•</span> For SK, prior SK exposure</p>
</td>
</tr>
</table>
<p class="h2a"><a id="page_1-10" class="calibre1"></a><b class="calibre4">Nonprimary PCI</b></p>
<p class="bl"><span class="sbl">•</span> Rescue PCI if shock, unstable, failed reperfusion, or persistent sx <span class="s1r">(<i class="calibre3">NEJM</i> 2005;353:2758)</span></p>
<p class="bl"><span class="sbl">•</span> Routine angio ± PCI w/in 24 h of successful lysis: ↓ D/MI/revasc <span class="s1r">(<i class="calibre3">Lancet</i> 2004;364:1045)</span> and w/in 6 h ↓ reMI, recurrent ischemia, &amp; HF compared to w/in 2 wk <span class="s1r">(<i class="calibre3">NEJM</i> 2009;360:2705)</span>;</p>
<p class="bl1">∴ <i class="calibre3">if lysed at non-PCI-capable hosp., consider transfer to PCI-capable hosp. ASAP espec if hi-risk (eg, ant. MI, IMI w/</i> ↓ <i class="calibre3">EF or RV infarct, extensive STE/LBBB, HF</i>, ↓ <i class="calibre3">BP or</i> ↑ <i class="calibre3">HR)</i></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Late</i> PCI (median day 8) of occluded infarct-related artery: no benefit <span class="s1r">(<i class="calibre3">NEJM</i> 2006;355:2395)</span></p>
<table class="t-topbot">
<colgroup class="calibre9">
<col class="calibre27"/>
<col class="calibre28"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Antiplatelet Therapy</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Aspirin</b> 162–325 mg × 1</p>
<p class="tab">(crushed/chewed) then 81 mg qd</p></td>
<td class="bg0-b"><p class="tab">23% ↓ in death (<span class="tfont"><i class="calibre3">Lancet</i> 1988;ii:349</span>)</p>
<p class="tab">Should not be stopped if CABG required</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">P2Y<sub class="calibre13">1</sub><sub class="calibre13">2</sub> inhibitor</b></p>
<p class="tabh">Give ASAP (do not wait for angio) b/c onset inhib delayed in STEMI pts</p>
<p class="tabh">Ticagrelor or prasugrel (if PCI) as detailed above</p>
<p class="tabh">Clopidogrel: 600 mg pre-PCI; 300 mg if lysis (no LD if &gt;75 y) → 75 mg qd</p></td>
<td class="bg0-b"><p class="tabh"><i class="calibre3">Lysis:</i> clopidogrel 41% ↑ in patency, 7% ↓ mort, no ∆ major bleed or ICH (<span class="tfont"><i class="calibre3">NEJM</i> 2005;352:1179; <i class="calibre3">Lancet</i> 2005;366:1607</span>); no data for pras or ticag w/ lytic</p>
<p class="tabh"><i class="calibre3">PCI:</i> prasugrel and ticagrelor ↓ CV events c/w clopi (<span class="tfont"><i class="calibre3">Lancet</i> 2009;373:723 &amp; <i class="calibre3">Circ</i> 2010;122:2131</span>)</p>
<p class="tabh">Prehospital ticagrelor may be safe &amp; ? ↓ rate of stent thrombosis (<span class="tfont"><i class="calibre3">NEJM</i> 2014;371:1016</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">GP IIb/IIIa inhibitors</b></p>
<p class="tab">abciximab, eptifibatide, tirofiban</p></td>
<td class="bg"><p class="tab"><i class="calibre3">Lysis:</i> no indication (<span class="tfont"><i class="calibre3">Lancet</i> 2001;357:1905</span>)</p>
<p class="tab"><i class="calibre3">Peri-PCI:</i> 60% ↓ D/MI/UR (<span class="tfont"><i class="calibre3">NEJM</i> 2001;344:1895</span>)</p></td>
</tr>
</table>
<p class="tsr">Adapted from ACC/AHA 2013 STEMI Guidelines Update (<i class="calibre3">Circ</i> 2013;127:529); <i class="calibre3">Lancet</i> 2013;382:633</p>
<table class="t-topbot">
<colgroup class="calibre9">
<col class="calibre27"/>
<col class="calibre28"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Anticoagulant Therapy (choose one)</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">UFH</b></p>
<p class="tab">60 U/kg IVB (max 4000 U)</p>
<p class="tab">12 U/kg/h (max 1000 U/h initially)</p></td>
<td class="bg0-b"><p class="tab">No demonstrated mortality benefit</p>
<p class="tab">↑ patency with fibrin-specific lytics</p>
<p class="tab">Titrate to aPTT 1.5–2× control (~50–70 sec)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Enoxaparin</b></p>
<p class="tabh"><i class="calibre3">Lysis:</i> 30 mg IVB → 1 mg/kg SC bid (adjust for age &gt;75 &amp; CrCl)</p>
<p class="tab"><i class="calibre3">PCI:</i> 0.5 mg/kg IVB</p></td>
<td class="bg0-b"><p class="tabh"><i class="calibre3">Lysis:</i> 17% ↓ D/MI w/ ENOX × 7 d vs. UFH × 2 d (<span class="tfont"><i class="calibre3">NEJM</i> 2006;354:1477</span>)</p>
<p class="tabh"><i class="calibre3">PCI:</i> ↓ D/MI/revasc and ≈ bleeding vs. UFH (<span class="tfont"><i class="calibre3">Lancet</i> 2011;378:693</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Bivalirudin</b></p>
<p class="tab">0.75 mg/kg IVB → 1.75 mg/kg/hr IV</p></td>
<td class="bg"><p class="tab"><i class="calibre3">PCI:</i> similar bleeding, ± ↑ MI, ↑ stent thromb (<span class="tfont"><i class="calibre3">Lancet</i> 2014;384:599; <i class="calibre3">NEJM</i> 2017;377:1132</span>)</p></td>
</tr>
</table>
<p class="tsr">Fondaparinux can be used (if CrCl &gt;30 mL/min) in setting of lysis, where superior to UFH w/ less bleeding (<i class="calibre3">JAMA</i> 2006;295:1519). Adapted from ACC/AHA 2013 STEMI Guidelines (<i class="calibre3">Circ</i> 2013;127:529; <i class="calibre3">Lancet</i> 2013;382:633)</p>
<p class="h2a"><b class="calibre4">LV failure</b> <span class="s2">(occurs in ~25%)</span></p>
<p class="bl"><span class="sbl">•</span> Diurese to achieve PCWP ~14 → ↓ pulmonary edema, ↓ myocardial O<sub class="calibre8">2</sub> demand</p>
<p class="bl"><span class="sbl">•</span> ↓ Afterload → ↑ stroke volume &amp; CO, ↓ myocardial O<sub class="calibre8">2</sub> demand. Can use IV NTG or nitroprusside (although risk of coronary steal) → short-acting ACEI.</p>
<p class="bl"><span class="sbl">•</span> Inotropes if HF despite diuresis &amp; ↓ afterload; use dopamine, dobutamine, or milrinone</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cardiogenic shock</b> (~7%) = MAP &lt;60 mmHg, CI &lt;2.2 L/min/m<sup class="calibre15">2</sup>, PCWP &gt;18 mmHg.</p>
<p class="bl1">If not done already, coronary revasc <span class="s1r">(<i class="calibre3">NEJM</i> 1999;341:625)</span></p>
<p class="bl1">Support w/ inotropes or mechanical circulatory support to keep CI &gt;2</p>
<p class="bl2"><b class="calibre4">Intraaortic balloon pump (IABP)</b> counterpulsation offers ~0.5 L/min CO and ↑ coronary perfusion, but no survival benefit if early revasc <span class="s1r">(<i class="calibre3">NEJM</i> 2012;367:1287)</span></p>
<p class="bl2"><b class="calibre4">Axial flow pumps (eg, Impella)</b> offer up to 3–5 L/min CO, but no data that improves clinical outcomes <span class="s1r">(<i class="calibre3">JACC</i> 2017;69:278)</span></p>
<p class="h2a"><b class="calibre4">IMI complications</b> <span class="s">(<i class="calibre3">Circ</i> 1990;81:401; <i class="calibre3">NEJM</i> 1994;330:1211; <i class="calibre3">JACC</i> 2003;41:1273)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Heart block:</b> ~20%, occurs in part because RCA typically supplies AV node</p>
<p class="bl1">40% on present., 20% w/in 24 h, rest by 72 h; high-grade AVB can develop abruptly</p>
<p class="bl1">Rx: atropine, epi, aminophylline (100 mg/min × 2.5 min), temp pacing wire</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">RV infarct:</b> proximal RCA occlusion → ↓ flow to RV marginals</p>
<p class="bl1">Angiographically present in 30–50% of cases, but only ~<sup class="calibre15">1</sup>/<sub class="calibre8">2</sub> clinically significant</p>
<p class="bl1">HoTN; ↑ JVP, ⊕ Kussmaul’s; ≥1 mm STE in V<sub class="calibre8">4</sub>R; RA/PCWP ≥0.8; RV dysfxn on TTE</p>
<p class="bl1">Rx: optimize preload (RA goal 10–14 mmHg; <i class="calibre3">BHJ</i> 1990;63:98); ↑ contractility (dobutamine); maintain AV synchrony (pacing as necessary); reperfusion <span class="s1r">(<i class="calibre3">NEJM</i> 1998;338:933)</span>; mechanical support (IABP or RVAD); pulmonary vasodilators (eg, inhaled NO)</p>
<p class="h2a"><b class="calibre4">Mechanical complications</b> <span class="s">(incid.</span> &lt;<span class="s">1% for each; typically occur a few days post-MI)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Free wall rupture:</b> ↑ risk w/ lysis, large MI, ↑ age, ♀, HTN; p/w PEA or hypoTN, pericardial sx, tamponade; Rx: volume resusc., ? pericardiocentesis, inotropes, <b class="calibre4">surgery</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">VSD:</b> large MI in elderly; AMI → apical VSD, IMI → basal septum; 90% w/ harsh murmur ± thrill <span class="s1r">(<i class="calibre3">NEJM</i> 2002;347:1426)</span>; Rx: diuretics, vasodil., inotropes, IABP, <b class="calibre4">surgery</b>, perc. closure</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Papillary muscle rupture:</b> more common after IMI (PM pap m. supplied by PDA alone) than AMI (AL supplied by OMs &amp; diags); 50% w/ new murmur; ↑ <i class="calibre3">v</i> wave in PCWP tracing; asymmetric pulmonary edema on CXR. Rx: diuretics, vasodilators, IABP, <b class="calibre4">surgery</b>.</p>
<p class="h2a"><a id="page_1-11" class="calibre1"></a><b class="calibre4">Arrhythmias post-MI</b> <span class="s">(treat all per ACLS protocols if unstable or symptomatic)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">AF</b> (10–16% incidence): βB or amio, ± digoxin (particularly if HF), heparin</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">VT/VF:</b> lido or amio × 6–24 h, then reassess; ↑ βB as tol., replete K &amp; Mg, r/o ischemia;</p>
<p class="bl1">VT &lt;48 h post-MI does <i class="calibre3">not</i> worsen prognosis; &gt;48 h, consider ICD (see below)</p>
<p class="bl"><span class="sbl">•</span> Accelerated idioventricular rhythm (AIVR): slow VT (&lt;100 bpm), often seen after</p>
<p class="bl1">successful reperfusion; typically asx, self-terminates, and does not require treatment</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Backup transcutaneous <i class="calibre3">or</i> transvenous pacing</b> if: 2° AVB type II; BBB + AVB</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Transvenous pacing</b> if: 3° AVB; new BBB + 2° AVB type II; alternating LBBB/RBBB</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre29"/>
<col class="calibre17"/>
<col class="calibre27"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">Other Post-MI Complications</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Complication</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Clinical Features</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Treatment</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">LV thrombus</b></p></td>
<td class="bg0-br"><p class="tab">~30% incid. (espec lg antero-apical MI)</p></td>
<td class="bg0-b"><p class="tab">Anticoagulate × 3–6 mo</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Ventricular aneurysm</b></p></td>
<td class="bg0-br"><p class="tab">Noncontractile outpouching of LV; 8–15% incid. (espec ant); persist STE</p></td>
<td class="bg0-b"><p class="tab">Surgery or perc repair if HF, thromboemboli, arrhythmia</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Ventricular pseudoaneurysm</b></p></td>
<td class="bg0-br"><p class="tab">Rupture (narrow neck) → sealed by thrombus and pericardium (esp in inf).</p></td>
<td class="bg0-b"><p class="tab">Urgent surgery (or percutaneous repair)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Pericarditis</b></p></td>
<td class="bg0-br"><p class="tab">10–20% incid.; 1–4 d post-MI ⊕ pericardial rub; ECG ∆s rare</p></td>
<td class="bg0-b"><p class="tab">High-dose ASA, colchicine, narcotics; minimize anticoag</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Dressler’s syndrome</b></p></td>
<td class="bg0-r"><p class="tab">&lt;4% incid.; 2–10 wk post-MI fever, pericarditis, pleuritis</p></td>
<td class="bg"><p class="tab">High-dose aspirin, NSAIDs</p></td>
</tr>
</table>
<p class="h2a"><b class="calibre4">Prognosis</b></p>
<p class="bl"><span class="sbl">•</span> In registries, in-hospital mortality is 6% w/ reperfusion Rx (lytic or PCI) and ~20% w/o</p>
<p class="bl"><span class="sbl">•</span> TIMI Risk Score for STEMI (includes age, time to Rx, anterior MI or LBBB, Killip class, tachycardia, HoTN) defines 30-d mortality after STEMI <span class="s1r">(<i class="calibre3">JAMA</i> 2001;286:1356)</span></p>
<p class="h">C<small class="calibre30">HECKLIST AND</small> L<small class="calibre30">ONG</small>-T<small class="calibre30">ERM</small> P<small class="calibre30">OST</small>-ACS M<small class="calibre30">ANAGEMENT</small></p>
<p class="h2a"><b class="calibre4">Risk stratification</b></p>
<p class="bl"><span class="sbl">•</span> Stress test if anatomy undefined; consider stress if signif residual CAD post-PCI of culprit</p>
<p class="bl"><span class="sbl">•</span> Assess LVEF prior to d/c; EF ↑ ~6% in STEMI over 6 mo <span class="s1r">(<i class="calibre3">JACC</i> 2007;50:149)</span></p>
<p class="h2a"><b class="calibre4">Medications (barring contraindications)</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Aspirin:</b> 81 mg daily (no clear benefit to higher doses)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">P2Y<sub class="calibre8">12</sub> inhib</b> (ticagrelor or prasugrel preferred over clopi): treat for <i class="calibre3">at least</i> 12 mo</p>
<p class="bl1">Prolonged Rx &gt;12 mo → ↓ MACE &amp; CV death, ↑ in bleeding, but no ↑ ICH. Beyond 1<sup class="calibre15">st</sup> 12 mo, ticag 60 bid preferred to 90, b/c better tolerability <span class="s1r">(<i class="calibre3">NEJM</i> 2015;372:1791; <i class="calibre3">EHJ</i> 2016;37:390)</span>.</p>
<p class="bl1">PPIs ↓ GI complic; some PPIs ↓ antiplt effect, but no clear ↑ in CV risk <span class="s1r">(<i class="calibre3">NEJM</i> 2010;363:1909)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">β-blocker:</b> 23% ↓ mortality after MI</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">LDL-C</b> management: benefit with lowering LDL-C to &lt;&lt;40 mg/dl <span class="s1r">(<i class="calibre3">Lancet</i> 2017;390:1962)</span></p>
<p class="bl1"><i class="calibre3">Statin</i>: high-intensity (eg, atorva 80 mg, PROVE-IT TIMI 22, <i class="calibre3">NEJM</i> 2004;350:1495)</p>
<p class="bl1"><i class="calibre3">Ezetimibe</i>: ↓ CV events when added to statin (IMPROVE-IT, <i class="calibre3">NEJM</i> 2015;372:1500)</p>
<p class="bl1"><i class="calibre3">PCSK9 inhibitor</i>: ↓ CV events when added to statin <span class="s1r">(<i class="calibre3">NEJM</i> 2017;376:1713; 2018;379:2097)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">ACEI:</b> lifelong if HF, ↓ EF, HTN, DM; 4–6 wk or at least until hosp. d/c in all STEMI</p>
<p class="bl1">? long-term benefit in CAD w/o HF <span class="s1r">(<i class="calibre3">NEJM</i> 2000;342:145 &amp; 2004;351:2058; <i class="calibre3">Lancet</i> 2003;362:782)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Aldosterone antag:</b> 15% ↓ mort. if EF &lt;40% &amp; either s/s of HF or DM <span class="s1r">(<i class="calibre3">NEJM</i> 2003;348:1309)</span></p>
<p class="bl"><span class="sbl">•</span> Nitrates: standing if symptomatic; SL NTG prn for all</p>
<p class="bl"><span class="sbl">•</span> Ranolazine: ↓ recurrent ischemia, no impact on CVD/MI <span class="s1r">(<i class="calibre3">JAMA</i> 2007;297:1775)</span></p>
<p class="bl"><span class="sbl">•</span> Oral anticoag: if needed (eg, AF, LV thrombus), consider DOAC instead of warfarin; some data for reduced-dose DOAC but unclear if ischemic stroke prevention adeq. <span class="s1r">(<i class="calibre3">NEJM</i> 2016; 375:2423 &amp; 2017;377:1513)</span>. Clopi (not ticag or pras). Stopping ASA (? after ~1 wk) ↓ bleed risk by 40–50%, but trend small ↑ MI &amp; stent thromb. <span class="s1r">(<i class="calibre3">Lancet</i> 2013;381:1107; <i class="calibre3">NEJM</i> 2019;379:1509)</span>.</p>
<p class="bl"><span class="sbl">•</span> In Pts w/o indic. for anticoag, once DAPT completed, rivaroxaban 2.5 bid + ASA ↓ MACE &amp; CV death and ↑ bleeding vs. ASA monoRx <span class="s1r">(<i class="calibre3">NEJM</i> 2017;377:1319)</span></p>
<p class="h2a"><b class="calibre4">ICD</b> <span class="s">(<i class="calibre3">NEJM</i> 2008;359:2245; <i class="calibre3">Circ</i> 2014;130:94)</span></p>
<p class="bl"><span class="sbl">•</span> Sust. VT/VF &gt;2 d post-MI w/o revers. isch; ? ↓ death w/ <i class="calibre3">wearable</i> defib <span class="s1r">(<i class="calibre3">NEJM</i> 2018;379:1205)</span></p>
<p class="bl"><span class="sbl">•</span> 1° prevention of SCD if post-MI EF ≤30–40% (NYHA II–III) or ≤30–35% (NYHA I); wait 40 d after MI <span class="s1r">(<i class="calibre3">NEJM</i> 2004;351:2481 &amp; 2009;361:1427)</span></p>
<p class="h2a"><b class="calibre4">Risk factors and lifestyle modifications</b> <span class="s">(<i class="calibre3">Circ</i> 2014;129(Suppl 2):S1 &amp; S76)</span></p>
<p class="bl"><span class="sbl">•</span> Low chol. (&lt;200 mg/d) &amp; fat (&lt;7% saturated) diet; ? Ω-3 FA.</p>
<p class="bl"><span class="sbl">•</span> LDL-C at least &lt;70 mg/dl (&amp; ≥50% ↓ in LDL-C) <span class="s1r">(<i class="calibre3">Circ</i> 2019;139:e1082)</span></p>
<p class="bl"><span class="sbl">•</span> BP &lt;130/80 <span class="s1r">(<i class="calibre3">JACC</i> 2018;71:e127)</span>; quit smoking</p>
<p class="bl"><span class="sbl">•</span> If diabetic, tailor HbA1c goal based on Pt (avoid TZDs and saxa if HF); GLP1-RA &amp; SGLT2i ↓ MACE &amp; SGLT2i ↓ hospitalization for HF <span class="s1r">(<i class="calibre3">Lancet</i> 2019;393:31 &amp; <i class="calibre3">Circ</i> 2019;139:2022)</span></p>
<p class="bl"><span class="sbl">•</span> Exercise (30–60′ 5–7×/wk) 1–2 wk after revasc; cardiac rehab; BMI goal 18.5–24.9 kg/m<sup class="calibre15">2</sup></p>
<p class="bl"><span class="sbl">•</span> Influenza &amp; <i class="calibre3">S. pneumo</i> vaccines <span class="s1r">(<i class="calibre3">JAMA</i> 2013;310:1711; <i class="calibre3">NEJM</i> 2018;378:345)</span>; ✔ for depression</p>
<h2 class="ct"><a id="h6" class="calibre7"></a><a id="page_1-12" class="calibre7"></a><a href="part0002.html#rh10" class="calibre7">PA CATHETER AND TAILORED THERAPY</a></h2>
<p class="h2a"><b class="calibre4">Rationale</b></p>
<p class="bl"><span class="sbl">•</span> Cardiac output (CO) = SV × HR; optimize SV (and thereby CO) by manipulating preload/ LVEDV (w/ IVF, diuretics), contractility (w/ inotropes), &amp; afterload (w/ vasodilators)</p>
<p class="bl"><span class="sbl">•</span> Balloon at catheter tip inflated → floats into “wedge” position. Column of blood extends from tip of catheter, through pulm venous circulation to a point just prox to LA. Under conditions of no flow, PCWP ≈ LA pressure ≈ LVEDP, which is proportional to LVEDV.</p>
<p class="bl"><span class="sbl">•</span> Situations in which these basic assumptions fail:</p>
<p class="bl1r"><span class="sbl1r">(1)</span> Catheter tip not in West lung zone 3 (and ∴ PCWP = alveolar pressure ≠ LA pressure); clues include lack of <i class="calibre3">a</i> &amp; <i class="calibre3">v</i> waves and if PA diastolic pressure &lt; PCWP</p>
<p class="bl1r"><span class="sbl1r">(2)</span> PCWP &gt; LA pressure (eg, mediastinal fibrosis, pulmonary VOD, PV stenosis)</p>
<p class="bl1r"><span class="sbl1r">(3)</span> Mean LA pressure &gt; LVEDP (eg, MR, MS)</p>
<p class="bl1r"><span class="sbl1r">(4)</span> ∆ LVEDP-LVEDV relationship (ie, abnl compliance, ∴ “nl” LVEDP may not be optimal)</p>
<p class="h2a"><b class="calibre4">Indications</b> <span class="s">(<i class="calibre3">Circ</i> 2009;119:e391; <i class="calibre3">NEJM</i> 2013;369:e35)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Diagnosis and evaluation</b></p>
<p class="bl1">Ddx of shock (cardiogenic vs. distributive; espec if trial of IVF failed or is high risk) and of pulmonary edema (cardiogenic vs. not; espec if trial of diuretic failed or is high risk)</p>
<p class="bl1">Evaluation of CO, intracardiac shunt, pulm HTN, MR, tamponade, cardiorenal syndrome</p>
<p class="bl1">Evaluation of unexplained dyspnea (PAC during provocation w/ exercise, vasodilator)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Therapeutics</b> <span class="s1r">(<i class="calibre3">Circ</i> 2006;113:1020)</span></p>
<p class="bl1">Tailored therapy to optimize PCWP, SV, S<sub class="calibre8">MV</sub>O<sub class="calibre8">2</sub>, RAP, PVR in heart failure or shock</p>
<p class="bl1">Guide to vasodilator therapy (eg, inhaled NO, nifedipine) in PHT, RV infarction</p>
<p class="bl1">Guide periop mgmt in some high-risk Pts, candidacy for mech circ support &amp; transplant</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Contraindications</b></p>
<p class="bl1"><b class="calibre4">Absolute:</b> right-sided endocarditis, thrombus/mass or mechanical valve; proximal PE</p>
<p class="bl1"><b class="calibre4">Relative:</b> coagulopathy (reverse), recent PPM or ICD (place under fluoroscopy), LBBB (~5% risk of RBBB → CHB, place under fluoro), bioprosthetic R-sided valve</p>
<p class="h2a"><b class="calibre4">Efficacy concerns</b> <span class="s">(<i class="calibre3">NEJM</i> 2006;354:2213; <i class="calibre3">JAMA</i> 2005;294:1664)</span></p>
<p class="bl"><span class="sbl">•</span> No benefit to routine PAC use in high-risk surgery, sepsis, ARDS</p>
<p class="bl"><span class="sbl">•</span> No benefit in decompensated HF <span class="s1r">(<i class="calibre3">JAMA</i> 2005;294:1625)</span>; untested in cardiogenic shock</p>
<p class="bl"><span class="sbl">•</span> But: ~<sup class="calibre15">1</sup>/<sub class="calibre8">2</sub> of <i class="calibre3">clinical</i> CO &amp; PCWP estimates incorrect; CVP &amp; PCWP not well correl.; ∴ use PAC to (a) answer hemodynamic ? and then remove, or (b) manage cardiogenic shock</p>
<p class="h2a"><b class="calibre4">Placement</b> <span class="s">(<i class="calibre3">NEJM</i> 2013;369:e35)</span></p>
<p class="bl"><span class="sbl">•</span> Insertion site: <b class="calibre4">R internal jugular</b> or <b class="calibre4">L subclavian veins</b> for “anatomic” flotation into PA</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Inflate</b> balloon (max 1.5 mL) when <b class="calibre4">advancing</b> and to <b class="calibre4">measure PCWP</b></p>
<p class="bl"><span class="sbl">•</span> Use resistance to inflation and pressure tracing to avoid overinflation &amp; risk of PA rupture</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Deflate</b> the balloon when <b class="calibre4">withdrawing</b> and at all other times</p>
<p class="bl"><span class="sbl">•</span> CXR should be obtained after placement to assess for catheter position and PTX</p>
<p class="bl"><span class="sbl">•</span> If catheter cannot be floated (i.e., severe TR, RV dilatation), consider fluoroscopic guidance</p>
<p class="h2a"><b class="calibre4">Complications</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Central venous access:</b> pneumo/hemothorax (~1%), arterial puncture (if inadvertent cannulation w/ dilation → surgical/endovasc eval), air embolism, thoracic duct injury</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Advancement:</b> atrial or ventricular arrhythmias (3% VT; 20% NSVT and &gt;50% PVC), RBBB (5%), catheter knotting, cardiac perforation/tamponade, PA rupture</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Maintenance:</b> infection (espec if catheter &gt;3 d old), thrombus, pulm infarction (≤1%), valve/chordae damage, PA rupture/pseudoaneurysm (espec w/ PHT), balloon rupture</p>
<p class="h2a"><b class="calibre4">Intracardiac pressures</b></p>
<p class="bl"><span class="sbl">•</span> Transmural pressure (≈ preload) = measured intracardiac pressure – intrathoracic pressure</p>
<p class="bl"><span class="sbl">•</span> Intrathoracic pressure (usually slightly ⊖) is transmitted to vessels and heart</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Always measure intracardiac pressure at end-expiration</b>, when intrathoracic pressure closest to 0 (“high point” in spont. breathing Pts; “low point” in Pts on ⊕ pressure vent.)</p>
<p class="bl"><span class="sbl">•</span> If ↑ intrathoracic pressure (eg, PEEP), measured PCWP <i class="calibre3">overestimates</i> true transmural pressures. Can approx by subtracting ~1/2 PEEP (× ¾ to convert cm H<sub class="calibre8">2</sub>O to mmHg).</p>
<p class="bl"><span class="sbl">•</span> PCWP: LV preload best estimated at <i class="calibre3">a</i> wave; risk of pulmonary edema from avg PCWP</p>
<p class="h2a"><b class="calibre4">Cardiac output</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Thermodilution:</b> saline injected in RA or prox thermal filament. ∆ in temp over time measured at thermistor (in PA) used to calc CO. Inaccurate if ↓ CO, sev TR, or shunt.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Fick method:</b> O<sub class="calibre8">2</sub> consumption <img class="mid" src="../images/00011.jpeg" alt=""/> (L/min) = CO (L/min) × ∆ arteriovenous O<sub class="calibre8">2</sub> content</p>
<p class="bl1">∴ <b class="calibre4">CO</b> = <img class="mid" src="../images/00012.jpeg" alt=""/><b class="calibre4">/ C(a-v)O<sub class="calibre8">2</sub></b></p>
<p class="bl1"><img class="mid" src="../images/00011.jpeg" alt=""/> ideally measured (esp. if ↑ metab demands), but freq estimated (125 mL/min/m<sup class="calibre15">2</sup>)</p>
<p class="bl1">C(a-v)O<sub class="calibre8">2</sub> = [10 × 1.36 mL O<sub class="calibre8">2</sub>/g of Hb × Hb g/dL × (S<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub> – S<sub class="calibre8">MV</sub>O<sub class="calibre8">2</sub>)]. <i class="calibre3">S</i><sub class="calibre8">MV</sub><i class="calibre3">O</i><sub class="calibre8">2</sub> <i class="calibre3">is key var that</i> ∆<i class="calibre3">s.</i></p>
<p class="bl1">If S<sub class="calibre8">MV</sub>O<sub class="calibre8">2</sub> &gt;80%, consider if the PAC is “wedged” (ie, pulm vein sat), L→R shunt, impaired O<sub class="calibre8">2</sub> utilization (severe sepsis, cyanide, carbon monoxide), ↑↑ FiO<sub class="calibre8">2</sub>.</p>
<p class="imagef"><a id="page_1-13" class="calibre1"></a><img src="../images/00013.jpeg" alt="" class="calibre2"/></p>
<p class="fn">PCWP waveform abnormalities: large <i class="calibre3">a</i> wave → ? mitral stenosis; large <i class="calibre3">v</i> wave → ? mitral regurgitation; blunted <i class="calibre3">y</i> descent → ? tamponade; steep <i class="calibre3">x</i> &amp; <i class="calibre3">y</i> descents → ? constriction.</p>
<p class="imagef"><img src="../images/00014.jpeg" alt="" class="calibre2"/></p>
<p class="fn">Surrogates: RA ≈ JVP (1 mmHg = 1.36 cm H<sub class="calibre13">2</sub>O); pulmonary edema on CXR implies ↑ PCWP; UOP ∝ CO (barring AKI); delayed capillary refill (ie, &gt;2–3 sec) implies ↑ SVR</p>
<p class="h2a"><b class="calibre4">Tailored therapy in cardiogenic shock</b> <span class="s">(<i class="calibre3">Circ</i> 2009;119:e391)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Goals:</b> optimize both MAP and CO while ↓ risk of pulmonary edema</p>
<p class="bl1">MAP = CO × SVR; CO = HR × SV (which depends on preload, afterload, and contractility)</p>
<p class="bl1">pulmonary edema when PCWP &gt;20–25 (↑ levels may be tolerated in chronic HF)</p>
<p class="bl1">hepatic and renal congestion when CVP/RAP &gt;15 mmHg</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Optimize preload</b> = LVEDV ≈ LVEDP ≈ LAP ≈ PCWP <span class="s1r">(<i class="calibre3">NEJM</i> 1973;289:1263)</span></p>
<p class="bl1">goal <b class="calibre4">PCWP</b> ~<b class="calibre4">14–18 in acute MI</b>, <b class="calibre4">≤14 in acute decompensated HF</b></p>
<p class="bl1">optimize in individual Pt by measuring SV w/ different PCWP to create Starling curve</p>
<p class="bl1">↑ by giving NS (albumin w/o clinical benefit over NS; PRBC if significant anemia)</p>
<p class="bl1">↓ by diuresis (qv), ultrafiltration or dialysis if refractory to diuretics</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Optimize afterload</b> ≈ wall stress during LV ejection = [(~SBP × radius) / (2 × wall thick.)] and ∴ ∝ MAP and ∝ SVR = (MAP – CVP / CO); goals: <b class="calibre4">MAP</b> &gt;<b class="calibre4">60</b>, <b class="calibre4">SVR 800–1200</b></p>
<p class="bl1">MAP &gt;60 &amp; SVR ↑: vasodilators (eg, nitroprusside, NTG, ACEI, hydral.) or wean pressors</p>
<p class="bl1">MAP &lt;60 &amp; SVR ↑ (&amp; ∴ CO ↓): temporize w/ pressors until can ↑ CO (see below)</p>
<p class="bl1">MAP &lt;60 &amp; SVR low/nl (&amp; ∴ inappropriate vasoplegia): vasopressors (eg, norepinephrine [α, β], dopamine [D, α, β], phenylephrine [α] or vasopressin [V<sub class="calibre8">1</sub>] if refractory); better outcomes w/ norepi than dopa even in cardiogenic shock <span class="s1r">(<i class="calibre3">NEJM</i> 2010;362:779)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Optimize contractility</b> ∝ CO for given preload &amp; afterload; <b class="calibre4">goal CI</b> = <b class="calibre4">(CO / BSA) &gt;2.2</b></p>
<p class="bl1">if too low despite optimal preload &amp; vasodilators (as MAP permits):</p>
<p class="bl1">⊕ <i class="calibre3">inotropes:</i> eg, dobutamine (mod inotrope &amp; mild vasodilator) or milrinone (strong inotrope &amp; vasodilator, incl pulm), both proarrhythmic, or epi (strong inotrope &amp; pressor)</p>
<p class="bl1"><i class="calibre3">mech circulatory support (L/min):</i> IABP (0.5), Impella (2–5), TandemHeart (5), VAD (L-sided, R-sided or both; temp or perm; 10) or ECMO (6) <span class="s1r">(<i class="calibre3">JACC</i> 2015;65:e7 &amp; 2542)</span></p>
<h2 class="ct"><a id="h7" class="calibre7"></a><a id="page_1-14" class="calibre7"></a><a href="part0002.html#rh11" class="calibre7">HEART FAILURE</a></h2>
<p class="h2a"><b class="calibre4">Definitions</b> <span class="s">(<i class="calibre3">Braunwald’s Heart Disease</i>, 11th ed., 2019)</span></p>
<p class="bl"><span class="sbl">•</span> Failure of heart to pump blood forward at rate sufficient to meet metabolic demands of peripheral tissues, or ability to do so only at abnormally high cardiac filling pressures</p>
<p class="bl"><span class="sbl">•</span> Low output (↓ cardiac output) vs. high output (↑ stroke volume ± ↑ cardiac output)</p>
<p class="bl"><span class="sbl">•</span> Left-sided (pulmonary edema) vs. right-sided (↑ JVP, hepatomegaly, peripheral edema)</p>
<p class="bl"><span class="sbl">•</span> Backward (↑ filling pressures, congestion) vs. forward (impaired systemic perfusion)</p>
<p class="bl"><span class="sbl">•</span> Systolic (inability to expel sufficient blood) vs. diastolic (failure to relax and fill normally)</p>
<p class="bl"><span class="sbl">•</span> Reduced (HFrEF, EF &lt;40%), mid-range (HFmrEF, EF 40–49%), &amp; preserved (HFpEF, EF &gt;50%); combination of systolic and diastolic dysfxn may occur regardless of EF</p>
<p class="capf"><b class="calibre4">Figure 1-3</b> Approach to left-sided heart failure</p>
<p class="image"><img src="../images/00015.jpeg" alt="" class="calibre2"/></p>
<p class="h2a"><b class="calibre4">History</b></p>
<p class="bl"><span class="sbl">•</span> Low output: fatigue, weakness, exercise intolerance, ∆ MS, anorexia</p>
<p class="bl"><span class="sbl">•</span> Congestive: left-sided → dyspnea, orthopnea, paroxysmal nocturnal dyspnea</p>
<p class="bl3">right-sided → peripheral edema, RUQ discomfort, bloating, satiety</p>
<p class="h2a"><b class="calibre4">Functional classification</b> <span class="s">(New York Heart Association class)</span></p>
<p class="bl"><span class="sbl">•</span> Class I: no sx w/ ordinary activity; class II: sx w/ ordinary activity; class III: sx w/ minimal activity; class IV: sx at rest</p>
<p class="h2a"><b class="calibre4">Physical exam</b> <span class="s">(“2-minute” hemodynamic profile; <i class="calibre3">JAMA</i> 1996;275:630 &amp; 2002;287:628)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Congestion (“dry” vs. “wet”):</b> ↑ JVP (~80% of the time JVP &gt;10 → PCWP &gt;22)</p>
<p class="bl1">⊕ hepatojugular reflux: ≥4 cm ↑ in JVP for ≥15 sec w/ abdominal pressure Se/Sp 73/87% for RA &gt;8 and Se/Sp 55/83% for PCWP &gt;15 <span class="s1r">(<i class="calibre3">AJC</i> 1990;66:1002)</span></p>
<p class="bl1">Abnl Valsalva response: square wave (↑ SBP w/ strain), no overshoot (no ↑ BP after strain)</p>
<p class="bl1">S<sub class="calibre8">3</sub> (in Pts w/ HF → ~40% ↑ risk of HF hosp. or pump failure death; <i class="calibre3">NEJM</i> 2001;345:574)</p>
<p class="bl1">rales, dullness at base 2° pleural effus. <span class="s1r">(<i class="calibre3">often absent</i> in chronic HF due to lymphatic compensation)</span> ± hepatomegaly, ascites and jaundice, peripheral edema</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Perfusion (“warm” <i class="calibre3">vs.</i> “cold”)</b></p>
<p class="bl1">narrow pulse pressure (&lt;25% of SBP) → CI &lt;2.2 (91% Se, 83% Sp; <i class="calibre3">JAMA</i> 1989;261:884);</p>
<p class="bl1">soft S<sub class="calibre8">1</sub> (↓ dP/dt), pulsus alternans, cool &amp; pale extremities, ↓ UOP, muscle atrophy</p>
<p class="bl"><span class="sbl">•</span> ± Other: Cheyne-Stokes resp., abnl PMI (diffuse, sustained or lifting depending on cause of HF), S<sub class="calibre8">4</sub> (diast. dysfxn), murmur (valvular dis., ↑ MV annulus, displaced papillary muscles)</p>
<p class="h2a"><b class="calibre4">Evaluation for the presence of heart failure</b></p>
<p class="bl"><span class="sbl">•</span> CXR (see Radiology insert): pulm edema, pleural effusions ± cardiomegaly, cephalization, Kerley B-lines; lung U/S better than CXR (PPV &amp; NPV 92% vs. 77%; <i class="calibre3">Chest</i> 2015;148:202)</p>
<p class="bl"><span class="sbl">•</span> BNP/NT-proBNP can help exclude HF; levels ↑ w/ age, renal dysfxn, AF; ↓ w/ obesity Se ≥95%, Sp: ~50%, PPV ~65%, NPV ≥ 94% for HF in Pts p/w SOB <span class="s1r">(<i class="calibre3">BMJ</i> 2015;350:h910)</span></p>
<p class="bl"><span class="sbl">•</span> Evidence of ↓ organ perfusion: ↑ Cr, ↓ Na, abnl LFTs</p>
<p class="bl"><span class="sbl">•</span> Echo (see inserts): ↓ EF &amp; ↑ chamber size → systolic dysfxn; hypertrophy, abnl MV inflow, abnl tissue Doppler → ? diastolic dysfxn; abnl valves or pericardium; ↑ estimated RVSP</p>
<p class="bl"><span class="sbl">•</span> PA catheterization: ↑ PCWP, ↓ CO, and ↑ SVR (in low-output failure)</p>
<p class="h2a"><a id="page_1-15" class="calibre1"></a><b class="calibre4">Evaluation for the potential causes of heart failure</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">ECG:</b> evidence for CAD, LVH, LAE, heart block or low voltage (? infiltrative CMP/DCMP)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">TTE:</b> LV &amp; RV size &amp; fxn, valve abnl (cause or consequence?), infiltrative or pericardial dis.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cardiac MRI:</b> distinguishes ischemic vs. nonischemic and can help determine etiol. of latter</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Coronary angio</b> (or noninvasive imaging, eg, CT angio); if no CAD, w/u for NICM</p>
<p class="h2a"><b class="calibre4">Precipitants of acute heart failure</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Dietary indiscretion or medical nonadherence</b> (~40% of cases)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Myocardial ischemia or infarction</b> (~10–15% of cases); myocarditis</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Renal failure</b> (acute, progression of CKD, or insufficient dialysis) → ↑ preload</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Hypertensive crisis (incl. from RAS)</b>, <b class="calibre4">worsening AS</b> → ↑ left-sided afterload</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Drugs</b> (βB, CCB, NSAIDs, TZDs), <b class="calibre4">chemo</b> (anthracyclines, trastuzumab), or <b class="calibre4">toxins</b> (EtOH)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Arrhythmias; acute valvular dysfxn</b> (eg, endocarditis), espec mitral or aortic regurgitation</p>
<p class="bl"><span class="sbl">•</span> COPD/PE → ↑ right-sided afterload; extreme stress; anemia; systemic infxn; thyroid dis.</p>
<p class="image1"><img src="../images/00016.jpeg" alt="" class="calibre2"/></p>
<p class="h2a"><b class="calibre4">Rx of acute decompens. HF</b> <span class="s">(<i class="calibre3">NEJM</i> 2017;377:1964)</span></p>
<p class="bl"><span class="sbl">•</span> Assess degree of congestion &amp; adequacy of perfusion</p>
<p class="bl"><span class="sbl">•</span> For <b class="calibre4">congestion: “LMNOP”</b></p>
<p class="bl1"><b class="calibre4">L</b>asix IV; total daily dose 2.5× usual daily PO dose → ↑ UOP, but transient ↑ in Cr vs. 1× usual dose; ∅ clear diff between contin. gtt vs. q12h <span class="s1r">(<i class="calibre3">NEJM</i> 2011;364:797)</span></p>
<p class="bl1"><b class="calibre4">M</b>orphine (↓ sx, venodilator, ↓ afterload)</p>
<p class="bl1"><b class="calibre4">N</b>itrates (venodilator)</p>
<p class="bl1"><b class="calibre4">O</b>xygen ± noninvasive vent (↓ sx, ↑ P<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub>; no ∆ mortality; see “Mechanical Ventilation”)</p>
<p class="bl1"><b class="calibre4">P</b>osition (sitting up &amp; legs dangling over side of bed → ↓ preload)</p>
<p class="bl"><span class="sbl">•</span> For <b class="calibre4">low perfusion</b>, see below</p>
<p class="bl"><span class="sbl">•</span> Adjustment of oral meds</p>
<p class="bl1">ACEI/ARB: hold if HoTN, consider ∆ to hydralazine &amp; nitrates if renal decompensation</p>
<p class="bl1">βB: reduce dose by at least <sup class="calibre15">1</sup>/<sub class="calibre8">2</sub> if mod HF, d/c if severe HF and/or need inotropes</p>
<p class="h2a"><b class="calibre4">Treatment of acute advanced heart failure</b> <span class="s">(<i class="calibre3">Circ</i> 2009;119:e391)</span></p>
<p class="bl"><span class="sbl">•</span> Consider PAC if not resp to Rx, unsure re: vol status, HoTN, ↑ Cr, need inotropes</p>
<p class="bl"><span class="sbl">•</span> Tailored Rx w/ PAC (qv); goals of MAP &gt;60, CI &gt;2.2 (MVO<sub class="calibre8">2</sub> &gt;60%), SVR &lt;800, PCWP &lt;18</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">IV vasodilators:</b> NTG, nitroprusside (risk of coronary steal if CAD)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Inotropes</b> (properties in addition to ↑ inotropy listed below)</p>
<p class="bl1">dobutamine: vasodilation at doses ≤5 µg/kg/min; mild ↓ PVR; desensitization over time</p>
<p class="bl1">dopamine: splanchnic vasodil. → ↑ GFR &amp; natriuresis; vasoconstrictor at ≥5 µg/kg/min</p>
<p class="bl1">milrinone: prominent systemic &amp; pulmonary vasodilation; ↓ dose by 50% in renal failure</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Mechanical circulatory support</b> (also see “Tailored Therapy;” <i class="calibre3">JACC</i> 2015;65:e7 &amp; 2542)</p>
<p class="bl1"><i class="calibre3">Temporary:</i> bridge to recovery, transplant, or durable MCS; periprocedural support</p>
<p class="bl2">Intra-aortic balloon pump (IABP): inflates in diastole &amp; deflates in systole to ↓ impedance to LV ejection, ↓ myocardial O<sub class="calibre8">2</sub> demand &amp; ↑ coronary perfusion. +0.5 L/min CO</p>
<p class="bl2">Axial flow pumps (eg, Impella): Archimedes screw principle in LV; +2.5–5 L/min</p>
<p class="bl2">Extracorporeal centrifugal pumps: TandemHeart (+5 L/min, percutaneous) &amp; CentriMag (10 L/min, surgical)</p>
<p class="bl2">Extracorporeal membrane oxygenation (ECMO): 6 L/min <span class="s1r">(<i class="calibre3">JACC HF</i> 2018;6:503)</span></p>
<p class="bl1"><i class="calibre3">Durable:</i> surgically placed LVAD ± RVAD as bridge to sufficient recovery (in 5–50% of niCMP; <i class="calibre3">JACC</i> 2017;69:1924), to transplant or as destination Rx (&gt;50% ↓ 1-y mort. vs. med Rx; <i class="calibre3">NEJM</i> 2001;345:1435 &amp; 2009;361:2241). Fully magnetically levitated centrifugal flow pump (HeartMate 3) ↓ stroke or re-op vs. axial flow HeartMate II <span class="s1r">(<i class="calibre3">NEJM</i> 2019;380:1618)</span>; HeartWare LVAD another centrifugal option <span class="s1r">(<i class="calibre3">NEJM</i> 2017;376:451)</span>.</p>
<p class="bl"><span class="sbl">•</span> Cardiac transplantation: ~2500/yr in U.S. 10% mort. in 1<sup class="calibre15">st</sup> y, median survival ~10 y</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre31"/>
<col class="calibre16"/>
<col class="calibre32"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">Recommended Chronic Therapy by HF Stage</b> (<span class="tfont"><i class="calibre3">Circ</i> 2009;119:e391</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br" colspan="2"><p class="tab"><b class="calibre4">Stage</b> (not NYHA Class)</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Therapy</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab"><b class="calibre4">A</b></p></td>
<td class="bg0-br"><p class="tab">At risk for HF (eg, HTN, FHx CMP); but asx &amp; w/o struct. heart dis.</p></td>
<td class="bg0-b"><p class="tab">Rx HTN, lipids, DM.</p>
<p class="tab">Stop smoking, EtOH. ↑ exercise.</p>
<p class="tab">ACEI/ARB if HTN/DM/CAD/PAD</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab"><b class="calibre4">B</b></p></td>
<td class="bg0-br"><p class="tab">⊕ Struct. heart dis.</p>
<p class="tab">(eg, CMP, LVH), but asx</p></td>
<td class="bg0-b"><p class="tab">As per stage A + ACEI/ARB &amp; βB if MI/CAD or ↓ EF. ? ICD.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab"><b class="calibre4">C</b></p></td>
<td class="bg0-br"><p class="tab">⊕ Struct. heart dis.</p>
<p class="tab">⊕ Any h/o Sx of HF</p></td>
<td class="bg0-b"><p class="tab">As per stage A + diuretics, ↓ Na. If ↓ EF: ACEI, ARB or ARNI; βB; aldo antag; ICD; ? CRT; nitrate/hydral; dig.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r1"><p class="tab"><b class="calibre4">D</b></p></td>
<td class="bg0-r"><p class="tab">Refractory HF requiring specialized interventions</p></td>
<td class="bg"><p class="tab">All measures for stages A–C. Consider IV inotropes, VAD, transplant, end-of-life care (4-y mortality &gt;50%)</p></td>
</tr>
</table>
<p class="bl"><span class="sbl">•</span> Utility of BNP-guided Rx (inPt and outPt) remains debated <span class="s1r">(<i class="calibre3">Eur Heart J</i> 2014;35:16)</span></p>
<p class="bl"><span class="sbl">•</span> Implantable PA pressure sensor in NYHA III → ~33% ↓ risk of hosp <span class="s1r">(<i class="calibre3">Lancet</i> 2016;387:453)</span></p>
<table class="t-topbot">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><a id="page_1-16" class="calibre1"></a><b class="calibre4">Treatment of Chronic HF with Reduced EF</b> (<span class="tfont1"><i class="calibre3">JACC</i> 2017;70:776</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Diet, exercise</p></td>
<td class="bg0-b"><p class="tab">Na &lt;2 g/d, fluid restriction, exercise training in ambulatory Pts</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">BP</p></td>
<td class="bg0-b"><p class="tab">Goal &lt;130/80 (<span class="tfont"><i class="calibre3">JACC</i> 2018;71:127</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">ACEI</b></p></td>
<td class="bg0-b"><p class="tabh">↓ mortality: 40% in NYHA IV, 16% in NYHA II/III, 20–30% in asx but ↓ EF (<span class="tfont"><i class="calibre3">NEJM</i> 1992;327:685; <i class="calibre3">Lancet</i> 2000;355:1575</span>)</p>
<p class="tabh">High-dose more effic. than low. Watch for ↑ Cr, ↑ K (ameliorate by low-K diet, diuretics, K binders), cough, angioedema.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">ATII receptor blockers (ARBs)</b></p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">Consider as alternative if cannot tolerate ACEI (eg, b/c cough)</i></p>
<p class="tab">Noninferior to ACEI (<span class="tfont"><i class="calibre3">Lancet</i> 2000;355:1582 &amp; 2003;362:772</span>)</p>
<p class="tab">As with ACEI, higher doses more efficacious (<span class="tfont"><i class="calibre3">Lancet</i> 2009;379:1840</span>)</p>
<p class="tab">Adding to ACEI → ↑ risk of ↑ K and ↑ Cr (<i class="calibre3">BMJ</i> 2013;346:f360)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">ARNI</b> (ARB + neprilysin inhib)</p>
<p class="tab"><i class="calibre3">(do not use w/ ACEI, allow 36-h washout)</i></p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">Preferred RAAS inhib in NYHA II-IV</i>. Neutral endopeptidase (NEP, aka neprilysin) degrades natriuretic peptides, bradykinin &amp; angiotensins. Valsartan + sacubitril (NEPi) ↓ CV mort &amp; HF hosp c/w ACEi; ↑ HoTN, AKI (<i class="calibre3">NEJM</i> 2014;371:993 &amp; 2019;380:539). Contraindicated if h/o angioedema.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Hydralazine + nitrates</p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">Consider if cannot tolerate ACEI/ARB or in blacks w/ class III/IV</i></p>
<p class="tab">25% ↓ mort. (<span class="tfont"><i class="calibre3">NEJM</i> 1986;314:1547</span>); infer. to ACEI (<i class="calibre3">NEJM</i> 1991;325:303)</p>
<p class="tab">40% ↓ mort. in blacks on standard Rx (A-HEFT, <i class="calibre3">NEJM</i> 2004;351:2049)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">β<b class="calibre4">-blocker</b></p>
<p class="tab">(data for carvedilol, metoprolol, bisoprolol)</p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">EF will transiently</i> ↓, <i class="calibre3">then</i> ↑<i class="calibre3">. Contraindic. in decompensated HF.</i></p>
<p class="tab">35% ↓ mort. &amp; 40% ↓ rehosp. in NYHA II–IV (<span class="tfont"><i class="calibre3">JAMA</i> 2002;287:883</span>)</p>
<p class="tabh">Carvedilol superior to low-dose metop in 1 trial (<span class="tfont"><i class="calibre3">Lancet</i> 2003;362:7</span>), but meta-analysis suggests no diff between βB (<span class="tfont"><i class="calibre3">BMJ</i> 2013;346:f55</span>).</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Aldosterone antagonists</b></p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">Consider if adeq. renal fxn and w/o hyperkalemia; watch for</i> ↑ <i class="calibre3">K</i></p>
<p class="tab">25–30% ↓ mort. in NYHA II–IV &amp; EF ≤35% (<span class="tfont"><i class="calibre3">NEJM</i> 2011;364:11</span>)</p>
<p class="tab">15% ↓ mort. in HF post-MI, EF ≤40% (EPHESUS, <span class="tfont"><i class="calibre3">NEJM</i> 2003;348:1309</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Cardiac resynch therapy (CRT, qv)</b></p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">Consider if EF</i> ≤<i class="calibre3">35%, LBBB (QRS</i> ≥1<i class="calibre3">30 ms) and symptomatic HF</i></p>
<p class="tab">36% ↓ mort. &amp; ↑ EF in NYHA III–IV (CARE-HF, <span class="tfont"><i class="calibre3">NEJM</i> 2005;352:1539</span>)</p>
<p class="tab">41% ↓ mort. if EF ≤30%, LBBB and NYHA I/II (<span class="tfont"><i class="calibre3">NEJM</i> 2014;370:1694</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">ICD</b> (see “Cardiac Rhythm Mgmt Devices”)</p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">For</i> 1° <i class="calibre3">prevention if EF</i> ≤<i class="calibre3">30–35</i>% or 2° <i class="calibre3">prevention; not if NYHA IV</i></p>
<p class="tab">↓ mort. in ischemic CMP but perhaps only SCD in modern era in niCMP (<span class="tfont"><i class="calibre3">NEJM</i> 2005;352:225 &amp; 2016;375:1221</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Diuretics</p></td>
<td class="bg0-b"><p class="tab">Loop ± thiazides diuretics (sx relief; no mortality benefit)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Digoxin</p></td>
<td class="bg0-b"><p class="tab">23% ↓ HF hosp., no ∆ mort (<i class="calibre3">NEJM</i> 1997;336:525); ? ↑ mort w/ ↑ levels (<span class="tfont"><i class="calibre3">NEJM</i> 2002;347:1403</span>); optimal 0.5–0.8 ng/mL (<span class="tfont"><i class="calibre3">JAMA</i> 2003;289:871</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Ivabradine (I<i class="calibre3"><sub class="calibre13">f</sub></i> blocker w/o ⊖ ino)</p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">Consider if EF</i> ≤<i class="calibre3">35%, NYHA II or III, HR</i> ≥<i class="calibre3">70, NSR on max</i> β<i class="calibre3">B.</i> 18% ↓ CV mort or HF hosp (<span class="tfont"><i class="calibre3">Lancet</i> 2010;376:875</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Iron supplementation</p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">? IV (not PO) if NYHA II/III, EF</i> ≤<i class="calibre3">40%, Fe-defic</i> (ferritin &lt;100 or 100–300 &amp; TSAT &lt;20%). ↑ QoL independent of Hct (<span class="tfont"><i class="calibre3">NEJM</i> 2009;361:2436</span>).</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Anticoagulation</p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">If AF, VTE, LV thrombus</i>, ± <i class="calibre3">if large akinetic LV segments.</i> In SR w/ rEF, ↓ isch stroke, but ↑ bleed (<span class="tfont"><i class="calibre3">NEJM</i> 2012;366:1859 &amp; 2018;379:1332</span>).</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Heart rhythm</p></td>
<td class="bg0-b"><p class="tab">If AF &amp; NYHA II-IV w/ EF &lt;35%, catheter ablation ↓ D/HF hosp vs. med Rx (rate or rhythm; <span class="tfont"><i class="calibre3">NEJM</i> 2018;378:417</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Other</p></td>
<td class="bg0-b"><p class="tab">SGLT2i ↓ death/HF hosp in DM (<span class="tfont"><i class="calibre3">Lancet</i> 2019;393:31</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Meds to avoid</p></td>
<td class="bg"><p class="tab">NSAIDs, nondihydropyridine CCB, TZDs</p></td>
</tr>
</table>
<p class="tsr">(<i class="calibre3">Circ</i> 2013;128:e240 &amp; 2016;134:e282; <i class="calibre3">EHJ</i> 2016;37:2129)</p>
<p class="h2a"><b class="calibre4">Heart failure with preserved EF (HFpEF; “Diastolic HF”)</b> <span class="s">(<i class="calibre3">NEJM</i> 2016;375:1868)</span></p>
<p class="bl"><span class="sbl">•</span> Epidemiology: ~<sup class="calibre15">1</sup>/<sub class="calibre8">2</sub> of Pts w/ HF have normal or only min. impaired systolic fxn (EF ≥40%); risk factors for HFpEF incl ↑ age, ♀, DM, AF. Mortality ≈ to those w/ systolic dysfxn.</p>
<p class="bl"><span class="sbl">•</span> Etiologies (impaired relaxation and/or ↑ passive stiffness): ischemia, prior MI, LVH, HCMP, infiltrative CMP, RCMP, aging, hypothyroidism</p>
<p class="bl"><span class="sbl">•</span> Precipitants of pulmonary edema: <i class="calibre3">volume overload</i> (poor compliance of LV → sensitive to even modest ↑ in volume); <i class="calibre3">ischemia</i> (↓ relaxation); <i class="calibre3">tachycardia</i> (↓ filling time in diastole), <i class="calibre3">AF</i> (loss of atrial boost to LV filling); <i class="calibre3">HTN</i> (↑ afterload → ↓ stroke volume)</p>
<p class="bl"><span class="sbl">•</span> Dx w/ clinical s/s of HF w/ preserved systolic fxn. Dx supported by evidence of diast dysfxn:</p>
<p class="bl1r"><span class="sbl1r">(1)</span> echo: abnl MV inflow (E/A reversal and ∆s in E wave deceleration time) &amp; ↓ myocardial relax. (↑ isovol relax. time &amp; ↓ early diastole tissue Doppler vel)</p>
<p class="bl1r"><span class="sbl1r">(2)</span> exercise-induced ↑ PCWP (± ↓ response chronotropic &amp; vasodilator reserve)</p>
<p class="bl"><span class="sbl">•</span> Treatment: diuresis for vol overload, BP control, prevention of tachycardia and ischemia;</p>
<p class="bl1">no benefit to: ACEI/ARB <span class="s1r">(<i class="calibre3">NEJM</i> 2008;359:2456)</span> or PDE5 inhib <span class="s1r">(<i class="calibre3">JAMA</i> 2013;309:1268)</span>;</p>
<p class="bl1">spironolactone ? ↓ CV death &amp; HF hosp (at least in Americas) <span class="s1r">(<i class="calibre3">NEJM</i> 2014;370:1383)</span>;</p>
<p class="bl1">ARNi <span class="s1r">(<i class="calibre3">JACC Heart Fail</i> 2017;5:471)</span> under study; transcatheter interatrial shunt reduces</p>
<p class="bl1">PCWP during exercise, ? whether improves sx/outcomes <span class="s1r">(<i class="calibre3">Circ</i> 2017;137:364)</span></p>
<h2 class="ct"><a id="h8" class="calibre7"></a><a id="page_1-17" class="calibre7"></a><a href="part0002.html#rh12" class="calibre7">CARDIOMYOPATHIES</a></h2>
<p class="cst"><i class="calibre3">Diseases with mechanical and/or electrical dysfunction of the myocardium</i></p>
<p class="h"><b class="calibre21">D<small class="calibre30">ILATED</small> C<small class="calibre30">ARDIOMYOPATHY</small> (DCM)</b></p>
<p class="h2a"><b class="calibre4">Definition and epidemiology</b> <span class="s">(<i class="calibre3">Circ</i> 2013;128:e240; <i class="calibre3">JACC</i> 2013;62:2046)</span></p>
<p class="bl"><span class="sbl">•</span> Ventricular dilatation and ↓ contractility ± ↓ wall thickness <i class="calibre3">in the absence of myocardial disease caused by ischemia/infarct, valvular disease or hypertension</i></p>
<p class="bl"><span class="sbl">•</span> Incidence: 5–8/100,000/y; prevalence: 1/2500. Most common reason for heart transplant.</p>
<p class="h2a"><b class="calibre4">Etiologies</b> <span class="s">(<i class="calibre3">JACC</i> 2011;57:1641; <i class="calibre3">Circ Res</i> 2012;111:131)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Familial</b> (~35%): Pt &amp; ≥2 closely related family members w/ otherwise unexplained DCM; ~30 genes identified to date, encoding structural &amp; nuclear proteins</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Idiopathic</b> (&lt;20%): ? undiagnosed infectious, alcoholic, or genetic cause</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Infectious myocarditis</b> (10–15%; <i class="calibre3">Lancet</i> 2012;379:738; <i class="calibre3">JACC</i> 2012;59:779)</p>
<p class="bl1">Viruses (parvoB19 &amp; HHV6 &gt; Coxsackie, adeno, echo, CMV, HCV): from subacute (dilated LV, mild–mod dysfxn) to fulminant (nondil., thick, edematous LV, sev dysfxn)</p>
<p class="bl1">Bacterial, fungal, rickettsial, TB, Lyme (mild myocarditis, often with AVB)</p>
<p class="bl1">HIV: ~8% of asx HIV ⊕; due to HIV, other virus <i class="calibre3">or</i> antiretrovirals; also premature CAD</p>
<p class="bl1">Chagas: apical aneurysm ± thrombus, RBBB, megaesophagus/colon <span class="s1r">(<i class="calibre3">Lancet</i> 2018;391:82)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Toxic:</b> alcohol (~20%) typ. 7–8 drinks/d × &gt;5 y, but variable; cocaine; XRT (usu RCMP);</p>
<p class="bl1">anthracyclines (risk ↑ &gt;550 mg/m<sup class="calibre15">2</sup>, may manifest late), cyclophosphamide, trastuzumab</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Infiltrative</b> (5%): often mix of DCMP + RCMP (qv) with thickened wall</p>
<p class="bl1">amyloidosis, sarcoidosis, hemochromatosis, tumor</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Autoimmune:</b> <i class="calibre3">collagen vasc. dis.</i> (3%): PM, SLE, scleroderma, PAN, RA, GPA;</p>
<p class="bl1"><i class="calibre3">peripartum</i> (last month → 5 mo postpartum; <i class="calibre3">EHJ</i> 2015;36:1090): ~1:3000 preg. ↑ risk w/ multiparity, ↑ age, Afr Am; stnd HF Rx (if preg, no ACEi or spironolact.); ? bromocriptine to ↓ prolactin; 72% normalize EF <span class="s1r">(<i class="calibre3">JACC</i> 2015;66:905)</span>; ~30% recur w/ next preg</p>
<p class="bl1">Idiopathic giant cell myocarditis (GCM): avg age 42, fulminant, AVB/VT <span class="s1r">(<i class="calibre3">Circ HF</i> 2013;6:15)</span></p>
<p class="bl1">Eosinophilic (variable peripheral eos): hypersensitivity (mild HF but at risk for SCD) or acute necrotizing eosinophilic myocarditis (ANEM; STE, effusion, severe HF)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Stress-induced</b> (Takotsubo = apical ballooning): typically postmenopausal ♀; mimics MI (chest pain, ± STE &amp; ↑ Tn; deep TWI &amp; ↑ QT); mid/apex dyskinesis; ? Rx w/ βB, ACEI; usu. improves over wks <span class="s1r">(<i class="calibre3">JAMA</i> 2011;306:277)</span>. In-hosp morb/mort similar to ACS <span class="s1r">(<i class="calibre3">NEJM</i> 2015;373:929)</span>.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Arrhythmogenic right ventricular cardiomyopathy</b> (ACM/ARVC): fibrofatty replacement of RV → dilation (dx w/ MRI); ECG: ± RBBB, TWI V<sub class="calibre8">1</sub>–V<sub class="calibre8">3</sub>, ε wave; risk VT <span class="s1r">(<i class="calibre3">NEJM</i> 2017;376:61)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Tachycardia:</b> likelihood ∝ rate/duration; often resolves w/ rate cntl <span class="s1r">(<i class="calibre3">Circ</i> 2005;112:1092)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">LV noncompaction</b> <span class="s1r">(<i class="calibre3">Lancet</i> 2015;386:813)</span>: prominent trabeculae, arrhythmias, cardioemboli</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Metab/other:</b> hypothyroid, acromegaly, pheo, OSA, Vit B<sub class="calibre8">1</sub>, selenium or carnitine defic.</p>
<p class="h2a"><b class="calibre4">Clinical manifestations</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Heart failure:</b> both congestive &amp; poor forward flow sx; signs of L- &amp; R-sided HF</p>
<p class="bl1"><b class="calibre4">diffuse</b>, <b class="calibre4">laterally displaced PMI</b>, <b class="calibre4">S3</b>, ± MR or TR (annular dilat., displaced pap. muscle)</p>
<p class="bl"><span class="sbl">•</span> Embolic events (~10%), supraventricular/ventricular arrhythmias, &amp; palpitations</p>
<p class="bl"><span class="sbl">•</span> Chest pain can be seen w/ some etiologies (eg, myocarditis)</p>
<p class="h2a"><b class="calibre4">Diagnostic studies and workup</b> <span class="s">(<i class="calibre3">JACC</i> 2016;67:2996)</span></p>
<p class="bl"><span class="sbl">•</span> CXR: moderate to marked cardiomegaly, ± pulmonary edema &amp; pleural effusions</p>
<p class="bl"><span class="sbl">•</span> ECG: may see PRWP, Q waves, or BBB; low-voltage; AF (20%); may be normal</p>
<p class="bl"><span class="sbl">•</span> Echocardiogram: LV dilatation, ↓ EF, <i class="calibre3">regional or global</i> LV HK ± RV HK, ± mural thrombi</p>
<p class="bl"><span class="sbl">•</span> Cardiac MRI: up to 76% Se, 96% Sp for myocarditis or infiltrative dis. <span class="s1r">(<i class="calibre3">JACC Imaging</i> 2014;7:254)</span>; extent of midwall fibrosis correlated w/ mortality in niCMP <span class="s1r">(<i class="calibre3">JAMA</i> 2013;309:896)</span> and may identify Pts w/ EF &gt;40% who benefit from ICD <span class="s1r">(<i class="calibre3">Circ</i> 2017;135:2106)</span></p>
<p class="bl"><span class="sbl">•</span> Labs: TFTs, Fe panel, HIV, SPEP, ANA; viral sero <i class="calibre3">not</i> recommended; others per suspicion</p>
<p class="bl"><span class="sbl">•</span> Family hx (20–35% w/ familial dis.), genetic counseling ± genetic testing <span class="s1r">(<i class="calibre3">JAMA</i> 2009;302:2471)</span></p>
<p class="bl"><span class="sbl">•</span> Stress test: useful to r/o ischemia (low false ⊖ rate), high false ⊕ rate, even w/ imaging</p>
<p class="bl"><span class="sbl">•</span> Coronary angiography to r/o CAD if risk factors, h/o angina, Qw MI on ECG, equivocal ETT; consider CT angiography <span class="s1r">(<i class="calibre3">JACC</i> 2007;49:2044)</span></p>
<p class="bl"><span class="sbl">•</span> ? Endomyocardial biopsy <span class="s1r">(<i class="calibre3">JACC</i> 2007;50:1914)</span>: yield 10%; of these, 75% myocarditis (for which no proven Rx) &amp; 25% systemic disease; 40% false ⊖ rate (patchy dis.) &amp; false ⊕ (necrosis → inflammation); ∴ biopsy if: acute &amp; hemodyn compromise (r/o GCM, ANEM); arrhythmia or RCMP features (r/o infiltrative); or suspect toxic, allergic, tumor</p>
<p class="h2a"><b class="calibre4">Treatment</b> <span class="s">(see “Heart Failure” for standard HF Rx)</span></p>
<p class="bl"><span class="sbl">•</span> Possibility of reversibility of CMP may temper implantation of devices</p>
<p class="bl"><span class="sbl">•</span> Immunosuppression: for giant cell myocarditis (prednisone + AZA), collagen vascular disease, peripartum (? IVIg), &amp; eosinophilic; no proven benefit for viral myocarditis</p>
<p class="bl"><span class="sbl">•</span> Prognosis differs by etiology <span class="s1r">(<i class="calibre3">NEJM</i> 2000;342:1077)</span>: postpartum (best), ischemic/GCM (worst)</p>
<p class="h"><a id="page_1-18" class="calibre7"></a><b class="calibre21">H<small class="calibre30">YPERTROPHIC</small> C<small class="calibre30">ARDIOMYOPATHY</small> (HCM)</b></p>
<p class="h2a"><b class="calibre4">Definition and epidemiology</b></p>
<p class="bl"><span class="sbl">•</span> LV (usually ≥15 mm) and/or RV hypertrophy disproportionate to hemodynamic load</p>
<p class="bl"><span class="sbl">•</span> Prevalence: 1/500; 50% sporadic, 50% familial, most asymptomatic</p>
<p class="bl"><span class="sbl">•</span> Ddx: LVH 2° to HTN, AS, elite athletes (wall usually &lt;13 mm &amp; symmetric and nl/↑ rates of tissue Doppler diastolic relaxation; <i class="calibre3">Circ</i> 2011;123:2723), Fabry dis. (↑ Cr, skin findings)</p>
<p class="h2a"><b class="calibre4">Pathology</b></p>
<p class="bl"><span class="sbl">•</span> Autosomal dominant mutations in cardiac sarcomere genes (eg, β-myosin heavy chain)</p>
<p class="bl"><span class="sbl">•</span> Myocardial fiber disarray with hypertrophy, which creates arrhythmogenic substrate</p>
<p class="bl"><span class="sbl">•</span> Many morphologic hypertrophy variants: asymmetric septal; concentric; midcavity; apical</p>
<p class="h2a"><b class="calibre4">Pathophysiology</b></p>
<p class="bl"><span class="sbl">•</span> LV outflow tract obstruction (LVOTO) in ≥70%: narrowed tract 2° hypertrophied septum + systolic anterior motion (SAM) of ant. MV leaflet (may be fixed, variable, or nonexistent) and papillary muscle displacement. Gradient (∇) worse w/ ↑ contractility (digoxin, β-agonists, exercise, PVCs), ↓ preload (eg, Valsalva maneuver) or ↓ afterload.</p>
<p class="bl"><span class="sbl">•</span> Mitral regurgitation: due to SAM (mid-to-late, post.-directed regurg. jet) and/or abnl</p>
<p class="bl1">mitral leaflets and papillary muscles (pansystolic, ant.-directed regurg. jet)</p>
<p class="bl"><span class="sbl">•</span> Diastolic dysfunction: ↑ chamber stiffness + impaired relaxation</p>
<p class="bl"><span class="sbl">•</span> Ischemia: small vessel dis., perforating artery compression (bridging), ↓ coronary perfusion</p>
<p class="bl"><span class="sbl">•</span> Syncope: ∆s in load-dependent CO, arrhythmias</p>
<p class="h2a"><b class="calibre4">Clinical manifestations</b> <span class="s">(70% are asymptomatic at dx)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Dyspnea</b> (90%): due to ↑ LVEDP, MR, and diastolic dysfunction</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Angina</b> (25%) even w/o epicardial CAD; microvasc. dysfxn <span class="s1r">(<i class="calibre3">NEJM</i> 2003;349:1027)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Arrhythmias</b> (AF in 20–25%; VT/VF): palpitations, syncope, sudden cardiac death</p>
<p class="h2a"><b class="calibre4">Physical exam</b></p>
<p class="bl"><span class="sbl">•</span> Sustained PMI, S<sub class="calibre8">2</sub> paradoxically split if severe outflow obstruction, ⊕ S<sub class="calibre8">4</sub> (occ. palpable)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Systolic murmur:</b> crescendo-decrescendo; LLSB; ↑ <b class="calibre4">w/ Valsalva</b> &amp; standing (↓ preload)</p>
<p class="bl"><span class="sbl">•</span> ± mid-to-late or holosystolic murmur of MR at apex</p>
<p class="bl"><span class="sbl">•</span> Bifid carotid pulse (brisk rise, decline, then 2<sup class="calibre15">nd</sup> rise); JVP w/ prominent <i class="calibre3">a</i> wave</p>
<p class="bl"><span class="sbl">•</span> Contrast to AS, which has murmur that ↓ w/ Valsalva and ↓ carotid pulses</p>
<p class="h2a"><b class="calibre4">Diagnostic studies</b> <span class="s">(<i class="calibre3">EHJ</i> 2014;35:2733)</span></p>
<p class="bl"><span class="sbl">•</span> CXR: cardiomegaly (LV and LA)</p>
<p class="bl"><span class="sbl">•</span> ECG: LVH, anterolateral TWI and inferior pseudo-Qw, ± apical giant TWI (apical variant)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Echo:</b> any LV wall segment ≥15 mm (or ? even ≥13 if ⊕ HFx), often but not necessarily involving septum; other findings include dynamic outflow obstruction, SAM, MR</p>
<p class="bl"><span class="sbl">•</span> MRI: hypertrophy + patchy delayed enhancement (useful for dx &amp; prog) <span class="s1r">(<i class="calibre3">Circ</i> 2015;132:292)</span></p>
<p class="bl"><span class="sbl">•</span> Cardiac cath: subaortic pressure ∇; <i class="calibre3">Brockenbrough sign</i> = ↓ pulse pressure post-PVC (in contrast to AS, in which pulse pressure ↑ post-PVC); spike &amp; dome Ao pressure pattern</p>
<p class="bl"><span class="sbl">•</span> ? Genotyping for family screening, but pathogenic mutation ID’d in &lt;<sup class="calibre15">1</sup>/<sub class="calibre8">2</sub> <span class="s1r">(<i class="calibre3">Circ</i> 2011;124:2761)</span></p>
<p class="h2a"><b class="calibre4">Treatment</b> <span class="s">(<i class="calibre3">EHJ</i> 2014;35:2733; <i class="calibre3">NEJM</i> 2018;379:655)</span></p>
<p class="bl"><span class="sbl">•</span> Heart failure</p>
<p class="bl1">⊖ <b class="calibre4">inotropes/chronotropes:</b> β-blockers, CCB (verapamil), disopyramide</p>
<p class="bl1">Careful use of diuretics, because may further ↓ preload. If LVOTO, <i class="calibre3">avoid vasodilators</i>. Avoid digoxin b/c ↑ contractility and ∴ outflow obstruction.</p>
<p class="bl1">If sx refractory to drug Rx + <i class="calibre3">obstructive</i> physiology (∇ ≥50 mmHg):</p>
<p class="bl1">(a) Surgical myectomy: long-term ↓ symptoms in 90% <span class="s1r">(<i class="calibre3">Circ</i> 2014;130:1617)</span></p>
<p class="bl1">(b) Alcohol septal ablation <span class="s1r">(<i class="calibre3">JACC</i> 2018;72:3095)</span>: ∇ ↓ by ~80%, only 5–20% remain w/ NYHA III–IV sx; 14% require repeat ablation or myectomy. Good alternative for older Pts, multiple comorbidities. Complic: transient (&amp; occ. delayed) 3° AVB w/ 10–20% req. PPM; VT due to scar formation.</p>
<p class="bl1">No clear benefit of dual-chamber pacing <span class="s1r">(<i class="calibre3">JACC</i> 1997;29:435; <i class="calibre3">Circ</i> 1999;99:2927)</span></p>
<p class="bl1">If refractory to drug therapy and there is <i class="calibre3">nonobstructive</i> pathophysiology: transplant</p>
<p class="bl"><span class="sbl">•</span> Acute HF: can be precip. by dehydration or tachycardia; Rx w/ fluids, βB, phenylephrine</p>
<p class="bl"><span class="sbl">•</span> AF: rate control w/ βB, maintain SR w/ disopyramide or amio; low threshold to anticoag</p>
<p class="bl"><span class="sbl">•</span> ICD if VT/VF. Consider for SCD prevention if: NSVT, ⊕ FHx SCD, unexplained syncope, LV wall ≥30 mm, failure of SBP to ↑ or fall from peak ≥20 mmHg w/ exercise, ? extensive MRI delayed enhancement. EPS <i class="calibre3">not</i> useful. HCM Risk-SCD Score <span class="s1r">(<i class="calibre3">EHJ</i> 2014;35:2010)</span>: consider ICD if high risk (≥6%/y), may consider if intermediate (4–&lt;6%/y).</p>
<p class="bl"><span class="sbl">•</span> Counsel to avoid dehydration, extreme exertion</p>
<p class="bl"><span class="sbl">•</span> Endocarditis prophylaxis not recommended <span class="s1r">(<i class="calibre3">Circ</i> 2007;16:1736)</span></p>
<p class="bl"><span class="sbl">•</span> 1<sup class="calibre15">st</sup>-degree relatives: screen w/ TTE q12–18m as teen or athlete then q5y as adult, ECG (because timing of HCMP onset variable). Genetic testing if known mutation.</p>
<p class="h"><a id="page_1-19" class="calibre7"></a><b class="calibre21">R<small class="calibre30">ESTRICTIVE</small> C<small class="calibre30">ARDIOMYOPATHY</small> (RCM)</b></p>
<p class="h2a"><b class="calibre4">Definition</b> <span class="s">(<i class="calibre3">Circ</i> 2006;113:1807)</span></p>
<p class="bl"><span class="sbl">•</span> Impaired ventricular filling with ↓ compliance in nonhypertrophied, nondilated ventricles; normal or ↓ diastolic volumes, normal or near-normal EF; must r/o pericardial disease</p>
<p class="h2a"><b class="calibre4">Etiology</b> <span class="s">(<i class="calibre3">JACC</i> 2010;55:1769 &amp; 2016;68:411)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Myocardial processes</b></p>
<p class="bl1">Autoimmune (scleroderma, polymyositis-dermatomyositis)</p>
<p class="bl1">Infiltrative diseases (see primary entries for extracardiac manifestations, Dx, Rx)</p>
<p class="bl2"><b class="calibre4">Amyloidosis</b> <span class="s1r">(<i class="calibre3">Circ</i> 2011;124:1079)</span>: age at presentation ~60 y; ♂:♀ = 3:2</p>
<p class="bl4">AL (eg, MM, etc.); familial (transthyretin, ATTR); AA/senile (dep. of TTR, ANP)</p>
<p class="bl4">ECG: ↓ QRS amplitude (50%), pseudoinfarction pattern (Qw), AVB (10–20%), hemiblock (20%), BBB (5–20%)</p>
<p class="bl4">Echo: biventricular wall thickening (<i class="calibre3">yet w/ low voltage on ECG</i>), granular sparkling (30%), biatrial enlargement (40%), valve thickening, small effusions</p>
<p class="bl4">Nl voltage/septal thickness has NPV ~90%</p>
<p class="bl4">Labs: ✔ SPEP/UPEP, serum free light chain ratio (&lt;0.25 or &gt;1.65 κ-to-λ ratio)</p>
<p class="bl4">MRI: distinct late gadolinium enhancement pattern <span class="s1r">(<i class="calibre3">JACC</i> 2008;51:1022)</span></p>
<p class="bl2"><b class="calibre4">Sarcoidosis</b> (can also be DCM): presents at age ~30 y; ↑‘d in blacks, N. Europe, ♀</p>
<p class="bl4">5% w/ systemic sarcoid have overt cardiac involvement; cardiac w/o systemic in 10%</p>
<p class="bl4">ECG: AVB (75%), RBBB (20–60%), VT; PET: ↑ FDG uptake in affected area</p>
<p class="bl4">Echo: regional WMA (particularly basal septum) w/ thinning or mild hypertrophy</p>
<p class="bl4">Gallium or FDG uptake at areas of inflam.; sestaMIBI w/ non-cor. perfusion defects</p>
<p class="bl4">Cardiac MRI: T2 early gad (edema); fibrosis/scar in basal septum; LGE prognostic</p>
<p class="bl4">Cardiac bx low-yield b/c patchy</p>
<p class="bl2"><b class="calibre4">Hemochromatosis:</b> in middle-aged men (espec N. European); 15% p/w cardiac sx</p>
<p class="bl1">Diabetes; storage diseases: Gaucher’s, Fabry, Hurler’s, glycogen storage diseases</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Endomyocardial processes</b></p>
<p class="bl1">Chronic eosinophilic: Löffler’s endocarditis (temperate climates; ↑ eos; mural thrombi that embolize); endomyocardial fibrosis (tropical climates; var. eos; mural thrombi)</p>
<p class="bl1">Toxins: radiation (also p/w constrictive pericarditis, valvular dis, ostial CAD), anthracyclines</p>
<p class="bl1">Serotonin: carcinoid, serotonin agonists, ergot alkaloids. Metastatic cancer.</p>
<p class="h2a"><b class="calibre4">Pathology &amp; pathophysiology</b></p>
<p class="bl"><span class="sbl">•</span> Path: normal or ↑ wall thickness ± infiltration or abnormal deposition</p>
<p class="bl"><span class="sbl">•</span> ↓ myocardial compliance → nl EDV but ↑ EDP → ↑ systemic &amp; pulm. venous pressures</p>
<p class="bl"><span class="sbl">•</span> ↓ ventricular cavity size → ↓ SV and ↓ CO</p>
<p class="h2a"><b class="calibre4">Clinical manifestations</b> <span class="s">(<i class="calibre3">Circ</i> 2000;101:2490)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Right-sided</b> &gt; <b class="calibre4">left-sided heart failure</b> with peripheral edema &gt; pulmonary edema</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Diuretic “refractoriness”; thromboembolic events</b></p>
<p class="bl"><span class="sbl">•</span> Poorly tolerated tachyarrhythmias; VT → syncope/sudden cardiac death</p>
<p class="h2a"><b class="calibre4">Physical exam</b></p>
<p class="bl"><span class="sbl">•</span> ↑ JVP, ± Kussmaul’s sign (JVP not ↓ w/ inspir., classically seen in <i class="calibre3">constrict. pericarditis</i>)</p>
<p class="bl"><span class="sbl">•</span> Cardiac: ± S<sub class="calibre8">3</sub> and S<sub class="calibre8">4</sub>, ± murmurs of MR and TR</p>
<p class="bl"><span class="sbl">•</span> Congestive hepatomegaly, ± ascites and jaundice, peripheral edema</p>
<p class="h2a"><b class="calibre4">Diagnostic studies</b></p>
<p class="bl"><span class="sbl">•</span> CXR: normal ventricular chamber size, enlarged atria, ± pulmonary congestion</p>
<p class="bl"><span class="sbl">•</span> ECG: low voltage, pseudoinfarction pattern (Qw), ± arrhythmias</p>
<p class="bl"><span class="sbl">•</span> Echo: ± symmetric wall thickening, biatrial enlarge., ± mural thrombi, ± cavity oblit. w/ diast dysfxn: ↑ early diast (E) and ↓ late atrial (A) filling, ↑ E/A ratio, ↓ decel. time</p>
<p class="bl"><span class="sbl">•</span> Cardiac MRI/PET: may reveal inflammation or evidence of infiltration (but nonspecific)</p>
<p class="bl"><span class="sbl">•</span> Cardiac catheterization</p>
<p class="bl1">Atria: <b class="calibre4">M’s</b> or <b class="calibre4">W’s</b> (prominent <i class="calibre3">x</i> and <i class="calibre3">y</i> descents)</p>
<p class="bl1">Ventricles: <b class="calibre4">dip &amp; plateau</b> (rapid ↓ pressure at onset of diastole, rapid ↑ to early plateau)</p>
<p class="bl1"><b class="calibre4">Concordance</b> of LV &amp; RV pressure peaks during respiratory cycle (vs. discordance in constrictive pericarditis; <i class="calibre3">Circ</i> 1996;93:2007)</p>
<p class="bl"><span class="sbl">•</span> Endomyocardial biopsy if suspect infiltrative process; fat pad bx for amyloid</p>
<p class="bl"><span class="sbl">•</span> Restrictive cardiomyopathy vs. constrictive pericarditis: see “Pericardial Disease”</p>
<p class="h2a"><b class="calibre4">Treatment</b> <span class="s">(in addition to Rx’ing underlying disease)</span></p>
<p class="bl"><span class="sbl">•</span> Gentle diuresis. May not tolerate CCB or other vasodilators.</p>
<p class="bl"><span class="sbl">•</span> Control HR (but can ↓ CO); maintain SR (helps filling). Digoxin ↑ arrhythmias in amyloid.</p>
<p class="bl"><span class="sbl">•</span> Anticoagulation (particularly with AF or low CO)</p>
<p class="bl"><span class="sbl">•</span> Transplantation for refractory cases</p>
<p class="bl"><span class="sbl">•</span> Tafamidis (TTR binder) ↓ death and CV hosp for TTR amyloid CM <span class="s1r">(<i class="calibre3">NEJM</i> 2018;379:1007)</span></p>
<h2 class="ct"><a id="h9" class="calibre7"></a><a id="page_1-20" class="calibre7"></a><a href="part0002.html#rh13" class="calibre7">VALVULAR HEART DISEASE</a></h2>
<p class="h"><b class="calibre21">A<small class="calibre30">ORTIC</small> S<small class="calibre30">TENOSIS</small> (AS)</b></p>
<p class="h2a"><b class="calibre4">Etiology</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Calcific:</b> predominant cause in Pts &gt;70 y; risk factors include HTN, ↑ chol., ESRD</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Congenital</b> (ie, bicuspid AoV w/ premature calcification): cause in 50% of Pts &lt;70 y</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Rheumatic heart disease</b> (AS usually accompanied by AR and MV disease)</p>
<p class="bl"><span class="sbl">•</span> AS mimickers: subvalvular (HCMP, subAo membrane) or supravalvular stenosis</p>
<p class="h2a"><b class="calibre4">Clinical manifestations</b> <span class="s">(usually indicates AVA &lt;1 cm2 or concomitant CAD)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Angina:</b> ↑ O<sub class="calibre8">2</sub> demand (hypertrophy) + ↓ O<sub class="calibre8">2</sub> supply (↓ cor perfusion pressure) ± CAD</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Syncope</b> (<i class="calibre3">exertional</i>): peripheral vasodil. w/ fixed CO → ↓ MAP → ↓ cerebral perfusion</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Heart failure:</b> outflow obstruct + diastolic dysfxn → pulm. edema, esp. if ↑ HR/AF (↓ LV fill.)</p>
<p class="bl"><span class="sbl">•</span> Acquired vWF disease (~20% of sev. AS): destruction of vWF; GI angiodysplasia</p>
<p class="bl"><span class="sbl">•</span> Natural hx: usually slowly progressive (AVA ↓ ~0.1 cm<sup class="calibre15">2</sup>/y, but varies; <i class="calibre3">Circ</i> 1997;95:2262), until sx develop; mean survival based on sx: angina = 5 y; syncope = 3 y; CHF = 2 y</p>
<p class="h2a"><b class="calibre4">Physical exam</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Midsystolic crescendo-decrescendo</b> murmur at <b class="calibre4">RUSB</b>, harsh, high-pitched, radiates to carotids, apex (holosystolic = Gallavardin effect), ↑ w/ passive leg raise, ↓ w/ standing &amp; Valsalva. Dynamic outflow obstruction (HCM) is the reverse.</p>
<p class="bl"><span class="sbl">•</span> Ejection click after S<sub class="calibre8">1</sub> sometimes heard with <i class="calibre3">bicuspid</i> AoV</p>
<p class="bl"><span class="sbl">•</span> Signs of severity: <i class="calibre3">late-peaking</i> murmur, paradoxically split S<sub class="calibre8">2</sub> or inaudible A<sub class="calibre8">2</sub>, small and delayed carotid pulse (“<i class="calibre3">pulsus parvus et tardus</i>”), LV heave, ⊕ S<sub class="calibre8">4</sub> (occasionally palpable)</p>
<p class="imagef"><img src="../images/00017.jpeg" alt="" class="calibre2"/></p>
<p class="fn"><i class="calibre3">Pathophys Heart Dis</i>., 6th ed., 2015, for this et al.</p>
<p class="h2a"><b class="calibre4">Diagnostic studies</b></p>
<p class="bl"><span class="sbl">•</span> ECG: may see LVH, LAE, LBBB, AF (in late disease)</p>
<p class="bl"><span class="sbl">•</span> CXR: cardiomegaly, AoV calcification, poststenotic dilation of ascending Ao, pulmonary congestion</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Echo:</b> valve morphology, jet velocity, estim pressure gradient (∇) &amp; calculate AVA, LVEF</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cardiac cath:</b> usually to <i class="calibre3">r/o CAD</i> (in ~<sup class="calibre15">1</sup>/<sub class="calibre8">2</sub> of calcific AS); for hemodyn. if disparity between exam &amp; echo: ✔ pressure gradient (∇) across AoV, calc AVA (underestim. if mod/sev AR)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Dobutamine challenge</b> (echo or cath): if low EF and mean ∇ &lt;40, use to differentiate:</p>
<p class="bl1"><i class="calibre3">Afterload mismatch:</i> 20% ↑ SV &amp; ∇, no ∆ AVA (implies contractile reserve, ↑ EF post-AVR)</p>
<p class="bl1"><i class="calibre3">Pseudostenosis:</i> 20% ↑ SV, no ∆ in ∇, ↑ AVA (implies low AVA <i class="calibre3">artifact</i> of LV dysfxn)</p>
<p class="bl1"><i class="calibre3">Limited contractile reserve:</i> no ∆ SV, ∇ or AVA (implies EF prob. will not improve w/ AVR)</p>
<p class="imagef"><img src="../images/00018.jpeg" alt="" class="calibre2"/></p>
<p class="fn"><sup class="calibre35">a</sup>AVA indexed to BSA &lt;0.6 cm<sup class="calibre35">2</sup>/m<sup class="calibre35">2</sup> also severe; <sup class="calibre35">b</sup>DSE → max jet vel ≥4 &amp; AVA ≤1.0; <sup class="calibre35">c</sup>small LV w/ ↓ stroke vol.</p>
<p class="h2a"><b class="calibre4">Treatment</b> <span class="s">(<i class="calibre3">Circ</i> 2014;129:e521; <i class="calibre3">Lancet</i> 2016;387:1312; <i class="calibre3">JACC</i> 2017; 69:1313)</span></p>
<p class="bl"><span class="sbl">•</span> Based on <i class="calibre3">symptoms:</i> once they develop, AVR needed.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">AVR:</b> indicated in <b class="calibre4">sx</b> (stage D1); <b class="calibre4">asx severe</b> + <b class="calibre4">EF</b> &lt;<b class="calibre4">50%</b> (stage C2); or severe (stage C1) <i class="calibre3">and</i> undergoing other cardiac surgery.</p>
<p class="bl1">Reasonable if:</p>
<p class="bl1"><b class="calibre4">Asx severe</b> (stage C1) <i class="calibre3">but</i> either <b class="calibre4">sx or</b> ↓ <b class="calibre4">BP w/ exercise</b> (can <i class="calibre3">carefully</i> exercise asx AS to uncover sx; do <i class="calibre3">not</i> exercise sx AS) or <b class="calibre4">very severe</b></p>
<p class="bl1"><b class="calibre4">Sx severe w/ low flow/</b>∇ w/ low EF &amp; response to dobuta (stage D2) or normal EF but AS felt to be cause of sx (stage D3)</p>
<p class="bl1">Asx moderate AS (stage B) <i class="calibre3">and</i> undergoing cardiac surgery</p>
<p class="bl"><span class="sbl">•</span> Transcatheter AoV replacement (TAVR, see below) attractive alternative to surgery</p>
<p class="bl"><span class="sbl">•</span> Medical (if not AVR candidate or to temporize): careful diuresis prn, control HTN, maintain <a id="page_1-21" class="calibre1"></a>SR; digoxin if ↓ EF &amp; HF or if AF; <i class="calibre3">avoid</i> venodilators (nitrates) &amp; ⊖ inotropes (βB/CCB) if severe AS; avoid vigorous physical exertion once AS mod–severe;</p>
<p class="bl1">? nitroprusside (w/ PAC) in HF w/ sev. AS, ↓ EF/CO, &amp; HTN <span class="s1r">(<i class="calibre3">Circ</i> 2013;128:1349)</span></p>
<p class="bl"><span class="sbl">•</span> IABP: stabilization, bridge to surgery</p>
<p class="bl"><span class="sbl">•</span> Balloon valvotomy: ↑ AVA, <i class="calibre3">but</i> risk of stroke/AR &amp; restenosis; ∴ bridge to AVR or palliation</p>
<p class="h2a"><b class="calibre4">TAVR</b> <span class="s">(transcatheter AoV replacement) (<i class="calibre3">JACC</i> 2017;135:e1159)</span></p>
<p class="bl"><span class="sbl">•</span> Valves: balloon-expandable or self-expanding. Most commonly deployed retrograde via perc. transfemoral access (best outcomes); also retrograde via axillary art. or ascend. Ao (via small sternotomy &amp; aortotomy). Alternatively, antegrade transapical via small thoracotomy &amp; LV puncture (if narrow iliofemoral artery or calcified Ao).</p>
<p class="bl"><span class="sbl">•</span> Peri- &amp; postprocedural complic.: low CO; annular rupture or coronary occlusion (both rare); stroke; local vascular; paravalvular leaks; CHB (? higher w/ self-expanding valve).</p>
<p class="bl"><span class="sbl">•</span> Post op: lifelong ASA 75–100 mg + clopidogrel 3–6 mo</p>
<p class="bl"><span class="sbl">•</span> Outcomes w/ TAVR. In <i class="calibre3">nonoperative Pts</i> (ie, vs. med Rx): 44% ↓ mortality but still ~20% annual mortality in TAVR group <span class="s1r">(<i class="calibre3">NEJM</i> 2012;366:1696; <i class="calibre3">JACC</i> 2014;63:1972)</span>.</p>
<p class="bl1"><i class="calibre3">High-risk Pts</i> (STS predicted 30d surg. mort. &gt;8%) vs. surgical AVR (SAVR): ≈ mortality &amp; ↑ early risk of stroke w/ balloon-expand.; 20–30% ↓ in death or stroke w/ self-expand. <span class="s1r">(<i class="calibre3">Lancet</i> 2015;385:2477; <i class="calibre3">JACC</i> 2016;67:2565)</span></p>
<p class="bl1"><i class="calibre3">Medium-risk Pts</i> (predicted 30d-mort. ~4–8%): ≈ death/stroke (? ↓ w/ balloon-expandable via transfemoral) <span class="s1r">(<i class="calibre3">NEJM</i> 2016;374:1609 &amp; 2017;376:1321)</span></p>
<p class="bl1"><i class="calibre3">Low-risk Pts</i> (predicted 30d-mort. &lt;4%): ↓ death or stroke <span class="s1r">(<i class="calibre3">NEJM</i> 2019;380:1695 &amp; 1706)</span></p>
<p class="bl1">TAVR w/ ↑ vasc. complic. but ↓ bleeding, AKI, AF; need for PPM in ~25% w/ self-expand.</p>
<p class="bl1">Mod/severe paravalvular AI in 5–10% at 2 y, ~14% at 5 y (may be lower in lower risk Pts). Repositionable valve has rate &lt;1% at 1 y, but ~40% rate of PPM <span class="s1r">(<i class="calibre3">JAMA</i> 2018;319:27)</span>.</p>
<p class="h"><b class="calibre21">A<small class="calibre30">ORTIC</small> R<small class="calibre30">EGURGITATION</small> (AR)</b></p>
<p class="h2a"><b class="calibre4">Etiology</b> <span class="s">(<i class="calibre3">Circ</i> 2006;114:422)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Valve disease</b> (43%): <b class="calibre4">rheumatic heart disease</b> (usually mixed AS/AR + MV disease); <b class="calibre4">bicuspid AoV</b> (natural hx: <sup class="calibre15">1</sup>/<sub class="calibre8">3</sub> → normal, <sup class="calibre15">1</sup>/<sub class="calibre8">3</sub> → AS, <sup class="calibre15">1</sup>/<sub class="calibre8">6</sub> → AR, <sup class="calibre15">1</sup>/<sub class="calibre8">6</sub> → endocarditis → AR); <b class="calibre4">infective endocarditis;</b> valvulitis (RA, SLE, certain anorectics &amp; serotonergics, XRT)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Root disease</b> (57%): <b class="calibre4">HTN</b>, aortic aneurysm/dissection, annuloaortic ectasia (ie, Marfan),</p>
<p class="bl1"><b class="calibre4">aortic inflammation</b> (GCA, Takayasu’s, ankylosing spond., reactive arthritis, syphilis)</p>
<p class="h2a"><b class="calibre4">Clinical manifestations</b></p>
<p class="bl"><span class="sbl">•</span> Acute: sudden ↓ forward SV and ↑ LVEDP (noncompliant ventricle) → pulmonary edema</p>
<p class="bl1">± hypotension and cardiogenic shock</p>
<p class="bl"><span class="sbl">•</span> Chronic: clinically silent while LV dilates (to ↑ compliance to keep LVEDP low) more than it hypertrophies → chronic volume overload → LV decompensation → CHF</p>
<p class="bl"><span class="sbl">•</span> Natural hx: <i class="calibre3">variable</i> progression (unlike AS, can be fast or slow); once decompensation begins, prognosis poor w/o AVR (mortality ~10%/y)</p>
<p class="image1"><img src="../images/00019.jpeg" alt="" class="calibre2"/></p>
<p class="h2a"><b class="calibre4">Physical exam</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Early diastolic decrescendo murmur at LUSB</b> (RUSB if dilated Ao root); ↑ w/ sitting forward, expir, handgrip; severity of AR ∝ duration of murmur (except in acute and severe late); <i class="calibre3">Austin Flint murmur:</i> mid-to-late diastolic rumble at apex (AR jet interfering w/ mitral inflow)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Wide pulse pressure</b> due to ↑ stroke volume, hyper-dynamic pulse; pulse pressure narrows in late AR with ↓ LV fxn; bisferiens (twice-beating) arterial pulse</p>
<p class="bl"><span class="sbl">•</span> PMI diffuse and laterally displaced; soft S<sub class="calibre8">1</sub> (early closure of MV); ± S<sub class="calibre8">3</sub> (≠ ↓ EF but rather just volume overload in AR)</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Classic Eponymous Signs in Chronic AR</b> (<span class="tfont1"><i class="calibre3">South Med J</i> 1981;74:459</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Sign</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Description</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Corrigan’s pulse</p></td>
<td class="bg0-b"><p class="tab">“water hammer” pulse (ie, rapid rise/fall or distention/collapse)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Hill’s sign</p></td>
<td class="bg0-b"><p class="tab">(popliteal SBP – brachial SBP) &gt;60 mmHg</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Duroziez’s sign</p></td>
<td class="bg0-b"><p class="tab">to-and-fro murmur heard over femoral artery w/ light compression</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Pistol shot sounds</p></td>
<td class="bg0-b"><p class="tab">pistol shot sound heard over femoral artery</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Traube’s sound</p></td>
<td class="bg0-b"><p class="tab">double sound heard over femoral artery when compressed distally</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">de Musset’s sign</p></td>
<td class="bg0-b"><p class="tab">head-bobbing with each heartbeat (low Se)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Müller’s sign</p></td>
<td class="bg0-b"><p class="tab">systolic pulsations of the uvula</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Quincke’s pulses</p></td>
<td class="bg"><p class="tab">subungual capillary pulsations (low Sp)</p></td>
</tr>
</table>
<p class="h2a"><b class="calibre4">Diagnostic studies</b></p>
<p class="bl"><span class="sbl">•</span> ECG: can see LVH, LAD, abnl repol; CXR: cardiomegaly ± ascending Ao dilatation</p>
<p class="bl"><a id="page_1-22" class="calibre1"></a><span class="sbl">•</span> <b class="calibre4">Echo:</b> severity of AR (severe = regurg jet width ≥65% LVOT, regurg fraction ≥50%, effective regurg orifice ≥0.3 cm<sup class="calibre15">2</sup>, holodiastolic flow reversal in descend. Ao; moderate = jet width 25–64%, regurg fraction 30–49%, regurg orifice 0.1–0.29 cm<sup class="calibre15">2</sup>); LV size &amp; fxn</p>
<p class="h2a"><b class="calibre4">Treatment</b> <span class="s">(<i class="calibre3">Circ</i> 2014;129:e521; <i class="calibre3">Lancet</i> 2016;387:1312)</span></p>
<p class="bl"><span class="sbl">•</span> Acute decompensation (consider endocarditis as possible acute precipitant):</p>
<p class="bl1"><i class="calibre3">surgery</i> usually urgently needed for acute severe AR, which is poorly tolerated by LV</p>
<p class="bl1">IV afterload reduction (nitroprusside) and inotropic support (dobutamine)</p>
<p class="bl1">± chronotropic support (↑ HR → ↓ diastole → ↓ time for regurgitation)</p>
<p class="bl1">pure vasoconstrictors and IABP contraindicated</p>
<p class="bl"><span class="sbl">•</span> In chronic AR, management decisions based on <i class="calibre3">LV size and fxn</i> (and before sx occur)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Surgery</b> (AVR, replacement or repair if possible):</p>
<p class="bl1"><b class="calibre4">Severe</b> and <b class="calibre4">sx</b> (if equivocal, consider stress test)</p>
<p class="bl1"><b class="calibre4">Asx</b> <i class="calibre3">and</i> either <b class="calibre4">EF</b> ≤<b class="calibre4">50%</b> or <b class="calibre4">LV dilation</b> [LVESD &gt;50 mm or LVESDi (indexed to BSA) ≥20 or 25 mm/m<sup class="calibre15">2</sup> <span class="s1r">(<i class="calibre3">JACC</i> 2019;73:1741)</span>] or undergoing cardiac surg</p>
<p class="bl"><span class="sbl">•</span> Transcatheter AoV replacement (TAVR) being explored <span class="s1r">(<i class="calibre3">JACC</i> 2013;61:1577 &amp; 2017;70:2752)</span></p>
<p class="bl"><span class="sbl">•</span> Medical therapy: <b class="calibre4">vasodilators</b> (nifedipine, ACEI/ARB, hydralazine) if severe AR w/ sx or LV dysfxn &amp; not operative candidate or to improve hemodynamics before AVR; no clear benefit in asx severe AR w/ mild LV dilation &amp; nl LV fxn <span class="s1r">(<i class="calibre3">NEJM</i> 2005;353:1342)</span></p>
<p class="h"><b class="calibre21">M<small class="calibre30">ITRAL</small> R<small class="calibre30">EGURGITATION</small> (MR)</b></p>
<p class="h2a"><b class="calibre4">Etiology</b> <span class="s">(<i class="calibre3">Lancet</i> 2009;373:1382; <i class="calibre3">NEJM</i> 2010;363:156)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Primary</b> (degeneration of valve apparatus)</p>
<p class="bl1"><i class="calibre3">Leaflet abnl:</i> myxomatous (MVP), endocarditis, calcific RHD, valvulitis (collagen-vascular disease), congenital, anorectic drugs (phen-fen), XRT</p>
<p class="bl1"><i class="calibre3">Chordae tendineae</i> rupture: myxomatous, endocarditis, spontaneous, trauma</p>
<p class="bl1"><i class="calibre3">Papillary muscle dysfxn</i> b/c of ischemia or <i class="calibre3">rupture</i> during MI [usu. posteromedial papillary m. (supplied predominantly by PDA) vs. anterolateral (suppl. by diags &amp; OMs)]</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Secondary (functional):</b> inferoapical papillary muscle displacement due to ischemic LV remodeling or DCM; HCM <span class="s1r">(<i class="calibre3">JACC</i> 2015;65:1231)</span></p>
<p class="h2a"><b class="calibre4">Clinical manifestations</b></p>
<p class="bl"><span class="sbl">•</span> Acute: <b class="calibre4">pulmonary edema</b>, hypotension, cardiogenic shock <span class="s1r">(<i class="calibre3">NEJM</i> 2004;351:1627)</span></p>
<p class="bl"><span class="sbl">•</span> Chronic: typically asx for yrs, then as LV fails → progressive DOE, fatigue, AF, PHT</p>
<p class="bl"><span class="sbl">•</span> Prognosis: 5-y survival w/ medical therapy is 80% if asx, but only 45% if sx</p>
<p class="h2a"><b class="calibre4">Physical exam</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">High-pitched, blowing, holosystolic murmur at apex;</b> radiates to axilla; ± thrill; ↑ w/ handgrip (Se 68%, Sp 92%),</p>
<p class="bl1">↓ w/ Valsalva (Se 93%) <span class="s1r">(<i class="calibre3">NEJM</i> 1988;318:1572)</span></p>
<p class="bl1">ant. leaflet abnl → post. jet heard at spine</p>
<p class="bl1">post. leaflet abnl → ant. jet heard at sternum</p>
<p class="bl"><span class="sbl">•</span> ± diastolic rumble b/c ↑ flow across valve</p>
<p class="bl"><span class="sbl">•</span> Lat. displ. hyperdynamic PMI, obscured S<sub class="calibre8">1</sub>, widely split S<sub class="calibre8">2</sub> (A<sub class="calibre8">2</sub> early b/c ↓ LV afterload, P<sub class="calibre8">2</sub> late if PHT); ± S<sub class="calibre8">3</sub></p>
<p class="bl"><span class="sbl">•</span> Carotid upstroke brisk (vs. diminished and delayed in AS)</p>
<p class="image1"><img src="../images/00020.jpeg" alt="" class="calibre2"/></p>
<p class="h2a"><b class="calibre4">Diagnostic studies</b> <span class="s">(<i class="calibre3">NEJM</i> 2005;352:875)</span></p>
<p class="bl"><span class="sbl">•</span> ECG: may see LAE, LVH, ± atrial fibrillation</p>
<p class="bl"><span class="sbl">•</span> CXR: dilated LA, dilated LV, ± pulmonary congestion</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Echo:</b> MV anatomy (ie, etiol); MR severity: jet area, jet width at origin (vena contracta) or effective regurgitant orifice (ERO; predicts survival); LV fxn (EF should be <i class="calibre3">supranormal</i> if compensated, ∴ EF &lt;60% w/ sev. MR = LV dysfxn)</p>
<p class="bl"><span class="sbl">•</span> TEE or cardiac MR if TTE not sufficiently informative</p>
<p class="bl"><span class="sbl">•</span> Cardiac cath: prominent PCWP <i class="calibre3">c-v</i> waves (not spec. for MR), LVgram for MR severity &amp; EF</p>
<p class="imagef"><img src="../images/00021.jpeg" alt="" class="calibre2"/></p>
<p class="fn1">*1+ = LA clears w/ each beat; 2+ = LA does not clear, faintly opac. after several beats; 3+ = LA &amp; LV opac. equal.</p>
<p class="fn"><sup class="calibre35">†</sup>For secondary MR, because ERO underestimated &amp; likely progressive LV dysfxn, ERO ≥0.20 is severe</p>
<p class="h2a"><b class="calibre4">Treatment</b> <span class="s">(<i class="calibre3">Lancet</i> 2016;387:1324; <i class="calibre3">Circ</i> 2017;135:e1159; <i class="calibre3">JACC</i> 2017;70:2421)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Acute severe MR:</b> consider ischemia &amp; endocarditis as precipitants; IV afterload reduction (nitroprusside), relieve congestion (diuresis &amp; NTG), ± inotropes (dobuta), IABP, avoid vasoconstrictors; <i class="calibre3">surgery</i> usually needed b/c prognosis poor w/o <span class="s1r">(<i class="calibre3">JAMA</i> 2013;310:609)</span></p>
<p class="bl"><a id="page_1-23" class="calibre1"></a><span class="sbl">•</span> <b class="calibre4">Chronic severe primary MR: surgery</b> (repair [preferred if feasible] vs. replacement) if <b class="calibre4">sx &amp; EF &gt;30%; asx &amp; either EF 30–60% or LVESD ≥40 mm;</b> ? asx, EF &gt;60%, LVESD &lt;40, but EF ↓ or LVESD ↑; MV repair reasonable if asx &amp; either EF &gt;60% + LVESD &lt;40 mm or new AF or PHT; if AF, concomitant surgical ablation ↓ AF recurrence, ∅ ∆ stroke; consider for sx cntl or if planning no anticoag <span class="s1r">(<i class="calibre3">NEJM</i> 2015;372:1399)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4"><i class="calibre3">Secondary MR:</i></b> if mod-sev MR (ideally ERO ≥0.40), EF 20–50%, sx despite optimized GDMT, transcatheter MV repair w/ edge-to-edge clips appears to ↓ mortality and HF hosp <span class="s1r">(<i class="calibre3">NEJM</i> 2018:379;2297 &amp; 2307)</span></p>
<p class="bl"><span class="sbl">•</span> For primary (degenerative) MR, surgery superior to percutaneous repair <span class="s1r">(<i class="calibre3">NEJM</i> 2011;364:1395)</span></p>
<p class="bl"><span class="sbl">•</span> Balloon-expandable bioprosthetic valve in severe MR w/ severe mitral annular calcification under study <span class="s1r">(<i class="calibre3">JACC</i> 2018;71:1841)</span></p>
<p class="bl"><span class="sbl">•</span> If sx &amp; EF&lt;60% but not operative candidate: HF Rx (βB, ACEI, ± aldo antag); ↓ preload w/ diuretics, NTG (espec. if ischemic MR) for sx relief ± ↓ ERO; maintain SR</p>
<p class="bl"><span class="sbl">•</span> Asymptomatic: ∅ proven benefit of medical therapy; βB ↑ LV fxn <span class="s1r">(<i class="calibre3">JACC</i> 2012;60:833)</span></p>
<p class="h">M<small class="calibre30">ITRAL</small> V<small class="calibre30">ALVE</small> P<small class="calibre30">ROLAPSE</small> (MVP)</p>
<p class="h2a"><b class="calibre4">Definition and Etiology</b></p>
<p class="bl"><span class="sbl">•</span> Billowing of MV leaflet ≥2 mm above mitral annulus in parasternal long axis echo view</p>
<p class="bl"><span class="sbl">•</span> Primary: sporadic or familial myxomatous proliferation of spongiosa of MV apparatus</p>
<p class="bl"><span class="sbl">•</span> Secondary: trauma, endocarditis, congenital, CTD (eg, Marfan’s, OI, Ehlers-Danlos)</p>
<p class="h2a"><b class="calibre4">Clinical manifestations (usually asymptomatic)</b></p>
<p class="bl"><span class="sbl">•</span> MR, endocarditis, emboli, arrhythmias (rarely SCD from VT from papillary muscle)</p>
<p class="bl"><span class="sbl">•</span> High-pitched, midsystolic click (earlier w/ ↓ preload) ± mid-to-late systolic murmur</p>
<p class="bl"><span class="sbl">•</span> No Rx <i class="calibre3">per se</i> [endocarditis Ppx not rec. <span class="s1r">(<i class="calibre3">Circ</i> 2007;116:1736)</span>]; Rx MR as above</p>
<p class="h">M<small class="calibre30">ITRAL</small> S<small class="calibre30">TENOSIS</small> (MS)</p>
<p class="h2a"><b class="calibre4">Etiology</b> <span class="s">(<i class="calibre3">Lancet</i> 2012;379:953)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Rheumatic heart disease</b> (RHD): <i class="calibre3">fusion of commissures</i> → “fish-mouth” valve</p>
<p class="bl1">from autoimmune rxn to β strep infxn; seen largely in developing world today</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Mitral annular calcification:</b> encroachment upon leaflets → fxnal MS; espec in ESRD</p>
<p class="bl"><span class="sbl">•</span> Congenital, infectious endocarditis w/ large lesion, myxoma near MV, thrombus</p>
<p class="bl"><span class="sbl">•</span> Valvulitis (eg, SLE, amyloid, carcinoid) or infiltration (eg, mucopolysaccharidoses)</p>
<p class="h2a"><b class="calibre4">Clinical manifestations</b> <span class="s">(<i class="calibre3">Lancet</i> 2009;374:1271)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Dyspnea and pulmonary edema</b> (if due to RHD, sx usually begin in 30s)</p>
<p class="bl1">precipitants: exercise, fever, anemia, volume overload (incl. pregnancy), tachycardia, AF</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Atrial fibrillation:</b> onset often precipitates heart failure in Pts w/ MS</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Embolic events:</b> commonly cerebral, espec in AF or endocarditis</p>
<p class="bl"><span class="sbl">•</span> Pulmonary: hemoptysis, frequent bronchitis (due to congestion), PHT, RV failure</p>
<p class="bl"><span class="sbl">•</span> Ortner’s syndrome: hoarseness from LA compression of recurrent laryngeal nerve</p>
<p class="image1"><img src="../images/00022.jpeg" alt="" class="calibre2"/></p>
<p class="h2a"><b class="calibre4">Physical exam</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Low-pitched mid-diastolic rumble at apex</b> w/ presystolic accentuation (if not in AF); best heard in L lat decubitus position during expiration, ↑ w/ exercise; severity proportional to <i class="calibre3">duration</i> (not intensity) of murmur; loud S<sub class="calibre8">1</sub></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Opening snap</b> (high-pitched early diastolic sound at apex) from fused leaflet tips;</p>
<p class="bl1">MVA proportional to S<sub class="calibre8">2</sub>–OS interval (tighter</p>
<p class="bl1">valve → ↑ LA pressure → shorter interval)</p>
<p class="bl"><span class="sbl">•</span> Loud S<sub class="calibre8">1</sub> (unless MV calcified and immobile)</p>
<p class="h2a"><b class="calibre4">Diagnostic studies</b></p>
<p class="bl"><span class="sbl">•</span> ECG: <b class="calibre4">LAE</b> (“P mitrale”), ± AF, ± RVH</p>
<p class="bl"><span class="sbl">•</span> CXR: <b class="calibre4">dilated LA</b> (flat L heart border, R double density, displaced L mainstem bronchus)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Echo:</b> estimate pressure gradient (∇), RVSP, valve area, valve echo score (0–16, based on leaflet mobility &amp; thick, subvalvular thick., Ca++); exer. TTE (to assess ∆ RVSP and ∇) if sx &amp; severity of MS at rest discrepant; TEE to assess for LA thrombus before PMBC</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cardiac cath:</b> ∇, calculated MVA; LA tall <i class="calibre3">a</i> wave &amp; blunted <i class="calibre3">y</i> descent; ↑ PA pressures</p>
<p class="image1"><img src="../images/00023.jpeg" alt="" class="calibre2"/></p>
<p class="h2a"><a id="page_1-24" class="calibre1"></a><b class="calibre4">Treatment</b> <span class="s">(<i class="calibre3">Circ</i> 2014;129:e521; <i class="calibre3">Lancet</i> 2016;387:1324)</span></p>
<p class="bl"><span class="sbl">•</span> Medical: Na restriction, cautious diuresis, βB, AF control, sx-limited physical stress</p>
<p class="bl"><span class="sbl">•</span> Antibiotic Ppx recommended if h/o RHD w/ valvular disease for 10 y or until age 40</p>
<p class="bl"><span class="sbl">•</span> Anticoag: AF; prior embolism; LA clot; ? LA &gt;55 mm or large LA w/ spont contrast</p>
<p class="bl"><span class="sbl">•</span> Mechanical intervention indicated if <b class="calibre4">heart failure sx w/ MVA</b> ≤<b class="calibre4">1.5;</b> reasonable if asx but very severe (MVA ≤1) and morphology favorable for PMBC; may consider PMBC if MVA &gt;1.5 but hemodyn signif w/ exercise, or if asx but MVA ≤1.5 and new-onset AF</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Percutaneous mitral balloon commissurotomy</b> (PMBC): preferred Rx if RHD; MVA doubles, ∇ ↓ by 50%; ≈ MVR <i class="calibre3">if</i> valvuloplasty score &lt;8, ∅ if mod-severe MR or LA clot</p>
<p class="bl"><span class="sbl">•</span> Surgical (MV repair if possible, o/w replacement): consider in sx Pts w/ MVA ≤1.5</p>
<p class="bl1">if PMBC unavailable/failed/contraindicated or valve morphology unsuitable</p>
<p class="bl"><span class="sbl">•</span> Pregnancy: if NYHA class III/IV → PMBC, o/w medical Rx w/ low-dose diuretic &amp; βB</p>
<p class="h">T<small class="calibre30">RICUSPID</small> R<small class="calibre30">EGURGITATION</small> <span class="s1">(<i class="calibre22">Circ</i> 2014;129:2440; <i class="calibre22">Lancet</i> 2016;388:2431)</span></p>
<p class="bl"><span class="sbl">•</span> 1° etiol: rheumatic, CTD, XRT, IE, Ebstein’s, carcinoid, tumors, pacemaker leads</p>
<p class="bl"><span class="sbl">•</span> Fxnl etiol (most common): RV and/or PHT (may be 2° to L-sided dis.), RV dilation ± MI</p>
<p class="bl"><span class="sbl">•</span> Holosystolic murmur, 3<sup class="calibre15">rd</sup>/4<sup class="calibre15">th</sup> ICS, ↑ w/ insp (Carvallo’s sign); S<sub class="calibre8">3</sub>; prominent <i class="calibre3">cv</i> wave in JVP</p>
<p class="bl"><span class="sbl">•</span> Consider repair or replacement for sx severe TR (eg, ERO ≥0.40 cm<sup class="calibre15">2</sup>); emerging transcatheter Rx under study: coaptation, caval implants, orthotopic valve <span class="s1r">(<i class="calibre3">JACC</i> 2018;71:2935)</span></p>
<p class="h">P<small class="calibre30">ROSTHETIC</small> H<small class="calibre30">EART</small> V<small class="calibre30">ALVES</small></p>
<p class="h2a"><b class="calibre4">Mechanical (60%)</b></p>
<p class="bl"><span class="sbl">•</span> Bileaflet (eg, St. Jude Medical); tilting disk; caged-ball</p>
<p class="bl"><span class="sbl">•</span> Very durable (20–30 y), but thrombogenic and ∴ require anticoagulation</p>
<p class="bl1">consider if age &lt;~50 y or if anticoagulation already indicated <span class="s1r">(<i class="calibre3">JACC</i> 2010;55:2413)</span></p>
<p class="h2a"><b class="calibre4">Bioprosthetic (40%)</b></p>
<p class="bl"><span class="sbl">•</span> Bovine pericardial or porcine heterograft (eg, Carpentier-Edwards), homograft</p>
<p class="bl"><span class="sbl">•</span> Less durable, but min. thrombogenic; consider if &gt;~70 y, lifespan &lt;20 y, or ∅ anticoag</p>
<p class="bl"><span class="sbl">•</span> If 50–69 y, 2× reop but <sup class="calibre15">1</sup>/<sub class="calibre8">2</sub> bleeding or stroke vs. mech <span class="s1r">(<i class="calibre3">JAMA</i> 2014;312:1323 &amp; 2015;313:1435)</span></p>
<p class="h2a"><b class="calibre4">Physical exam</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Crisp sounds</b> ± soft murmur during forward flow (normal to have small ∇)</p>
<p class="h2a"><b class="calibre4">Anticoagulation &amp; antiplatelet therapy for surgical valves</b> <span class="s">(<i class="calibre3">Circ</i> 2017;135:e1159)</span></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">High-risk features:</i> prior thromboembolism, AF, EF &lt;30–35%, hypercoagulable</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Warfarin (ØNOACs):</b> mech MVR or high-risk mech AVR: INR 3. Low-risk mech AVR or high-risk bio MVR/AVR: INR 2.5. Consider in bio MVR/AVR for 3–6 mo if low bleed risk.</p>
<p class="bl"><span class="sbl">•</span> + <b class="calibre4">ASA</b> (≤100 mg): all prosth. valves unless hx GIB, uncontrolled HTN, erratic INR, or &gt;80 y</p>
<p class="bl"><span class="sbl">•</span> If thrombosis, ↑ intensity (eg, INR 2–3 → 2.5–3.5; 2.5–3.5 → 3.5–4.5; add ASA if not on)</p>
<p class="bl"><span class="sbl">•</span> For TAVR, dual antiplatelet therapy (see TAVR section in “Aortic Stenosis”)</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Periprocedural “Bridging” of Anticoagulation in Pts with Mechanical Valve(s)</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">AVR w/o risk factors</p></td>
<td class="bg0-b"><p class="tab">d/c warfarin 2–4 d before surg; restart 12–24 h after surg</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">MVR or AVR w/ risk factors</p></td>
<td class="bg"><p class="tab">Preop: d/c warfarin, start UFH (preferred to LMWH) when INR &lt;2 4–6 h preop: d/c UFH; postop: restart UFH &amp; warfarin ASAP</p></td>
</tr>
</table>
<p class="tsr"><i class="calibre3">JACC</i> 2017;70:253. Procedures include noncardiac surgery, invasive procedures, and major dental work.</p>
<p class="h2a"><b class="calibre4">Correction of overanticoagulation</b> <span class="s">(<i class="calibre3">Circ</i> 2014;129:e521)</span></p>
<p class="bl"><span class="sbl">•</span> Risk from major bleeding must be weighed against risk of valve thrombosis</p>
<p class="bl"><span class="sbl">•</span> Not bleeding: if INR 5–10, withhold warfarin; if INR &gt;10 also give vit K 1–2.5 mg PO</p>
<p class="bl"><span class="sbl">•</span> Bleeding: FFP or PCC ± low-dose (1 mg) vit K IV</p>
<p class="h2a"><b class="calibre4">Endocarditis prophylaxis:</b> <span class="s">for all prosthetic valves (see “Endocarditis”)</span></p>
<p class="h2a"><b class="calibre4">Complications</b></p>
<p class="bl"><span class="sbl">•</span> Structural failure (r/o endocarditis); mechanical valves: rare except for Bjork-Shiley; bioprosth: up to 30% rate w/in 10–15 y, mitral &gt; aortic; consider TAVR <span class="s1r">(<i class="calibre3">JACC</i> 2017; 69:2253)</span></p>
<p class="bl"><span class="sbl">•</span> Paravalvular leak (r/o endocarditis); small <i class="calibre3">central</i> jet of regurg is normal in mech. valves</p>
<p class="bl"><span class="sbl">•</span> Obstruction from thrombosis <span class="s1r">(<i class="calibre3">JACC</i> 2013;62:1731)</span> or pannus: ✔ TTE, TEE, CTA, or fluoro significantly symptomatic <i class="calibre3">pannus</i> ingrowth: remove w/ surgery</p>
<p class="bl1"><b class="calibre4">thrombosis</b>: surgery if L-sided valve &amp; either severe sx or large (≥1 cm or 0.8 cm<sup class="calibre15">2</sup>); o/w UFH × days; if persists, consider lytic (eg, tPA 10 mg IVB → 90 mg over 2 hrs or 25 mg over 6 hrs repeating prn <i class="calibre3">JACC CV Imaging</i> 2013;6:206), success in ~80%, but ~10% risk of death, stroke or major bleed; lytic reasonable for R-sided</p>
<p class="bl"><span class="sbl">•</span> Infective endocarditis ± valvular abscess and conduction system dis. (see “Endocarditis”)</p>
<p class="bl"><span class="sbl">•</span> Embolization (r/o endocarditis); risk highest 1<sup class="calibre15">st</sup> 90 d, ~1%/y w/ warfarin (vs. 2% w/ ASA, or 4% w/o meds); mech MVR 2× risk of embolic events vs. mech AVR <span class="s1r">(<i class="calibre3">Circ</i> 1994;89:635)</span></p>
<p class="bl"><span class="sbl">•</span> Bleeding (from anticoag), hemolysis (espec w/ caged-ball valves or paravalvular leak)</p>
<h2 class="ct"><a id="h10" class="calibre7"></a><a id="page_1-25" class="calibre7"></a><a href="part0002.html#rh14" class="calibre7">PERICARDIAL DISEASE</a></h2>
<p class="h">P<small class="calibre30">ERICARDITIS</small> <small class="calibre30">AND</small> P<small class="calibre30">ERICARDIAL</small> E<small class="calibre30">FFUSION</small></p>
<p class="h2a"><b class="calibre4">Anatomy</b></p>
<p class="bl"><span class="sbl">•</span> Tissue sac surrounding heart &amp; proximal great vessels; 2 layers (parietal &amp; visceral)</p>
<p class="h2a"><b class="calibre4">Disease states</b></p>
<p class="bl"><span class="sbl">•</span> Inflammation (w/ or w/o fluid accumulation) → pericarditis</p>
<p class="bl"><span class="sbl">•</span> Fluid accumulation → effusion ± tamponade</p>
<p class="bl"><span class="sbl">•</span> Decrease in compliance (sequela of inflammation) → constrictive pericarditis</p>
<p class="bl"><span class="sbl">•</span> Tamponade and constriction characterized by increased ventricular interdependence</p>
<p class="h">P<small class="calibre30">ERICARDITIS</small> <small class="calibre30">AND</small> P<small class="calibre30">ERICARDIAL</small> E<small class="calibre30">FFUSION</small></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Etiologies of Acute Pericarditis</b> (<span class="tfont1"><i class="calibre3">JAMA</i> 2015;314:1498; <i class="calibre3">EHJ</i> 2015;36:2873</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Idiopathic</b> (&gt;80%)</p></td>
<td class="bg0-b"><p class="tab">Most presumed to be undiagnosed viral etiologies</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Infectious</b> (&lt;5% can be confirmed infectious)</p></td>
<td class="bg0-b"><p class="tab">Viral: Coxsackie, echo, adeno, EBV, VZV, CMV, parvo, HIV, flu</p>
<p class="tabh">Bacterial (from endocarditis, pneumonia, or s/p cardiac surgery): <i class="calibre3">S. pneumo, Neisseria, Coxiella, S. aureus, Borrelia</i> (Lyme); TB</p>
<p class="tab">Fungi: <i class="calibre3">Histo, Coccidio, Candida;</i> Parasite: <i class="calibre3">Entamoeba, Echino, Toxo</i></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Neoplastic</b> (&lt;10%)</p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">Common:</i> metastatic (lung, breast, lymphoma, leukemia, RCC)</p>
<p class="tab"><i class="calibre3">Rare:</i> primary cardiac &amp; serosal tumors (mesothelioma)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Autoimmune</b></p></td>
<td class="bg0-b"><p class="tab">Connective tissue diseases: SLE, RA, scleroderma, Sjögren’s</p>
<p class="tab">Vasculitides: PAN, ANCA ! (EGPA, GPA)</p>
<p class="tab">Drug-induced: procainamide, hydralazine, INH, CsA</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Uremia</b></p></td>
<td class="bg0-b"><p class="tab">~5–13% of Pts prior to HD; ~20% occurrence in chronic HD Pts</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Cardiovascular</b></p></td>
<td class="bg0-b"><p class="tab">STEMI, late post-MI (Dressler’s syndrome); ascending AoD; chest trauma; postpericardiotomy; procedural complic. (ie, PCI, PPM)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Radiation</b></p></td>
<td class="bg0-b"><p class="tab">&gt;40 Gy to mediastinum; acute or delayed; may be transudative</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Effusion w/o pericarditis</b></p></td>
<td class="bg"><p class="tab">CHF, cirrhosis, nephrotic syndrome, hypothyroidism, amyloidosis. Transudative.</p></td>
</tr>
</table>
<p class="h2a"><b class="calibre4">Clinical manifestations</b> <span class="s">(<i class="calibre3">NEJM</i> 2014;371:2410)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pericarditis:</b> retrosternal CP, pleuritic, positional (often ↓ by sitting forward), → trapezius; may be <i class="calibre3">absent</i> in TB, neoplastic, XRT, or uremic; ± fever; ± s/s of systemic etiologies</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Effusion:</b> present in ~2/3 of Pts w/ pericarditis; ranges from asx to tamponade</p>
<p class="h2a"><b class="calibre4">Physical exam</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pericarditis:</b> multiphasic <b class="calibre4">friction rub</b> best heard at LLSB w/ diaphragm of stethoscope. Notoriously variable and evanescent leathery sound w/ up to 3 components: atrial contraction, ventricular contraction, ventricular relaxation <span class="s1r">(<i class="calibre3">NEJM</i> 2012;367:e20)</span>.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Effusion:</b> distant heart sounds, dullness over left posterior lung field due to compressive atelectasis from pericardial effusion (Ewart’s sign)</p>
<p class="h2a"><b class="calibre4">Diagnostic studies</b> <span class="s">(<i class="calibre3">JAMA</i> 2015;314:1498; <i class="calibre3">EHJ</i> 2015;36:2921)</span></p>
<p class="bl"><span class="sbl">•</span> Need ≥2 of the following: chest pain (as noted above), friction rub, ECG findings, effusion</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">ECG:</b> may show diffuse STE (<i class="calibre3">concave up</i>) &amp; PR depression (except in aVR: ST ↓ &amp; PR ↑), TWI; classically and in contrast to STEMI, TWI do not occur until STs normalize</p>
<p class="bl1">Stages: (I) STE &amp; PR ↓; (II) ST &amp; PR normalize; (III) diffuse TWI; (IV) Tw normalize</p>
<p class="bl1">ECG may show evidence of large effusion w/ low-voltage &amp; electrical alternans (beat-to-beat ∆ in QRS amplitude and/or axis due to swinging heart)</p>
<p class="bl"><span class="sbl">•</span> CXR: if lg effusion (&gt;250 mL) → ↑ cardiac silhouette w/ “water-bottle” heart &amp; epicardial halo</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Echocardiogram:</b> presence, size, &amp; location of <i class="calibre3">effusion;</i> presence of <i class="calibre3">tamponade physiology;</i> pericarditis itself w/o spec. abnl (∴ echo can be nl), although can see pericardial stranding (fibrin or tumor); can also detect LV/RV dysfxn (myocarditis?)</p>
<p class="bl"><span class="sbl">•</span> CT: pericardial effusions (often appear larger by CT than by echo) ± calcifications</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">MRI:</b> may reveal pericardial thickening/inflammation, as well as myocardial involvement</p>
<p class="bl"><span class="sbl">•</span> CK-MB or troponin (⊕ in ~30%; <i class="calibre3">JACC</i> 2003;42:2144) if myopericarditis. Consider CRP/ESR.</p>
<p class="h2a"><b class="calibre4">Workup for effusion</b></p>
<p class="bl"><span class="sbl">•</span> r/o infxn: usually apparent from Hx &amp; CXR; ? value of ✔ acute and convalescent serologies</p>
<p class="bl"><span class="sbl">•</span> r/o noninfectious etiologies: BUN, Cr, ANA, RF, HIV, meds, relevant malignancy evaluation</p>
<p class="bl"><span class="sbl">•</span> Pericardiocentesis if suspect infxn or malignancy or large effusion (&gt;2 cm) or recurrent</p>
<p class="bl1">✔ cell counts, TP, LDH, glc, Gram stain &amp; Cx, AFB, cytology</p>
<p class="bl1">ADA, PCR for MTb, and specific tumor markers as indicated by clinical suspicion</p>
<p class="bl1">“exudate”: TP &gt;3 g/dL, TP<sub class="calibre8">eff</sub>/TP<sub class="calibre8">serum</sub> &gt;0.5, LDH<sub class="calibre8">eff</sub>/LDH<sub class="calibre8">serum</sub> &gt;0.6 or glc &lt;60 mg/dL; high Se (~90%) but <i class="calibre3">very low</i> Sp (~20%); overall low utility <span class="s1r">(<i class="calibre3">Chest</i> 1997;111:1213)</span></p>
<p class="bl"><span class="sbl">•</span> Pericardial bx if suspicion for malignancy or TB; perform during every surgical drainage</p>
<p class="h2a"><a id="page_1-26" class="calibre1"></a><b class="calibre4">Treatment of pericarditis</b> <span class="s">(<i class="calibre3">JAMA</i> 2015;314:1498; <i class="calibre3">EHJ</i> 2015;36:2921)</span></p>
<p class="bl"><span class="sbl">•</span> High-dose <b class="calibre4">NSAID</b> (eg, ibuprofen 600–800 mg tid) or ASA (eg, 650–1000 mg tid) × 7–14 d then taper over wks; ASA preferred over NSAID in acute MI; consider PPI to ↓ risk of GIB</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Add colchicine</b> 0.6 mg bid (qd if ≤70 kg) × 3 mo; 50% ↓ risk of refractory or recurrent pericarditis <span class="s1r">(<i class="calibre3">NEJM</i> 2013;369:1522)</span>. Amio, dilt, verap &amp; atorva ↓ P-gp, <span class="s">↑</span> risk of colchicine tox.</p>
<p class="bl"><span class="sbl">•</span> Avoid steroids except for systemic autoimmune disorder, uremic, preg., NSAIDs contraindicated, or refractory idiopathic disease. Appear to ↑ rate of pericarditis recurrence <span class="s1r">(<i class="calibre3">Circ</i> 2008;118:667)</span>. If due to TB, steroids ↓ risk of constriction <span class="s1r">(<i class="calibre3">NEJM</i> 2014;371:1121)</span>.</p>
<p class="bl"><span class="sbl">•</span> Avoid anticoagulants (although no convincing data that ↑ risk of hemorrhage/tamponade)</p>
<p class="bl"><span class="sbl">•</span> Infectious effusion → pericardial drainage (preferably surgically) + systemic antibiotics</p>
<p class="bl"><span class="sbl">•</span> Restrict activity until sx resolve/hsCRP ↓; athletes must also wait ≥3 mos w/ nl TTE/ECG</p>
<p class="bl"><span class="sbl">•</span> Acute idiopathic pericarditis self-limited in 70–90% of cases</p>
<p class="bl"><span class="sbl">•</span> Recurrent pericarditis <span class="s1r">(<i class="calibre3">Circ</i> 2007;115:2739)</span> risk factors: subacute, large effusion/tamponade, T &gt;38°C, no NSAID response after 7 d. Treatment: colchicine 0.6 mg bid × 6 mo <span class="s1r">(<i class="calibre3">Annals</i> 2011;155:409; <i class="calibre3">Lancet</i> 2014;383:2232)</span>. Nb drug-drug interactions (noted above).</p>
<p class="bl"><span class="sbl">•</span> Recurrent effusions: consider pericardial window (percutaneous vs. surgical)</p>
<p class="h">P<small class="calibre30">ERICARDIAL</small> T<small class="calibre30">AMPONADE</small></p>
<p class="h2a"><b class="calibre4">Etiology</b></p>
<p class="bl"><span class="sbl">•</span> Any cause of pericarditis but espec <b class="calibre4">malignancy</b>, <b class="calibre4">infectious</b>, uremia, ascending AoD, myocardial rupture, periprocedural complication, trauma, post-cardiotomy</p>
<p class="bl"><span class="sbl">•</span> Rapidly accumulating effusions most likely to cause tamponade b/c no time for pericardium to stretch (eg, to ↑ compliance) and accommodate ↑ intrapericardial fluid volume</p>
<p class="h2a"><b class="calibre4">Pathophysiology</b> <span class="s">(<i class="calibre3">NEJM</i> 2003;349:684)</span></p>
<p class="bl"><span class="sbl">•</span> ↑ intrapericardial pressure, compression of heart chambers, ↓ venous return → ↓ CO</p>
<p class="bl"><span class="sbl">•</span> Diastolic pressures ↑ &amp; equalize in all cardiac chambers → minimal flow of blood from RA to RV when TV opens → blunted <i class="calibre3">y</i> descent</p>
<p class="bl"><span class="sbl">•</span> ↑ ventricular interdependence → pulsus paradoxus (pathologic exaggeration of nl physio)</p>
<p class="bl1">Inspiration → ↓ intrapericardial &amp; RA pressures → ↑ venous return → ↑ RV size → septal shift to left. Also, ↑ pulmonary vascular compliance → ↓ pulm venous return. Result is ↓ LV filling → ↓ <b class="calibre4">LV stroke volume</b> &amp; blood pressure &amp; pulse pressure.</p>
<p class="h2a"><b class="calibre4">Clinical manifestations</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cardiogenic shock</b> (hypotension, fatigue) <b class="calibre4">without pulmonary edema</b></p>
<p class="bl"><span class="sbl">•</span> Dyspnea (seen in ~85%) may be due to ↑ respiratory drive to augment venous return</p>
<p class="h2a"><b class="calibre4">Physical exam</b> <span class="s">(<i class="calibre3">EHJ</i> 2014;35:2279)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Beck’s triad</b> (present in minority of cases): <b class="calibre4">distant heart sounds</b>, ↑ <b class="calibre4">JVP</b>, <b class="calibre4">hypotension</b></p>
<p class="bl"><span class="sbl">•</span> ↑ JVP (76%) w/ blunted <i class="calibre3">y</i> descent</p>
<p class="bl"><span class="sbl">•</span> Reflex tachycardia (77%), hypotension (26%; occasionally hypertensive), cool extremities</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pulsus paradoxus</b> (Se 82%, Sp 70%) = ↓ SBP ≥10 mmHg during inspiration</p>
<p class="bl1">⊕ LR 3.3 (5.9 if pulsus &gt;12), ⊖ LR 0.03</p>
<p class="bl1">Ddx = PE, hypovolemia, severe COPD, auto-PEEP, periconstriction (~<sup class="calibre15">1</sup>/<sub class="calibre8">3</sub>), RV infarct</p>
<p class="bl1">? absent if pre-existing ↑ LVEDP, irregular rhythm, severe AI, ASD, regional tamponade</p>
<p class="bl"><span class="sbl">•</span> Distant heart sounds (28%), ± pericardial friction rub (30%)</p>
<p class="bl"><span class="sbl">•</span> Tachypnea and orthopnea but clear lungs</p>
<p class="h2a"><b class="calibre4">Diagnostic studies</b></p>
<p class="bl"><span class="sbl">•</span> ECG: ↑ HR, ↓ voltage (seen in 42%), electrical alternans (20%), ± signs of pericarditis</p>
<p class="bl"><span class="sbl">•</span> CXR: ↑ cardiac silhouette (89%)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Echocardiogram:</b> ⊕ <b class="calibre4">effusion</b>, IVC plethora, <b class="calibre4">septal shift</b> with inspiration</p>
<p class="bl1"><b class="calibre4">diastolic collapse</b> of RA (Se 85%, Sp 80%) and/or RV (Se &lt;80%, Sp 90%)</p>
<p class="bl1"><b class="calibre4">respirophasic</b> ∆’<b class="calibre4">s in transvalvular velocities</b> (↑ across TV &amp; ↓ across MV w/ inspir.)</p>
<p class="bl1">postsurgical tamponade may be localized and not easily visible</p>
<p class="bl"><span class="sbl">•</span> Cardiac cath (right heart and pericardial): elevation (15–30 mmHg) and equalization of</p>
<p class="bl1">intrapericardial and diastolic pressures (RA, RV, PCWP), blunted <i class="calibre3">y</i> descent in RA</p>
<p class="bl1">↑ in stroke volume postpericardiocentesis = ultimate proof of tamponade</p>
<p class="bl1">if RA pressure remains high after drainage, Ddx: effusive-constrictive dis. (visceral pericardium constriction), myocard. dysfxn (eg, concomitant myocarditis)</p>
<p class="h2a"><b class="calibre4">Treatment</b> <span class="s">(<i class="calibre3">EHJ</i> 2014;35:2279)</span></p>
<p class="bl"><span class="sbl">•</span> Volume (but be careful b/c overfilling can worsen tamponade) and ⊕ inotropes (avoid βB)</p>
<p class="bl"><span class="sbl">•</span> Avoid vasoconstrictors b/c will ↓ stroke volume &amp; potentially ↓ HR</p>
<p class="bl"><span class="sbl">•</span> Avoid positive pressure ventilation b/c it can further impair cardiac filling <span class="s1r">(<i class="calibre3">Circ</i> 2006;113:1622)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pericardiocentesis</b> (except if due to aortic/myocardial rupture, for which emergent surgery treatment of choice; if too unstable, consider small pericardiocentesis to prevent PEA)</p>
<p class="bl"><span class="sbl">•</span> Surgical drainage considered if fluid rapidly reaccumulates, loculated, or hemorrhagic</p>
<p class="h"><a id="page_1-27" class="calibre7"></a>C<small class="calibre30">ONSTRICTIVE</small> P<small class="calibre30">ERICARDITIS</small></p>
<p class="h2a"><b class="calibre4">Etiology</b> <span class="s">(<i class="calibre3">Circ</i> 2011;124:1270)</span></p>
<p class="bl"><span class="sbl">•</span> Any cause of pericarditis (~1–2% incidence overall after acute pericarditis)</p>
<p class="bl"><span class="sbl">•</span> Highest risk w/ <b class="calibre4">TB</b>, <b class="calibre4">bacterial</b>, <b class="calibre4">neoplastic</b>, <b class="calibre4">XRT</b>, connective tissue, postcardiac surgery</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Viral/idiopathic</b>, b/c most common cause of pericarditis, also account for signif proportion</p>
<p class="h2a"><b class="calibre4">Pathophysiology</b></p>
<p class="bl"><span class="sbl">•</span> Adhesion of visceral and parietal pericardial layers → rigid pericardium that limits diastolic filling of ventricles → ↑ systemic venous pressures</p>
<p class="bl"><span class="sbl">•</span> Venous return is limited only after early rapid filling phase; ∴ rapid ↓ in RA pressure with atrial relaxation and opening of tricuspid valve and <i class="calibre3">prominent x and y descents</i></p>
<p class="bl"><span class="sbl">•</span> Kussmaul sign: JVP does not decrease with inspiration (↑ venous return with inspiration, but negative intrathoracic pressure not transmitted to heart because of rigid pericardium)</p>
<p class="h2a"><b class="calibre4">Clinical manifestations</b> <span class="s">(<i class="calibre3">NEJM</i> 2011;364:1350)</span></p>
<p class="bl"><span class="sbl">•</span> Right-sided &gt; left-sided heart failure (systemic congestion &gt; pulmonary congestion)</p>
<p class="h2a"><b class="calibre4">Physical exam</b></p>
<p class="bl"><span class="sbl">•</span> ↑ <b class="calibre4">JVP</b> with <b class="calibre4">prominent <i class="calibre3">y</i> descent</b>, ⊕ <b class="calibre4">Kussmaul sign</b> [Ddx: tricuspid stenosis, acute cor pulmonale, RV dysfxn (CMP, RV MI), SVC syndrome]</p>
<p class="bl"><span class="sbl">•</span> Hepatosplenomegaly, ascites, peripheral edema. Consider in Ddx of idiopathic cirrhosis.</p>
<p class="bl"><span class="sbl">•</span> PMI usually not palpable, <b class="calibre4">pericardial knock</b>, usually no pulsus paradoxus</p>
<p class="h2a"><b class="calibre4">Diagnostic studies</b></p>
<p class="bl"><span class="sbl">•</span> ECG: nonspecific, AF common (up to 33%) in advanced cases</p>
<p class="bl"><span class="sbl">•</span> CXR: calcification (MTb most common), espec in lateral view (although not specific)</p>
<p class="bl"><span class="sbl">•</span> Echocardiogram: ± thickened pericardium, “<b class="calibre4">septal bounce</b>” = abrupt displacement of septum during rapid filling in early diastole</p>
<p class="bl"><span class="sbl">•</span> Cardiac catheterization: atria w/ <b class="calibre4">Ms</b> or <b class="calibre4">Ws</b> (prominent <i class="calibre3">x</i> and <i class="calibre3">y</i> descents)</p>
<p class="bl1">ventricles: <b class="calibre4">dip-and-plateau</b> or <b class="calibre4">square-root sign</b> (rapid ↓ pressure at onset of diastole, rapid ↑ to early plateau)</p>
<p class="bl1"><i class="calibre3">discordance</i> between LV &amp; RV pressure peaks during respiratory cycle <span class="s1r">(<i class="calibre3">Circ</i> 1996;93:2007)</span></p>
<p class="bl"><span class="sbl">•</span> CT or <b class="calibre4">MRI:</b> thickened pericardium (&gt;4 mm; Se ~80%) w/ tethering <span class="s1r">(<i class="calibre3">Circ</i> 2011;123:e418)</span></p>
<p class="h2a"><b class="calibre4">Treatment</b></p>
<p class="bl"><span class="sbl">•</span> Diuresis if intravascular volume overload; surgical pericardiectomy if infectious or advanced</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre27"/>
<col class="calibre36"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">Constrictive Pericarditis vs. Restrictive Cardiomyopathy</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Evaluation</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Constrictive Pericarditis</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Restrictive Cardiomyopathy</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab">Physical exam</p></td>
<td class="bg0-br"><p class="tab">⊕ Kussmaul sign</p>
<p class="tab">Absent PMI</p>
<p class="tab">⊕ Pericardial knock</p></td>
<td class="bg0-b"><p class="tab">± Kussmaul sign</p>
<p class="tab">Powerful PMI, ± S<sub class="calibre13">3</sub> and S<sub class="calibre13">4</sub></p>
<p class="tab">± <b class="calibre4">Murmurs of MR</b>, <b class="calibre4">TR</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab">ECG</p></td>
<td class="bg0-br"><p class="tab">± Low voltage</p></td>
<td class="bg0-b"><p class="tab">Low voltage if infiltrative myopathy</p>
<p class="tab">± <b class="calibre4">Conduction abnormalities</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab">Echocardiogram</p></td>
<td class="bg0-br"><p class="tabh"><b class="calibre4">Respirophasic variation</b> (25–40%): inspir. → ↑ flow across TV and ↓ flow across MV</p>
<p class="tab">E′ (tissue velocity) nl/↑ (&gt;12 cm/sec)</p>
<p class="tab"><b class="calibre4">Expir.</b> hepatic vein flow reversal</p>
<p class="tab"><b class="calibre4">Septal bounce in early diastole</b></p>
<p class="tab">Normal wall thickness</p></td>
<td class="bg0-b"><p class="tab">&lt;10% respirophasic variation</p>
<p class="tab">Slower peak filling rate</p>
<p class="tab">Longer time to peak filling rate</p>
<p class="tabh"><b class="calibre4">E</b>′ ↓ (&lt;8 cm/sec) (Se 95%, Sp 96%; <i class="calibre3">HF Rev</i> 2013;18:255)</p>
<p class="tab"><b class="calibre4">Inspir.</b> hepatic vein flow reversal</p>
<p class="tab"><b class="calibre4">Biatrial enlargement</b></p>
<p class="tab">± ↑ wall thickness</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab">CT/MRI</p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Usually w/ thickened pericardium</b></p></td>
<td class="bg0-b"><p class="tab">Normal pericardium</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab">NT-proBNP</p></td>
<td class="bg0-br"><p class="tab">Variable</p></td>
<td class="bg0-b"><p class="tab">Typically ↑/↑↑ (<span class="tfont"><i class="calibre3">JACC</i> 2005;45:1900</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2" rowspan="3"><p class="tab">Cardiac catheterization</p></td>
<td class="bg0-b" colspan="2"><p class="tabc">Prominent <i class="calibre3">x</i> and <i class="calibre3">y</i> descents (more so in constriction)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b2" colspan="2"><p class="tabc">Dip-and-plateau sign (more so in constriction)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab">LVEDP = RVEDP</p>
<p class="tab">RVSP &lt;55 mmHg (Se 90%, Sp 29%)</p>
<p class="tab">RVEDP &gt;⅓ RVSP (Se 93%, Sp 46%)</p>
<p class="tabh"><b class="calibre4">Discordance</b> of LV &amp; RV pressure peaks during respiratory cycle</p>
<p class="tabh"><b class="calibre4">Systolic area index</b> (ratio of RV to LV pressure–time area in inspir vs. expir) &gt;1.1 (Se 97%, Sp 100%)</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">LVEDP</b> &gt; <b class="calibre4">RVEDP</b> (esp. w/ vol.)</p>
<p class="tab">RVSP &gt;55 mmHg</p>
<p class="tab">RVEDP &lt;⅓ RVSP</p>
<p class="tabh">Concordance of LV &amp; RV pressure peaks during respiratory cycle</p>
<p class="tabh">Systolic area index ≤1.1 (<span class="tfont"><i class="calibre3">JACC</i> 2008;51:315</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r1"><p class="tab">Endomyocardial biopsy</p></td>
<td class="bg0-r"><p class="tab">Usually normal</p></td>
<td class="bg"><p class="tab">± <b class="calibre4">Specific etiology of RCMP</b> (fibrosis, infiltration, hypertrophy)</p></td>
</tr>
</table>
<h2 class="ct"><a id="h11" class="calibre7"></a><a id="page_1-28" class="calibre7"></a><a href="part0002.html#rh15" class="calibre7">HYPERTENSION</a></h2>
<table class="t-topbot2">
<colgroup class="calibre9">
<col class="calibre17"/>
<col class="calibre16"/>
<col class="calibre16"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">JNC 8 Classification</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Category</b></p></td>
<td class="bg0-br"><p class="tabc"><b class="calibre4">Systolic</b></p></td>
<td class="bg0-b"><p class="tabc"><b class="calibre4">Diastolic</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Normal</p></td>
<td class="bg0-br"><p class="tabc">&lt;120</p></td>
<td class="bg0-b"><p class="tabc">&lt;80</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Pre-HTN</p></td>
<td class="bg0-br"><p class="tabc">120–139</p></td>
<td class="bg0-b"><p class="tabc">80–89</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Stage 1 HTN*</p></td>
<td class="bg0-br"><p class="tabc">140–159</p></td>
<td class="bg0-b"><p class="tabc">90–99</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Stage 2 HTN</p></td>
<td class="bg0-r"><p class="tabc">≥160</p></td>
<td class="bg"><p class="tabc">≥100</p></td>
</tr>
</table>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre17"/>
<col class="calibre16"/>
<col class="calibre16"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">2017 AHA/ACC BP Classification</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Category</b></p></td>
<td class="bg0-br"><p class="tabc"><b class="calibre4">Systolic</b></p></td>
<td class="bg0-b"><p class="tabc"><b class="calibre4">Diastolic</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Normal</p></td>
<td class="bg0-br"><p class="tabc">&lt;120</p></td>
<td class="bg0-b"><p class="tabc">&lt;80</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Elevated BP</p></td>
<td class="bg0-br"><p class="tabc">120–129</p></td>
<td class="bg0-b"><p class="tabc">&lt;80</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Stage 1HTN</p></td>
<td class="bg0-br"><p class="tabc">130–139</p></td>
<td class="bg0-b"><p class="tabc">80–89</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Stage 2 HTN</p></td>
<td class="bg0-r"><p class="tabc">≥140</p></td>
<td class="bg"><p class="tabc">≥90</p></td>
</tr>
</table>
<p class="tsr">BP in mmHg. Average ≥2 measurements &gt;1–2 min apart. Confirm stage 1 w/in 1–4 wk; can Rx stage 2 immediately. (<i class="calibre3">J Clin HTN</i> 2014;16:14; <i class="calibre3">Circ</i> 2018;138:e426)</p>
<p class="h2a"><b class="calibre4">Epidemiology</b> <span class="s">(<i class="calibre3">JAMA</i> 2014;311:1424; <i class="calibre3">Circ</i> 2018;138:e426)</span></p>
<p class="bl"><span class="sbl">•</span> Prevalence ~30% in U.S. adults, ≥44% in African-Americans; M = F</p>
<p class="bl"><span class="sbl">•</span> Of those with HTN, ~3/4 were treated, ~1/2 achieve target BP, ~1/6 were unaware of dx</p>
<p class="h2a"><b class="calibre4">Etiologies</b> <span class="s">(<i class="calibre3">JACC</i> 2017;71:127)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Essential</b> (95%): onset 25–55 y; ⊕ FHx. Unclear mechanism but ? additive microvasc</p>
<p class="bl1">renal injury over time w/ contribution of hyperactive sympathetics <span class="s1r">(<i class="calibre3">NEJM</i> 2002;346:913)</span>.</p>
<p class="bl1">↑ Age → ↓ art compliance → HTN. Genetics + environment involved <span class="s1r">(<i class="calibre3">Nature</i> 2011;478:103)</span>.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Secondary:</b> Consider if Pt &lt;30 y or if sudden onset, severe, refractory HTN</p>
<p class="image1"><img src="../images/00024.jpeg" alt="" class="calibre2"/></p>
<p class="h2a"><b class="calibre4">Standard workup</b></p>
<p class="bl"><span class="sbl">•</span> Goals: (1) identify CV risk factors; (2) consider 2° causes (3) assess for target-organ damage</p>
<p class="bl"><span class="sbl">•</span> History: CAD, HF, TIA/CVA, PAD, DM, renal insufficiency, sleep apnea, preeclampsia; ⊕ FHx for HTN; diet, Na intake, smoking, alcohol, prescription and OTC meds, OCP</p>
<p class="bl"><span class="sbl">•</span> Physical exam: ✔ <b class="calibre4">BP in both arms;</b> funduscopic exam, BMI, cardiac (LVH, murmurs), vascular (bruits, radial-femoral delay), abdominal (masses or bruits), neuro exam</p>
<p class="bl"><span class="sbl">•</span> Testing: K, BUN, Cr, Ca, glc, Hct, U/A, lipids, TSH, urinary albumin:creatinine (if ↑ Cr, DM, peripheral edema), ? renin, ECG (for LVH), CXR, TTE (eval for valve abnl, LVH)</p>
<p class="bl"><span class="sbl">•</span> Ambulatory BP monitoring (ABPM): consider for episodic, masked, resistant, or white coat HTN; stronger predictor of mortality than clinic BP <span class="s1r">(<i class="calibre3">NEJM</i> 2018;378:1509)</span>; 24 h target &lt;130/80</p>
<p class="h2a"><b class="calibre4">Complications of HTN</b></p>
<p class="bl"><span class="sbl">•</span> Neurologic: <b class="calibre4">TIA/CVA</b>, ruptured aneurysms, vascular dementia</p>
<p class="bl"><span class="sbl">•</span> Retinopathy: stage I = arteriolar narrowing; II = copper-wiring, AV nicking; III = hemorrhages and exudates; IV = papilledema</p>
<p class="bl"><span class="sbl">•</span> Cardiac: <b class="calibre4">CAD</b>, <b class="calibre4">LVH</b>, <b class="calibre4">HF, AF</b></p>
<p class="bl"><span class="sbl">•</span> Vascular: aortic dissection, aortic aneurysm (HTN = key risk factor for aneurysms)</p>
<p class="bl"><span class="sbl">•</span> Renal: proteinuria, <b class="calibre4">renal failure</b></p>
<p class="h2a"><b class="calibre4">Treatment</b> <span class="s">(<i class="calibre3">J Clin HTN</i> 2014;16:14; <i class="calibre3">Circ</i> 2018;138:e426; <i class="calibre3">NEJM</i> 2018;378:636)</span></p>
<p class="bl"><span class="sbl">•</span> Every ↓ 10 mmHg → 20% ↓ MACE, 28% ↓ HF, 13% ↓ mort. <span class="s1r">(<i class="calibre3">Lancet</i> 2016;387:957)</span></p>
<p class="bl"><span class="sbl">•</span> ACC/AHA: initiate BP med if BP ≥130/80 &amp; <i class="calibre3">either</i> clinical CVD (ischemic heart disease, HF, stroke) <i class="calibre3">or</i> 10-y ASCVD risk ≥10%; otherwise if BP ≥140/90</p>
<p class="bl"><span class="sbl">•</span> JNC8: target &lt;140/90 if &lt;60 y or DM or CKD, &lt;150/90 if ≥60 y w/o DM or CKD</p>
<p class="bl"><span class="sbl">•</span> In high CV risk w/o DM, SBP target of &lt;120 (via unattended automated cuff) ↓ MACE &amp; mortality vs. target of &lt;140, but w/ ↑ HoTN, AKI, syncope, electrolyte abnl <span class="s1r">(<i class="calibre3">NEJM</i> 2015;373:2103)</span>. Same pattern in subgp ≥75 y <span class="s1r">(<i class="calibre3">JAMA</i> 2016;315:2673)</span>.</p>
<p class="bl"><a id="page_1-29" class="calibre1"></a><span class="sbl">•</span> <b class="calibre4">Lifestyle modifications</b> (each may ↓ SBP ~5 mmHg)</p>
<p class="bl1">weight loss: goal BMI 18.5–24.9; aerobic exercise: 90–150 min exercise/wk</p>
<p class="bl1">diet: rich in fruits &amp; vegetables, low in saturated &amp; total fat (DASH, <i class="calibre3">NEJM</i> 2001;344:3)</p>
<p class="bl1">limit Na: ideally ≤1.5 g/d or ↓ 1 g/d; enhance K intake (3.5–5 g/d)</p>
<p class="bl1">limit alcohol: ≤2 drinks/d in men; ≤1 drink/d in women &amp; lighter-wt Pts; avoid NSAIDs</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pharmacologic options</b></p>
<p class="bl1"><b class="calibre4"><span class="underline">Pre-HTN</span>:</b> ARB prevents onset of HTN, no ↓ in clinical events <span class="s1r">(<i class="calibre3">NEJM</i> 2006;354:1685)</span></p>
<p class="bl1"><b class="calibre4"><span class="underline">HTN</span>:</b> <i class="calibre3">choice of therapy controversial, concomitant disease and stage may help guide Rx</i></p>
<p class="bl1"><b class="calibre4">Uncomplicated:</b> CCB, ARB/ACEI, or thiazide (chlorthalidone preferred) are 1<sup class="calibre15">st</sup> line; βB not</p>
<p class="bl2"><i class="calibre3">For black, elderly, and ? obese Pts:</i> reasonable to start with CCB or thiazide</p>
<p class="bl1"><b class="calibre4">+ CAD</b> <span class="s1r">(<i class="calibre3">Circ</i> 2015;131:e435)</span>: ACEI or ARB <span class="s1r">(<i class="calibre3">NEJM</i> 2008;358:1547)</span>; ACEI+CCB superior to ACEI+thiazide <span class="s1r">(<i class="calibre3">NEJM</i> 2008;359:2417)</span> or βB+diuretic <span class="s1r">(<i class="calibre3">Lancet</i> 2005;366:895)</span>; may require βB and/or nitrates for anginal relief; if h/o MI, βB ± ACEI/ARB ± aldo antag (see “ACS”)</p>
<p class="bl1"><b class="calibre4">+ HF:</b> ACEI/ARB/ARNi, βB, diuretics, aldosterone antagonist (see “Heart Failure”)</p>
<p class="bl1"><b class="calibre4">+ prior stroke:</b> ACEI ± thiazide <span class="s1r">(<i class="calibre3">Lancet</i> 2001;358:1033)</span></p>
<p class="bl1"><b class="calibre4">+ diabetes mellitus:</b> consider ACEI or ARB; can also consider thiazide or CCB</p>
<p class="bl1"><b class="calibre4">+ chronic kidney disease:</b> ACEI or ARB <span class="s1r">(<i class="calibre3">NEJM</i> 1993;329:1456 &amp; 2001;345:851 &amp; 861)</span></p>
<p class="bl"><span class="sbl">•</span> Tailoring therapy: if stage 1, start w/ monoRx; if stage 2, consider starting w/ combo (eg, ACEI + CCB; <i class="calibre3">NEJM</i> 2008;359:2417); start at <sup class="calibre15">1</sup>/<sub class="calibre8">2</sub> max dose; after 1 mo, uptitrate or add drug</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pregnancy:</b> methyldopa, labetalol, &amp; nifed pref. Hydral OK; avoid diuretics; ∅ ACEI/ARB. Targeting DBP 85 vs. 105 safe and ↓ severe HTN <span class="s1r">(<i class="calibre3">NEJM</i> 2015;372:407)</span>.</p>
<p class="h2a"><b class="calibre4">Resistant HTN</b> (BP &gt; goal on ≥3 drugs incl diuretic; <span class="s"><i class="calibre3">HTN</i> 2018;72:e53</span>)</p>
<p class="bl"><span class="sbl">•</span> Exclude: 2° causes (see table) and <i class="calibre3">pseudoresistance:</i> inaccurate measure (cuff size), diet noncomp (↑ Na), poor Rx compliance/dosing, white coat HTN (✔ ABPM)</p>
<p class="bl"><span class="sbl">•</span> Ensure effective diuresis (chlorthalidone or indapamide &gt; HCTZ; loop &gt; thiazide if eGFR &lt;30)</p>
<p class="bl"><span class="sbl">•</span> Can add aldosterone antagonist <span class="s1r">(<i class="calibre3">Lancet</i> 2015;386:2059)</span>, β-blocker (particularly vasodilators such as labetalol, carvedilol, or nebivolol), α-blocker, or direct vasodilator</p>
<p class="h">H<small class="calibre30">YPERTENSIVE</small> C<small class="calibre30">RISES</small></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Hypertensive emergency:</b> SBP &gt;180 or DBP &gt;120 w/ target-organ damage</p>
<p class="bl1">Neurologic damage: encephalopathy, hemorrhagic or ischemic stroke, papilledema</p>
<p class="bl1">Cardiac damage: ACS, HF/pulmonary edema, aortic dissection</p>
<p class="bl1">Renal damage: proteinuria, hematuria, acute renal failure; scleroderma renal crisis</p>
<p class="bl1">Microangiopathic hemolytic anemia; preeclampsia-eclampsia</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Hypertensive urgency:</b> SBP &gt;180 or DBP &gt;120 w/o target-organ damage</p>
<p class="h2a"><b class="calibre4">Precipitants</b></p>
<p class="bl"><span class="sbl">•</span> Progression of essential HTN ± medical noncompliance (espec clonidine) or ∆ in diet</p>
<p class="bl"><span class="sbl">•</span> Progression of renovascular disease; acute glomerulonephritis; scleroderma; preeclampsia</p>
<p class="bl"><span class="sbl">•</span> Endocrine: pheochromocytoma, Cushing’s</p>
<p class="bl"><span class="sbl">•</span> Sympathomimetics: cocaine, amphetamines, MAO inhibitors + foods rich in tyramine</p>
<p class="h2a"><b class="calibre4">Treatment – tailor to clinical condition</b> <span class="s">(<i class="calibre3">Circ</i> 2018;138:e426)</span></p>
<p class="bl"><span class="sbl">•</span> AoD, eclampsia/severe preeclampsia, pheo: target SBP &lt;140 (&lt;120 for AoD) in <b class="calibre4">1 hour</b></p>
<p class="bl"><span class="sbl">•</span> Emerg w/o above: ↓ BP by ~25% in 1 h; to 160/100–110 over next 2–6 h, then nl over 1–2 d</p>
<p class="bl"><span class="sbl">•</span> Acute ischemic stroke (w/in 72 hr from sx onset): &lt;185/110 before lysis initiated, o/w target &lt;220/120 (same SBP goal for ICH)</p>
<p class="bl"><span class="sbl">•</span> Watch UOP, Cr, mental status: may indicate a lower BP is not tolerated</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre36"/>
<col class="calibre27"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">IV Drugs for Hypertensive Emergency</b> (<span class="tfont1"><i class="calibre3">Circ</i> 2018;138:e426; <i class="calibre3">Stroke</i> 2018;49:46</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Drug</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Dose</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Preferred for</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Labetalol</p></td>
<td class="bg0-br"><p class="tab">20–80 mg IVB q10min or 0.4–2 mg/min</p></td>
<td class="bg0-b"><p class="tab">AoD, ACS, Stroke, Eclampsia</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Esmolol</p></td>
<td class="bg0-br"><p class="tab">0.5–1 mg/kg load → 50–200 µg/kg/min</p></td>
<td class="bg0-b"><p class="tab">AoD, ACS</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Nitroprusside<a id="st2" class="calibre1"></a><a href="part0006.html#sst2" class="calibre1">*</a></p></td>
<td class="bg0-br"><p class="tab">0.25–10 µg/kg/min</p></td>
<td class="bg0-b"><p class="tab">Pulm edema</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Nitroglycerin</p></td>
<td class="bg0-br"><p class="tab">5–500 µg/min</p></td>
<td class="bg0-b"><p class="tab">Pulm edema, ACS</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Nicardipine</p></td>
<td class="bg0-br"><p class="tab">5–15 mg/h (can ↑ 2.5 mg/h q 5 min)</p></td>
<td class="bg0-b"><p class="tab">Stroke, AKI, Eclampsia, Pheo</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Clevidipine</p></td>
<td class="bg0-br"><p class="tab">1–32 mg/h (can titrate q 5–10 min)</p></td>
<td class="bg0-b"><p class="tab">Stroke, Pulm edema, AKI, Pheo</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Fenoldopam</p></td>
<td class="bg0-br"><p class="tab">0.1–1.6 µg/kg/min</p></td>
<td class="bg0-b"><p class="tab">AKI</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Hydralazine</p></td>
<td class="bg0-br"><p class="tab">10–20 mg q20–30min prn</p></td>
<td class="bg0-b"><p class="tab">Eclampsia</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Phentolamine</p></td>
<td class="bg0-br"><p class="tab">5–15 mg bolus q5–15min</p></td>
<td class="bg0-b"><p class="tab">Pheo</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Enalaprilat</p></td>
<td class="bg0-r"><p class="tab">1.25–5 mg q6h</p></td>
<td class="bg"> </td>
</tr>
</table>
<p class="tsr"><a id="sst2" class="calibre1"></a><a href="part0006.html#st2" class="calibre1">*</a>Metabolized to cyanide →Δ MS, lactic acidosis, death. Limit use of very high doses (8–10 μg/kg/min) to &lt;10 min.</p>
<p class="bl"><span class="sbl">•</span> HTN urgency: goal to return to normal BP over hrs to days. Reinstitute/intensify anti-HTN Rx. Additional PO options: labetalol 200–800 mg q8h, captopril 12.5–100 mg q8h, hydralazine 10–75 mg q6h, clonidine 0.2 mg load → 0.1 mg q1h.</p>
<h2 class="ct"><a id="h12" class="calibre7"></a><a id="page_1-30" class="calibre7"></a><a href="part0002.html#rh16" class="calibre7">AORTIC ANEURYSMS</a></h2>
<p class="h2a"><b class="calibre4">Definitions</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">True</b> aneurysm (≥50% dilation of all 3 layers of aorta) vs. <b class="calibre4">false</b> (rupture within adventitia)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Location:</b> root (annuloaortic ectasia), thoracic aortic aneurysm (TAA), thoracoabdominal aortic aneurysm (TAAA), abdominal aortic aneurysm (AAA)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Type:</b> fusiform (circumferential dilation) vs. saccular (localized dilation of aortic wall)</p>
<p class="h2a"><b class="calibre4">Epidemiology</b> <span class="s">(<i class="calibre3">Circ</i> 2010;121:e266, 2011;124:2020; <i class="calibre3">Nat Rev Cardiol</i> 2011;8:92)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">TAA:</b> ♂:♀ 2:1; ~60% root/ascending; 40% desc.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">AAA:</b> ~4–8% prev in those &gt;60 y; 5× more common in ♂; mostly infrarenal</p>
<p class="h2a"><b class="calibre4">Pathophysiology &amp; risk factors</b> <span class="s">(<i class="calibre3">NEJM</i> 2009;361:1114; <i class="calibre3">Nat Med</i> 2009;15:649)</span></p>
<p class="bl"><span class="sbl">•</span> Medial degen and/or ↑ wall stress; wall stress ∝ [(∆P × r) / (wall thickness)] (Laplace’s law)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">TAA:</b> medial degeneration (muscle apoptosis, elastin fiber weakening); a/w CTD, aortitis</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">AAA:</b> long-standing HTN + athero/inflammation → medial weakening</p>
<p class="bl"><span class="sbl">•</span> Classic <b class="calibre4">clinical risk factors:</b> HTN, atherosclerosis, smoking, age, ♂</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">CTD</b> (Marfan, Ehlers-Danlos type IV, Loeys-Dietz); <b class="calibre4">congenital</b> (bicuspid AoV, Turner’s) <b class="calibre4">aortitis</b> (Takayasu’s GCA, spondyloarthritis, IgG4, syphilis); trauma</p>
<p class="h2a"><b class="calibre4">Screening</b> <span class="s">(<i class="calibre3">Circ</i> 2010;121:e266 &amp; 2011;124:2020; <i class="calibre3">Annals</i> 2014;161:281; <i class="calibre3">JAMA</i> 2015;313:1156)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">TAA:</b> if bicuspid AoV or 1° relative w/: (a) TAA or bicuspid AoV, (b) CTD as above</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">AAA:</b> ✔ for pulsatile abd mass; U/S ♂ &gt;60 y w/ FHx of AAA &amp; ♂ 65–75 y w/ prior tobacco</p>
<p class="h2a"><b class="calibre4">Diagnostic studies</b> <span class="s">(<i class="calibre3">Circ</i> 2010;121:e266 &amp; 2011;124:2020)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Contrast CT:</b> quick, noninvasive, high Se &amp; Sp for all aortic aneurysms</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">TTE/TEE:</b> TTE most useful for root and proximal Ao; TEE can visualize other sites of TAA</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">MRI:</b> favored over CT for AoRoot imaging; useful in AAA but time consuming; noncontrast “black blood” MR to assess aortic wall</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Abdominal U/S:</b> screening/surveillance test of choice for infrarenal AAA</p>
<p class="h2a"><b class="calibre4">Treatment</b> <span class="s">(<i class="calibre3">Circ</i> 2008;117:1883 &amp; 2010;121:e266 &amp; 2016;133:680; <i class="calibre3">NEJM</i> 2014;371:2101)</span></p>
<p class="bl"><span class="sbl">•</span> Goal is to prevent rupture (50% mortality prior to hospital) by modifying risk factors</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Risk factor modification:</b> smoking cessation; LDL-C &lt;70–100 mg/dl</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">BP control: βB</b> (↓ dP/dt) ↓ aneurysm growth <span class="s1r">(<i class="calibre3">NEJM</i> 1994;330:1335)</span>; <b class="calibre4">ACEI</b> a/w ↓ rupture risk <span class="s1r">(<i class="calibre3">Lancet</i> 2006;368:659)</span>; <b class="calibre4">ARB</b> may ↓ rate of aortic root growth in Marfan <span class="s1r">(<i class="calibre3">NEJM</i> 2008;358:2787)</span></p>
<p class="bl"><span class="sbl">•</span> Mod CV exercise OK, no burst activity requiring Valsalva maneuvers (eg, heavy lifting)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Indications for surgery</b> (individualized based on FHx, body size, gender, anatomy)</p>
<p class="bl1"><b class="calibre4">TAA:</b> sxs; ascending Ao ≥5.5 cm (4–5 cm if Marfan, L-D, EDS, bicuspid AoV); descending Ao &gt;6 cm; ≥4.5 cm and planned AoV surgery; ↑ &gt;0.5 cm/y</p>
<p class="bl1"><b class="calibre4">AAA:</b> sx; infrarenal &gt;5.5 cm; consider ≥5.0 cm in ♀; ↑ &gt;0.5 cm/y; inflam/infxn</p>
<p class="h2a"><b class="calibre4">Endovascular repair (EVAR)</b> <span class="s">(<i class="calibre3">NEJM</i> 2008;358:494; <i class="calibre3">Circ</i> 2011;124:2020 &amp; 2015;131:1291)</span></p>
<p class="bl"><span class="sbl">•</span> Requires favorable aortic anatomy</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">TEVAR</b> (thoracic EVAR) for descending TAA ≥5.5 cm may ↓ periop morbidity and possibly mortality <span class="s1r">(<i class="calibre3">Circ</i> 2010;121:2780; <i class="calibre3">JACC</i> 2010;55:986; <i class="calibre3">J Thorac CV Surg</i> 2010;140:1001 &amp; 2012;144:604)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">AAA:</b> guidelines support open repair or EVAR for infrarenal AAA in good surg candidates</p>
<p class="bl1">↓ short-term mort., bleeding, LOS; but long-term graft complic. (3–4%/y; endoleak, need for reintervention, rupture) necessitate periodic surveillance, with no difference in mortality long term <span class="s1r">(<i class="calibre3">Lancet</i> 2016;388:2366; <i class="calibre3">NEJM</i> 2019;380:2126)</span></p>
<p class="bl1">In Pts unfit for surgery or high periop risks: ↓ aneurysm-related mortality but no ∆ in overall mortality over med Rx <span class="s1r">(<i class="calibre3">NEJM</i> 2010;362:1872)</span>. EVAR noninferior (? superior) to open repair in ruptured AAA w/ favorable anatomy <span class="s1r">(<i class="calibre3">Ann Surg</i> 2009;250:818)</span>.</p>
<p class="h2a"><b class="calibre4">Complications</b> <span class="s">(<i class="calibre3">Circ</i> 2010;121:e266; <i class="calibre3">Nat Rev Cardiol</i> 2011;8:92)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pain:</b> gnawing chest, back, or abdominal pain; new or worse pain may signal rupture</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Rupture:</b> risk ↑ w/ diameter, ♀, current smoking, HTN</p>
<p class="bl1"><b class="calibre4">TAA:</b> ~2.5%/y if &lt;6 cm vs. 7%/y if &gt;6 cm</p>
<p class="bl1"><b class="calibre4">AAA:</b> ~1%/y if &lt;5 cm vs. 6.5%/y if 5–5.9 cm; ~80% mortality at 24 h</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Aortic insufficiency (TAA)</b>, <b class="calibre4">CHF, acute aortic syndromes</b> (qv)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Thromboembolic ischemic events</b> (eg, to CNS, viscera, extremities)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Compression of adjacent structures</b> (eg, SVC, trachea, esophagus, laryngeal nerve)</p>
<p class="h2a"><b class="calibre4">Follow-up</b> <span class="s">(<i class="calibre3">Circ</i> 2010;121:e266; <i class="calibre3">Nat Rev Cardiol</i> 2011;8:92; <i class="calibre3">JAMA</i> 2013;309:806)</span></p>
<p class="bl"><span class="sbl">•</span> Expansion rate ~0.1 cm/y for TAA, ~0.3–0.4 cm/y for AAA</p>
<p class="bl"><span class="sbl">•</span> AAA: &lt;4 cm q2–3y; 4–5.4 cm q6–12mo; more often if rate of expansion &gt;0.5 cm in 6 mo</p>
<p class="bl"><span class="sbl">•</span> TAA: 6 mo after dx to ensure stable, and if stable, then annually <span class="s1r">(<i class="calibre3">Circ</i> 2005;111:816)</span></p>
<p class="bl"><span class="sbl">•</span> Screen for CAD, PAD, and aneurysms elsewhere, espec popliteal. About 25% of Pts w/ TAA will also have AAA, and 25% of AAA Pts will have a TAA: consider pan-Ao imaging.</p>
<h2 class="ct"><a id="h13" class="calibre7"></a><a id="page_1-31" class="calibre7"></a><a href="part0002.html#rh17" class="calibre7">ACUTE AORTIC SYNDROMES</a></h2>
<p class="h2a"><b class="calibre4">Definitions</b> <span class="s">(<i class="calibre3">Circ</i> 2010;121:e266; <i class="calibre3">Eur Heart J</i> 2012;33:26)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Aortic dissection:</b> intimal tear → blood extravasates into Ao media (creates false lumen)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Intramural hematoma</b> (IMH): vasa vasorum rupture → medial hemorrhage that does not communicate with aortic lumen; 6% of aortic syndromes; clinically managed as AoD</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Penetrating ulcer:</b> atherosclerotic plaque penetrates elastic lamina → medial hemorrhage</p>
<p class="h2a"><b class="calibre4">Classification</b> <span class="s">(proximal twice as common as distal)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Proximal:</b> involves ascending Ao, regardless of origin (= Stanford A, DeBakey I &amp; II)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Distal:</b> involves descending Ao only, distal to L subclavian art. (= Stanford B, DeBakey III)</p>
<p class="h2a"><b class="calibre4">Risk factors</b> <span class="s">(<i class="calibre3">Lancet</i> 2015;385:800)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Classic</b> (in older Pts): <b class="calibre4">HTN</b> (h/o HTN in &gt;70% of dissections); <b class="calibre4">age</b> (60s–70s), <b class="calibre4">sex</b> (~65% ♂); <b class="calibre4">smoking;</b> ↑ lipids. <b class="calibre4">Acute</b> ↑ <b class="calibre4">BP:</b> cocaine, Valsalva (eg, weightlifting).</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Genetic or acquired predisposition:</b> <i class="calibre3">CTD</i> (Marfan, Loeys-Dietz, Ehlers-Danlos type IV); <i class="calibre3">congenital anomaly</i> (bicuspid AoV, coarct [eg, Tuner’s syndrome], PCKD); <i class="calibre3">aortitis</i> (Takayasu’s, GCA, Behçet’s, syphilis); <i class="calibre3">preg.</i> (typically 3<sup class="calibre15">rd</sup> trim.); fluoroquinolone exposure</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Trauma:</b> blunt, decel. injury (eg, MVA); IABP, cardiac/aortic surgery, Impella, cardiac cath</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre24"/>
<col class="calibre33"/>
<col class="calibre33"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">Clinical Manifestations and Physical Exam<a id="st3" class="calibre1"></a><a href="part0006.html#sst3" class="calibre1">*</a></b> (<span class="tfont1"><i class="calibre3">JAMA</i> 2000;283:897</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Feature</b></p></td>
<td class="bg0-br"><p class="tabc"><b class="calibre4">Proximal</b></p></td>
<td class="bg0-b"><p class="tabc"><b class="calibre4">Distal</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">“Aortic” pain</b> (abrupt, severe, tearing or ripping quality, <i class="calibre3">maximal at onset</i> [vs. crescendo for ACS])</p></td>
<td class="bg0-br"><p class="tabc"><b class="calibre4">94%</b></p>
<p class="tabc">(chest, back)</p></td>
<td class="bg0-b"><p class="tabc"><b class="calibre4">98%</b></p>
<p class="tabc">(back, chest, abd)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Syncope</b> (often due to tamponade)</p></td>
<td class="bg0-br"><p class="tabc"><b class="calibre4">13%</b></p></td>
<td class="bg0-b"><p class="tabc">4%</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">HF</b> (usually due to acute AI)</p></td>
<td class="bg0-br"><p class="tabc"><b class="calibre4">9%</b></p></td>
<td class="bg0-b"><p class="tabc">3%</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">CVA</b></p></td>
<td class="bg0-br"><p class="tabc"><b class="calibre4">6%</b></p></td>
<td class="bg0-b"><p class="tabc">2%</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">HTN</b></p></td>
<td class="bg0-br"><p class="tabc">36%</p></td>
<td class="bg0-b"><p class="tabc"><b class="calibre4">70%</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">HoTN or shock</b> (tamponade, AI, MI, rupture)</p></td>
<td class="bg0-br"><p class="tabc"><b class="calibre4">25%</b></p></td>
<td class="bg0-b"><p class="tabc">4%</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Pulse deficit</b> (if involves carotid, subclavian, fem)</p></td>
<td class="bg0-br"><p class="tabc"><b class="calibre4">19%</b></p></td>
<td class="bg0-b"><p class="tabc"><b class="calibre4">9%</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">AI murmur</b></p></td>
<td class="bg0-r"><p class="tabc"><b class="calibre4">44%</b></p></td>
<td class="bg"><p class="tabc">12%</p></td>
</tr>
</table>
<p class="tsr"><a id="sst3" class="calibre1"></a><a href="part0006.html#st3" class="calibre1">*</a>S/S correlate w/ affected branch vessels &amp; distal organs; may Δ as dissection progresses</p>
<p class="h2a"><b class="calibre4">Initial evaluation &amp; diagnostic studies</b> <span class="s">(<i class="calibre3">Circ</i> 2010;121:e266; <i class="calibre3">JACC CV Img</i> 2014;7:406)</span></p>
<p class="bl"><span class="sbl">•</span> H&amp;P, incl. bilat BP &amp; radial pulses for symmetry; ECG w/ STE if propagates to cor</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">CXR</b>: abnl in 60–90% [↑ mediast. (absence ⊖ LR 0.3), L pl effusion] but <i class="calibre3">cannot</i> r/o AoD</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">CT:</b> quick and available, Se ≥93%, Sp 98%; facilitates “triple rule-out” ACS vs. PE vs. AoD</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">MRI:</b> Se &amp; Sp &gt;98%, but time-consuming test &amp; not readily available</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">TEE:</b> Se &gt;95% prox, 80% for distal; can assess cors/peric/AI; “blind spot” behind trachea</p>
<p class="bl"><span class="sbl">•</span> ⊖ Initial imaging but high clinical suspicion → further studies (<sup class="calibre15">2</sup>/<sub class="calibre8">3</sub> w/ AoD have ≥2 studies)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">D-dimer</b> &lt;500 ng/mL has Se/NPV ~97%, Sp ~50%, <i class="calibre3">but not if high risk</i> and not for IMH</p>
<p class="bl"><span class="sbl">•</span> ? risk score (0–3 points): high-risk (eg, genetics, recent Ao manip); aortic pain; e/o perfusion deficit, AI or shock. Score &gt;1 → imaging; ≤1 &amp; DD &lt;500 has NPV &gt;99% <span class="s1r">(<i class="calibre3">Circ</i> 2018;137:250)</span></p>
<p class="h2a"><b class="calibre4">Treatment</b> <span class="s">(<i class="calibre3">Circ</i> 2010;121:1544; <i class="calibre3">JACC</i> 2013;61:1661; <i class="calibre3">Lancet</i> 2015;385:800)</span></p>
<p class="bl"><span class="sbl">•</span> ↓ <b class="calibre4">dP/dt</b> targeting HR &lt;60 &amp; central BP &lt;120 (or lowest that preserves perfusion; r/o pseudohypotension, eg, arm BP ↓ due to subclavian dissection; use highest BP reading)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4"><i class="calibre3">First</i> IV βB</b> (eg, esmolol, labetalol) to blunt reflex ↑ HR &amp; inotropy in response to vasodilators; verap/dilt if <b class="calibre4">β</b>B contraindic; <b class="calibre4"><i class="calibre3">then</i></b> ↓ <b class="calibre4"><i class="calibre3">SBP w/</i> IV vasodilators</b> (eg, nitroprusside)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">If HoTN:</b> urgent surgical consult, IVF to achieve euvolemia, pressors to keep (MAP 70 mmHg); r/o complication (eg, tamponade, contained rupture, severe AI)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Proximal:</b> surgery considered in <b class="calibre4">all acute</b> and in chronic if c/b progression, AI or aneurysm</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Distal:</b> med Rx unless complication (see below), however pre-emptive endovascular intervention may ↓ late complications, mort <span class="s1r">(<i class="calibre3">JACC</i> 2013;61:1661; <i class="calibre3">Circ Cardiovasc Int</i> 2013;6:407)</span></p>
<p class="h2a"><b class="calibre4">Complications</b> <span class="s">(occur in ~20%; <i class="calibre3">Circ</i> 2010;121:e266; <i class="calibre3">Lancet</i> 2015;385:800)</span></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Freq assess (sx, BP, UOP), pulses, labs (Cr, Hb, lactic acid), imaging (~7 d or sooner if</i> ∆<i class="calibre3">s)</i></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Uncontrolled BP or persistent pain may indicate complication/extension</i></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Progression:</b> propagation of dissection, ↑ aneurysm size, ↑ false lumen size</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Rupture:</b> pericardial sac → tamponade (avoid pericardiocentesis unless PEA); blood in pleural space, mediast., retroperitoneum; ↑ in hematoma on imaging portends rupture</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Malperfusion</b> (partial or complete obstruction of branch artery) <i class="calibre3">coronary</i> → MI (usually RCA → IMI b/c dissection follows outer Ao curvature); <i class="calibre3">innominate/carotid</i> → CVA, Horner; <i class="calibre3">intercostal/lumbar</i> → spinal cord ischemia/paraplegia; <i class="calibre3">innominate/subclavian</i> → upper ext ischemia; <i class="calibre3">iliac</i> → lower ext ischemia; <i class="calibre3">celiac/mesenteric</i> → bowel ischemia; <i class="calibre3">renal</i> → AKI or slow ↑ Cr, refractory HTN</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">AI:</b> due to annular dilatation or disruption or displacement of leaflet by false lumen</p>
<p class="bl"><span class="sbl">•</span> Mortality: ~1%/h × 48 h for acute prox AoD w/ 10–35% at 30 d; ↑ mort. if HTN or HoTN</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Long-term serial imaging</b> (CT or MRI; ↓ rad w/ MRI) at 1, 3, and 6 mo, and then annually</p>
<h2 class="ct"><a id="h14" class="calibre7"></a><a id="page_1-32" class="calibre7"></a><a href="part0002.html#rh18" class="calibre7">ARRHYTHMIAS</a></h2>
<p class="h">B<small class="calibre30">RADYCARDIAS</small>, AV B<small class="calibre30">LOCK</small>, <small class="calibre30">AND</small> AV D<small class="calibre30">ISSOCIATION</small></p>
<p class="h2a"><b class="calibre4">Sinus bradycardia (SB)</b> <span class="s">(<i class="calibre3">NEJM</i> 2000;342:703)</span></p>
<p class="bl"><span class="sbl">•</span> Etiologies: <b class="calibre4">meds</b> (incl βB, CCB, amio, Li, dig), ↑ <b class="calibre4">vagal tone</b> (incl. athletes, sleep, IMI), <b class="calibre4">metabolic</b> (hypoxia, sepsis, myxedema, hypothermia, ↓ glc), OSA, ↑ ICP</p>
<p class="bl"><span class="sbl">•</span> Treatment: if no sx, none; atropine, β<sub class="calibre8">1</sub> agonists (short-term) or pacing if symptomatic</p>
<p class="bl"><span class="sbl">•</span> Most common cause of sinus pause is <i class="calibre3">blocked premature atrial beat</i></p>
<p class="h2a"><b class="calibre4">Sick sinus syndrome (SSS)</b></p>
<p class="bl"><span class="sbl">•</span> Features may include: periods of unprovoked SB, SA arrest, paroxysms of SB and atrial</p>
<p class="bl1">tachyarrhythmias (“tachy-brady” syndrome), chronotropic incompetence w/ ETT</p>
<p class="bl"><span class="sbl">•</span> Treatment: meds alone usually fail (adeq. control tachy → unacceptable brady); usually need <b class="calibre4">combination of meds</b> (βB, CCB, dig) for tachy &amp; <b class="calibre4">PPM</b> for brady</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">AV Block</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Type</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Features</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">1°</b></p></td>
<td class="bg0-b"><p class="tab">Prolonged PR (&gt;200 ms), all atrial impulses conducted (1:1).</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">2° Mobitz I (Wenckebach)</b></p></td>
<td class="bg0-b"><p class="tab">Progressive ↑ PR until impulse not conducted (→ “grouped beating”).</p>
<p class="tabh">Due to <b class="calibre4">AV node</b> abnl: ischemia (IMI), inflammation (myocarditis, endocarditis, MV surgery), high vagal tone (athletes), drug induced.</p>
<p class="tabh">Classically (~50%), absolute ↑ in PR <i class="calibre3">decreases</i> over time (→ ↓ RR intervals, duration of pause &lt;2× preceding RR interval); nl QRS.</p>
<p class="tab">AVB usually worsens w/ carotid sinus massage, improves w/ atropine.</p>
<p class="tab">Often paroxysmal/nocturnal/asx, no Rx required.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">2° Mobitz II</b></p></td>
<td class="bg0-b"><p class="tab">Blocked impulses w/ consistent PR interval, often prolonged QRS</p>
<p class="tabh">Due to <b class="calibre4">His-Purkinje</b> abnl: ischemia (AMI), degeneration of conduction system, infiltrative disease, inflammation/AoV surgery/TAVR.</p>
<p class="tab">AVB may improve w/ carotid sinus massage, may worsen w/ atropine.</p>
<p class="tab">May progress to 3° AVB. Pacing pads; transven. pacing often required.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">3° (complete)</b></p></td>
<td class="bg"><p class="tab">No AV conduction. Escape, if present, narrow (jxnal) or wide (vent.)</p></td>
</tr>
</table>
<p class="tsr">Nb, if 2:1 block, cannot distinguish type I vs. II 2° AVB (no chance to observe PR prolongation); usually categorize based on other ECG &amp; clinical data. High-grade AVB usually refers to block of ≥2 successive impulses.</p>
<p class="h2a"><b class="calibre4">AV dissociation</b></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Default:</i> slowing of SA node allows subsidiary pacemaker (eg, AV junction) to take over</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Usurpation:</i> acceleration of subsidiary pacemaker (eg, AV junctional tach, VT)</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">3</i>° <i class="calibre3">AV block:</i> atrial pacemaker unable to capture ventricles, subsidiary pacemaker emerges distinguish from <i class="calibre3">isorhythmic dissociation</i> (A ≈ V rate, some P waves nonconducting)</p>
<p class="h2a"><b class="calibre4">Temporary pacing wires</b></p>
<p class="bl"><span class="sbl">•</span> Consider w/ bradycardia with hemodyn instability or unstable escape rhythm when perm pacer not readily available. Risks: infxn, RV perf, VT, PTX, CHB if existing LBBB.</p>
<p class="bl"><span class="sbl">•</span> Consider instead of PPM for sx brady from reversible cause (βB/CCB O/D, Lyme, SBE, myocarditis, s/p cardiac surgery/trauma/TAVR), TdP, acute MI (sx brady/high-grade AVB)</p>
<p class="h">S<small class="calibre30">UPRAVENTRICULAR</small> T<small class="calibre30">ACHYCARDIAS</small> (SVT<small class="calibre30">S</small>)</p>
<p class="cst"><i class="calibre3">Arise above the ventricles</i>, ∴ <b class="calibre4"><i class="calibre3">narrow QRS</i></b> <i class="calibre3">unless aberrant conduction or pre-excitation.</i></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre37"/>
<col class="calibre17"/>
<col class="calibre26"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">Common Etiologies of SVT</b> (<span class="tfont1"><i class="calibre3">NEJM</i> 2012;367:1438</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"> </p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Type</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Features</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2" rowspan="5"><p class="tab"><b class="calibre4">Atrial</b></p></td>
<td class="bg0-br"><p class="tab">Sinus tachycardia (ST)</p></td>
<td class="bg0-b"><p class="tab">Caused by pain, fever, hypovolemia, hypoxia, PE, anemia, anxiety, withdrawal, β-agonists, etc.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Atrial tachycardia (AT)</p></td>
<td class="bg0-b"><p class="tab">Originate at site in atria other than SA node. Seen w/ CAD, COPD, ↑ catechols, EtOH, dig.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Multifocal atrial tachycardia (MAT)</p></td>
<td class="bg0-b"><p class="tab">↑ automaticity at multiple sites in the atria; seen with underlying pulmonary disease</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Atrial flutter (AFL)</p></td>
<td class="bg0-b"><p class="tab">Clockwise or counterclockwise macroreentry, usually w/in right atrium</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Atrial fibrillation (AF)</p></td>
<td class="bg0-b"><p class="tab">Chaotic atrial activation with rapid, irregular AVN bombardment; often from pulmonary veins</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r1" rowspan="3"><p class="tab"><b class="calibre4">AV Jxn</b></p></td>
<td class="bg0-br"><p class="tab">AV nodal reentrant tach (AVNRT)</p></td>
<td class="bg0-b"><p class="tab">Reentrant circuit using dual pathways w/in AVN</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Atrioventricular reciprocating tachycardia (AVRT)</p></td>
<td class="bg0-b"><p class="tab">Reentry using AVN &amp; access. path. May show pre-excitation (WPW) or not (concealed access. path.). Can be ortho or antidromic (see below).</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Nonparoxysmal junctional tachycardia (NPJT)</p></td>
<td class="bg"><p class="tab">↑ jxnal automaticity. May see retro. P, AV dissoc. A/w myo/endocarditis, cardiac surg, IMI, dig.</p></td>
</tr>
</table>
<table class="t-topbot2">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Diagnosis of SVT Type</b> (<span class="tfont1"><i class="calibre3">NEJM</i> 2012;367:1438</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><a id="page_1-33" class="calibre1"></a><b class="calibre4">Onset</b></p></td>
<td class="bg0-b"><p class="tab">Abrupt on/off argues against sinus tachycardia</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Rate</b></p></td>
<td class="bg0-b"><p class="tab">Not dx b/c most can range from 140–250 bpm, <i class="calibre3">but:</i> ST usually &lt;150; AFL often conducts 2:1 → vent. rate 150; AVNRT &amp; AVRT usually &gt;150</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Rhythm</b></p></td>
<td class="bg0-b"><p class="tab">Irregular → AF, AFL w/ variable block, or MAT</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">P wave</b></p>
<p class="tab"><b class="calibre4">morphology</b></p></td>
<td class="bg0-b"><p class="tab">Before QRS (ie, long RP) → ST, AT (P ≠ sinus), MAT (≥3 morphologies)</p>
<p class="tab">After QRS (ie, short RP) &amp; inverted in inf. leads → <i class="calibre3">retrograde</i> atrial activ.</p>
<p class="tabh1">AVNRT: buried in or distort terminal portion of QRS (pseudo RSR′ in V<sub class="calibre13">1</sub>)</p>
<p class="tabh1">AVRT: slightly after QRS (RP interval &gt;100 ms favors AVRT vs. AVNRT)</p>
<p class="tabh1">NPJT: either no P wave or retrograde P wave similar to AVNRT</p>
<p class="tab"><i class="calibre3">Fibrillation or no P waves</i> → AF</p>
<p class="tab"><i class="calibre3">Saw-toothed “F” waves</i> (best seen in inferior leads &amp; V<sub class="calibre13">1</sub>) → AFL</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Response to vagal stim. or adenosine</b></p></td>
<td class="bg"><p class="tab">Slowing of HR often seen with ST, AF, AFL, AT, whereas reentrant rhythms (AVNRT, AVRT) may abruptly terminate (classically w/ P wave after last QRS) or no response. Occ AT may terminate.</p>
<p class="tab">In AFL &amp; AF, ↑ AV block may unmask “F” waves or fibrillation</p></td>
</tr>
</table>
<p class="capf"><b class="calibre4">Figure 1-4</b> Approach to SVT (adapted from <i class="calibre3">NEJM</i> 2012;367:1438)</p>
<p class="image"><img src="../images/00025.jpeg" alt="" class="calibre2"/></p>
<table class="t-topbot">
<colgroup class="calibre9">
<col class="calibre37"/>
<col class="calibre17"/>
<col class="calibre26"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">Treatment of SVT</b> (<span class="tfont1"><i class="calibre3">Circ</i> 2016;133:e506</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Rhythm</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Acute Treatment</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Long-term Treatment</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Unstable</p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Cardioversion</b> per ACLS</p></td>
<td class="bg0-b"><p class="tab">n/a</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">ST</p></td>
<td class="bg0-br"><p class="tab">Treat underlying stressor(s)</p></td>
<td class="bg0-b"><p class="tab">n/a</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">AT</p></td>
<td class="bg0-br"><p class="tab">βB, CCB or adenosine; ? amiodarone</p></td>
<td class="bg0-b"><p class="tab">radiofrequency ablation (RFA); βB or CCB, ± class IC/III AAD</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">AVNRT</p>
<p class="tab">or AVRT</p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Vagal maneuvers</b></p>
<p class="tab"><b class="calibre4">Adenosine</b> (caution in AVRT<a id="st4" class="calibre1"></a><a href="part0006.html#sst4" class="calibre1">*</a>)</p>
<p class="tab"><b class="calibre4">CCB</b> or βB, DCCV if other Rx fail</p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">For AVNRT</i> (<i class="calibre3">see next section for AVRT</i>):</p>
<p class="tab"><b class="calibre4">RFA.</b> CCB, βB, or dig (chronic or prn)</p>
<p class="tab">± Class IC/III AAD (if nl heart)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">NPJT</p></td>
<td class="bg0-br"><p class="tab">CCB, βB, amiodarone</p></td>
<td class="bg0-b"><p class="tab">Rx underlying dis. (eg, dig tox, ischemia)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">AF</p></td>
<td class="bg0-br"><p class="tab">β<b class="calibre4">B</b>, <b class="calibre4">CCB</b>, <b class="calibre4">digoxin</b>, <b class="calibre4">AAD</b></p></td>
<td class="bg0-b"><p class="tab">See “Atrial Fibrillation”</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">AFL</p></td>
<td class="bg0-br"><p class="tab">β<b class="calibre4">B</b>, <b class="calibre4">CCB</b>, <b class="calibre4">AAD</b></p></td>
<td class="bg0-b"><p class="tab">RFA; βB or CCB ± class III AAD</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">MAT</p></td>
<td class="bg0-r"><p class="tab">CCB or βB if tolerated</p></td>
<td class="bg"><p class="tab">Treat underlying disease. CCB or βB.</p>
<p class="tab">AVN ablation + PPM if refractory to meds</p></td>
</tr>
</table>
<p class="tsr"><a id="sst4" class="calibre1"></a><a href="part0006.html#st4" class="calibre1">*</a>Avoid adenosine &amp; nodal agents if accessory pathway + pre-excited tachycardia, see below (<i class="calibre3">JACC</i> 2003;42:1493)</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Catheter ablation:</i> high overall success rate (AFL/AVNRT ~95%, AVRT ~90%, AF ~70%)</p>
<p class="bl1">complications: stroke, MI, bleeding, perforation, conduction block <span class="s1r">(<i class="calibre3">JAMA</i> 2007;290:2768)</span></p>
<p class="h">A<small class="calibre30">CCESSORY</small> P<small class="calibre30">ATHWAYS</small> (W<small class="calibre30">OLFF</small>-P<small class="calibre30">ARKINSON</small>-W<small class="calibre30">HITE</small>)</p>
<p class="h2a"><b class="calibre4">Definitions</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Accessory pathway</b> (bypass tract) of conducting myocardium connecting atria &amp; ventricles, allowing impulses to bypass normal AVN delay</p>
<p class="image1"><img src="../images/00026.jpeg" alt="" class="calibre2"/></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pre-excitation (WPW) pattern:</b> ↓ PR interval, ↑ QRS width w/ δ wave (slurred onset, <i class="calibre3">can be subtle</i>). ST &amp; Tw abnl (can mimic old IMI).</p>
<p class="bl1"><i class="calibre3">Only seen w/ pathways that conduct antegrade</i> (if pathway only conducts retrograde, then ECG will be normal during SR; “concealed” bypass tract).</p>
<p class="bl"><span class="sbl">•</span> PAC can exaggerate pre-excitation if AV node conduction slowed</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">WPW syndrome:</b> WPW accessory pathway + paroxysmal tachycardia</p>
<p class="h2a"><b class="calibre4">Classic tachycardias of WPW accessory pathways</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Orthodromic AVRT:</b> <i class="calibre3">narrow-complex</i> SVT (typically), conducting ↓ AVN &amp; ↑ accessory pathway; requires retrograde conduction and ∴ can occur w/ concealed bypass tracts</p>
<p class="bl"><a id="page_1-34" class="calibre1"></a><span class="sbl">•</span> <b class="calibre4">Antidromic AVRT</b> (rare): <i class="calibre3">wide-complex</i> SVT, conducting ↓ accessory pathway &amp; ↑ AVN;</p>
<p class="bl1">requires antegrade conduction and ∴ should see pre-excitation pattern during SR</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">AF</b> w/ rapid conduction down accessory pathway; ∴ wide-complex irregular SVT; requires antegrade conduction; ∴ should see pre-excitation in SR. Rarely can degenerate into VF.</p>
<p class="h2a"><b class="calibre4">Treatment</b> <span class="s">(<i class="calibre3">Heart Rhythm</i> 2012;9:1006; <i class="calibre3">Circ</i> 2016;133:e506)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">AVRT</b> (orthodromic): vagal, βB, CCB; care w/ adenosine (can precip AF); <i class="calibre3">have defib ready</i></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">AF/AFL</b> w/ conduction down accessory pathway: need to Rx arrhythmia <i class="calibre3">and</i> ↑ pathway</p>
<p class="bl1">refractoriness. Use <b class="calibre4">procainamide</b>, <b class="calibre4">ibutilide</b>, or DCCV; <b class="calibre4"><i class="calibre3">avoid</i></b> CCB, βB, amio, dig, &amp; adenosine, b/c can ↓ refractoriness of pathway → ↑ vent. rate → VF <span class="s1r">(<i class="calibre3">Circ</i> 2016;133:e506)</span>.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Long term:</b> RFA if sx; if not candidate for RFA, then AAD (IA, III) or CCB/βB.</p>
<p class="bl1">Consider RFA if asx but AVRT or AF inducible on EPS <span class="s1r">(<i class="calibre3">NEJM</i> 2003;349:1803)</span> or if rapid conduction possible (✔ w/ EPS if pre-excitation persists during exercise testing)</p>
<p class="bl1">Risk of SCD related to how short RR interval is in AF (eg, ≤250 ms) and if SVT inducible</p>
<p class="h">W<small class="calibre30">IDE</small>-C<small class="calibre30">OMPLEX</small> T<small class="calibre30">ACHYCARDIAS</small> (WCT<small class="calibre30">S</small>)</p>
<p class="h2a"><b class="calibre4">Etiologies</b> <span class="s">(<i class="calibre3">Lancet</i> 2012;380:1520)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Ventricular tachycardia (VT):</b> accounts for 80% of WCT in unselected population</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">SVT conducted with aberrancy:</b> either fixed BBB, rate-dependent BBB (usually RBBB), conduction via an accessory pathway or atrially triggered ventricular pacing</p>
<p class="h2a"><b class="calibre4">Monomorphic ventricular tachycardia (MMVT)</b></p>
<p class="bl"><span class="sbl">•</span> All beats look similar; predominantly upward in V<sub class="calibre8">1</sub> = RBBB-type vs. downward = LBBB-type</p>
<p class="bl"><span class="sbl">•</span> In structurally <i class="calibre3">abnormal</i> heart: <b class="calibre4">prior MI</b> (scar); <b class="calibre4">CMP; myocarditis</b></p>
<p class="image1"><img src="../images/00027.jpeg" alt="" class="calibre2"/></p>
<p class="bl1"><b class="calibre4">arrhythmogenic RV CMP (ARVC):</b> incomplete RBBB,</p>
<p class="bl1">ε wave (terminal notch in QRS) &amp; TWI in V<sub class="calibre8">1</sub>–V<sub class="calibre8">3</sub> on resting ECG</p>
<p class="bl1">LBBB-type VT, dx w/ MRI <span class="s1r">(<i class="calibre3">Lancet</i> 2009;373:1289)</span></p>
<p class="bl"><span class="sbl">•</span> In structurally <i class="calibre3">normal</i> heart (w/ normal resting ECG):</p>
<p class="bl1"><b class="calibre4">RVOT VT:</b> LBBB-type VT or PVCs w/ inferior axis; typically ablate</p>
<p class="bl1"><b class="calibre4">Idiopathic LV VT:</b> RBBB-type VT or PVCs w/ superior axis; responds to verapamil</p>
<p class="h2a"><b class="calibre4">Polymorphic ventricular tachycardia (PMVT)</b></p>
<p class="bl"><span class="sbl">•</span> QRS morphology changes from beat to beat</p>
<p class="bl"><span class="sbl">•</span> Etiologies: <b class="calibre4">ischemia; CMP;</b> catecholaminergic;</p>
<p class="bl1"><b class="calibre4">torsades de pointes</b> (TdP = “twisting of the points,” PMVT + ↑ QT): ↑ QT <b class="calibre4"><i class="calibre3">acquired</i></b> (meds, lytes, stroke, see “ECG”) w/ risk ↑ w/ ↓ HR, freq PVCs (pause dependent) <b class="calibre4"><i class="calibre3">or congenital</i></b> (K/Na channelopathies) w/ resting Tw abnl &amp; TdP triggered by sympathetic stimulation (eg, exercise, emotion, sudden loud noises) <span class="s1r">(<i class="calibre3">Lancet</i> 2008;372:750)</span></p>
<p class="bl1"><b class="calibre4">Brugada syndrome</b> (Na channelopathy; <i class="calibre3">JACC</i> 2018;72:1046): ♂ &gt; ♀; pseudo-RBBB w/ STE in V<sub class="calibre8">1</sub>–V<sub class="calibre8">3</sub> (provoked w/class IA or IC) on resting ECG</p>
<p class="image1"><img src="../images/00028.jpeg" alt="" class="calibre2"/></p>
<p class="h2a"><b class="calibre4">Diagnostic clues that favor VT</b> <span class="s">(assume until proven o/w)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Prior MI</b>, <b class="calibre4">CHF</b>, or <b class="calibre4">LV dysfunction</b> <i class="calibre3">best predictors</i> that WCT is VT <span class="s1r">(<i class="calibre3">Am J Med</i> 1998;84:53)</span></p>
<p class="bl"><span class="sbl">•</span> Hemodynamics and rate do <i class="calibre3">not</i> reliably distinguish VT from SVT</p>
<p class="bl"><span class="sbl">•</span> MMVT is regular, but initially it may be slightly irregular, mimicking AF w/ aberrancy; <i class="calibre3">grossly</i> irregularly irregular rhythm suggests AF w/ aberrancy or pre-excitation</p>
<p class="bl"><span class="sbl">•</span> ECG features that favor VT <span class="s1r">(<i class="calibre3">Circ</i> 2016;133:e506)</span></p>
<p class="bl1"><i class="calibre3">AV dissociation</i> (independent P waves, capture or fusion beats) proves VT</p>
<p class="bl1"><i class="calibre3">Very wide QRS</i> (&gt;140 ms in RBBB-type or &gt;160 in LBBB-type); <i class="calibre3">extreme axis deviation</i></p>
<p class="bl1"><i class="calibre3">QRS morphology atypical for BBB</i></p>
<p class="bl2">RBBB-type: absence of tall R′ (or presence of monophasic R) in V<sub class="calibre8">1</sub>, r/S ratio &lt;1 in V<sub class="calibre8">6</sub></p>
<p class="bl2">LBBB-type: onset to nadir &gt;60–100 ms in V<sub class="calibre8">1</sub>, q wave in V<sub class="calibre8">6</sub></p>
<p class="bl1"><i class="calibre3">Initial R wave in aVR; concordance</i> (QRS in all precordial leads w/ same pattern/direction)</p>
<p class="h2a"><b class="calibre4">Long-term management</b> <span class="s">(<i class="calibre3">EHJ</i> 2015;36:2793; <i class="calibre3">Circ</i> 2016;133:1715; <i class="calibre3">NEJM</i> 2019;380:1555)</span></p>
<p class="bl"><span class="sbl">•</span> Workup: <b class="calibre4">echo</b> to ✔ LV fxn, <b class="calibre4">cath</b> or <b class="calibre4">stress test</b> to r/o ischemia, ? MRI and/or RV bx to look for infiltrative CMP or ARVC, ? <b class="calibre4">EP study</b> to assess inducibility</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">ICD:</b> 2° prevention after documented VT/VF arrest (unless due to reversible cause). 1° prev. if high risk, eg, EF &lt;30–35%, ? ARVC, ? Brugada, certain LQTS, severe HCMP. See “Cardiac Rhythm Mgmt Devices.” Wearable vest if reversible or waiting for ICD? <span class="s1r">(<i class="calibre3">NEJM</i> 2018;379:1205)</span>. Antitachycardia pacing (ATP = burst pacing faster than VT) can terminate VT w/o shock.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Meds:</b> βB, verapamil if idiopathic LV VT, or AAD (eg, amio, mexiletine) to suppress VT</p>
<p class="bl"><span class="sbl">•</span> If med a/w TdP → QT &gt;500 ± VPBs: d/c med, replete K, give Mg, ± pacing <span class="s1r">(<i class="calibre3">JACC</i> 2010;55:934)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">RFA</b> if isolated VT focus or if recurrent VT triggering ICD firing (↓ VT storm by 34%; <i class="calibre3">NEJM</i> 2016;375:111); ablation before ICD implantation ↓ discharge rate by 40% <span class="s1r">(<i class="calibre3">Lancet</i> 2010;375:31)</span>. Non-invasive radioablation (15-min ablation time) under investigation <span class="s1r">(<i class="calibre3">Circ</i> 2019;139:313)</span>.</p>
<h2 class="ct"><a id="h15" class="calibre7"></a><a id="page_1-35" class="calibre7"></a><a href="part0002.html#rh19" class="calibre7">ATRIAL FIBRILLATION</a></h2>
<p class="h2a"><b class="calibre4">Classification</b> <span class="s">(<i class="calibre3">Circ</i> 2014;130:e199)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Paroxysmal</b> (self-terminating, usually &lt;48 h, often triggered in pulm veins) vs. <b class="calibre4">persistent</b> (&gt;7 d) vs. <b class="calibre4">long-standing persistent</b> (&gt;1 y) vs. <b class="calibre4">permanent</b> (no plan for SR)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Nonvalvular</b> (AF absent rheumatic MS, prosthetic valve, or mitral valve repair) vs. <b class="calibre4">valvular</b></p>
<p class="h2a"><b class="calibre4">Epidemiology and etiologies</b> <span class="s">(<i class="calibre3">Circ</i> 2011;124:1982; <i class="calibre3">Nat Rev</i> 2016;2:1)</span></p>
<p class="bl"><span class="sbl">•</span> 1–2% of pop. has AF (10% of those age ≥80); M &gt; F; lifetime risk ~25%</p>
<p class="bl"><span class="sbl">•</span> Acute (up to 50% w/o identifiable cause)</p>
<p class="bl1"><b class="calibre4">Cardiac:</b> HF, new CMP, myo/pericarditis, ischemia/MI, HTN crisis, valve dis., cardiac surg</p>
<p class="bl1"><b class="calibre4">Pulmonary:</b> acute pulmonary disease or hypoxemia (eg, COPD flare, PNA), PE, OSA</p>
<p class="bl1"><b class="calibre4">Metabolic:</b> high catecholamine states (stress, infection, postop, pheo), thyrotoxicosis</p>
<p class="bl1"><b class="calibre4">Drugs:</b> alcohol, cocaine, amphetamines, theophylline, caffeine, smoking, ibrutinib</p>
<p class="bl1"><b class="calibre4">Neurogenic:</b> subarachnoid hemorrhage, ischemic stroke</p>
<p class="bl"><span class="sbl">•</span> Chronic: ↑ age, HTN, ischemia, valve dis. (MV, TV, AoV), CMP, hyperthyroidism, obesity</p>
<p class="h2a"><b class="calibre4">Evaluation</b></p>
<p class="bl"><span class="sbl">•</span> H&amp;P, ECG, CXR, TTE (LA size, thrombus, valves, LV fxn, pericardium), K, Mg, Cr, FOBT before anticoag, TFTs; r/o MI not necessary unless other ischemic sx</p>
<p class="bl"><span class="sbl">•</span> In acute AF &lt;48º, ~70% spont. convert to SR w/in 48 hrs <span class="s1r">(<i class="calibre3">NEJM</i> 2019;380:1499)</span></p>
<p class="capf"><b class="calibre4">Figure 1-5</b> Approach to acute AF (Adapted from <i class="calibre3">Circ</i> 2014;130:e199)</p>
<p class="image"><img src="../images/00029.jpeg" alt="" class="calibre2"/></p>
<p class="imagef"><img src="../images/00030.jpeg" alt="" class="calibre2"/></p>
<p class="fn1"><i class="calibre3">Lancet</i> 2016;388:818. IV βB, CCB &amp; dig <b class="calibre4"><i class="calibre3">contraindic.</i></b> if evidence (ie, pre-excitation or WCT) of WPW (qv).</p>
<p class="fn">*Many meds incl. amio, verapamil, quinidine, propafenone, macrolides &amp; azole antifungals ↑ digoxin levels.</p>
<p class="h2a"><b class="calibre4">Cardioversion</b></p>
<p class="bl"><span class="sbl">•</span> Consider if: 1<sup class="calibre15">st</sup> AF, sx, tachycardia-mediated CMP, or difficult to rate control</p>
<p class="bl1">If AF &gt;48 h 2–5% risk stroke w/ cardioversion (<i class="calibre3">pharmacologic or electric</i>) ∴ either TEE to r/o thrombus or ensure therapeutic anticoagulation ≥3 wk prior</p>
<p class="bl1">If needs to cardiovert urgently, often anticoagulate acutely (eg, IV UFH)</p>
<p class="bl"><span class="sbl">•</span> Likelihood of success ∝ AF duration &amp; atrial size; control precipitants (eg, vol status, thyroid)</p>
<p class="bl"><span class="sbl">•</span> Before electrical cardiovert, consider pre-Rx w/ AAD (eg, ibutilide), esp. if 1<sup class="calibre15">st</sup> cardiovert failed</p>
<p class="bl"><span class="sbl">•</span> For pharmacologic cardioversion, class III and IC drugs have best proven efficacy</p>
<p class="bl"><span class="sbl">•</span> If SR returns (spont. or w/ Rx), atria may be <i class="calibre3">mech. stunned;</i> also, high risk of recurrent AF over next 3 mo. ∴ <b class="calibre4">Anticoag postcardioversion</b> ≥<b class="calibre4">4 wk</b> (? unless AF &lt;48 h and low risk).</p>
<p class="h2a"><a id="page_1-36" class="calibre1"></a><b class="calibre4">Rhythm control</b> <span class="s">(<i class="calibre3">Lancet</i> 2016;388:829)</span></p>
<p class="bl"><span class="sbl">•</span> No ↓ mortality or stroke vs rate control <span class="s1r">(<i class="calibre3">NEJM</i> 2002;347:1825 &amp; 2008;358:2667 &amp; 2016;374:1911)</span></p>
<p class="bl"><span class="sbl">•</span> Consider if <i class="calibre3">sx</i> w/ rate control (eg, HF), difficult to control rate, or tachycardia-mediated CMP</p>
<p class="image1"><img src="../images/00031.jpeg" alt="" class="calibre2"/></p>
<p class="h2a"><b class="calibre4">Ablation</b></p>
<p class="bl"><span class="sbl">•</span> Pulm vein isolation (radiofreq or cryo; <i class="calibre3">NEJM</i> 2016;374:2235): ~70% success; no need to interrupt anticoag; superior to AAD <span class="s1r">(<i class="calibre3">JAMA</i> 2014;311:692)</span> &amp; ↑ QoL <span class="s1r">(<i class="calibre3">JAMA</i> 2019;321:1059)</span></p>
<p class="bl"><span class="sbl">•</span> If NYHA II-IV + EF &lt;35%, ablation ↓ D/HF hosp vs. rate/rhythm meds <span class="s1r">(<i class="calibre3">NEJM</i> 2018;378:417)</span></p>
<p class="bl"><span class="sbl">•</span> AV node ablation + PPM if other Rx inadequate <span class="s1r">(<i class="calibre3">NEJM</i> 2001;344:1043 &amp; 2002;346:2062)</span></p>
<p class="h2a"><b class="calibre4">Oral anticoagulation</b> <span class="s">(<i class="calibre3">Circ</i> 2014;130:e199 &amp; 2019;139:epub; <i class="calibre3">EHJ</i> 2018;39:1330)</span></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">All valvular AF</i> (ie, rheum MS, valve prosthesis or repair), because stroke risk very high</p>
<p class="bl"><span class="sbl">•</span> Nonvalvular AF (NVAF): stroke risk ~4.5%/y</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">CHA<sub class="calibre8">2</sub>DS<sub class="calibre8">2</sub></b>-<b class="calibre4">VASc</b> to guide Rx: <b class="calibre4">C</b>HF (1 point); <b class="calibre4">H</b>TN (1); <b class="calibre4">A</b>ge ≥75 y (2); <b class="calibre4">D</b>M (1), <b class="calibre4">S</b>troke/TIA (2); <b class="calibre4">V</b>ascular disease (eg, MI, PAD, Ao plaque) (1); <b class="calibre4">A</b>ge 65–74 (1); ♀ <b class="calibre4">S</b>ex <b class="calibre4">c</b>ategory (1)</p>
<p class="bl1">Annual risk of stroke <span class="s1r">(<i class="calibre3">Lancet</i> 2012;379:648)</span>: at low end, ~1% per point: 0 → ~0%, 1 → 1.3%, 2 → 2.2%, 3 → 3.2%, 4 → 4.0%; at higher scores, risk ↑↑ (5 → 6.7%, ≥6 → ≥10%)</p>
<p class="bl1"><b class="calibre4">Score</b> ≥<b class="calibre4">2</b> → <b class="calibre4">anticoagulate; score 1</b> → <b class="calibre4">consider anticoag.</b> or ASA (? latter reasonable if risk factor 65–74 y, vasc dz or ♀) or no Rx; <b class="calibre4">score 0</b> → reasonable to not Rx</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Rx options: DOAC</b> (NVAF only) prefered over warfarin (INR 2–3); if Pt refuses anticoag, ASA + clopi or, even less effective, ASA alone <span class="s1r">(<i class="calibre3">NEJM</i> 2009;360:2066)</span></p>
<p class="bl"><span class="sbl">•</span> AF + CAD/ PCI: consider DOAC (some data for reduced dose but unclear if ischemic stroke prevention adequate), clopi (not ticag or prasugrel), and consider stopping ASA (? after ~1 wk) <span class="s1r">(<i class="calibre3">Lancet</i> 2013;381:1107; <i class="calibre3">NEJM</i> 2016;375:2423 &amp; 2017;377:1513 &amp; 2019;380:1509)</span>.</p>
<p class="bl"><span class="sbl">•</span> If concern for procedural bleed, interrupt OAC (1–2 d DOAC, 4–5 d VKA). If CHA<sub class="calibre8">2</sub>DS<sub class="calibre8">2</sub>-VASc ≥7 (or ≥5 w/ h/o CVA/TIA), consider bridge w/ UFH/LMWH, else no <span class="s1r">(<i class="calibre3">JACC</i> 2017;69:735)</span>.</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre38"/>
<col class="calibre39"/>
<col class="calibre26"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">Direct Oral Anticoagulants (DOACs) for NVAF</b> (<span class="tfont1"><i class="calibre3">Lancet</i> 2014;383:955</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Anticoag</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Dosing</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Efficacy &amp; Safety vs. Warfarin</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Dabigatran</b></p>
<p class="tab">(Direct thromb inhib)</p></td>
<td class="bg0-br"><p class="tab">150 mg bid (110 not avail in U.S.) (75 mg bid if CrCl 15–30)</p></td>
<td class="bg0-b"><p class="tab">150 mg: ↓ ischemic stroke &amp; ICH, but ↑ GIB</p>
<p class="tab">110 mg: ≈ ischemic stroke &amp; ↓ major bleed/ICH</p>
<p class="tab">Risks: GI side effects, ↑ MI c/w warfarin</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Rivaroxaban</b></p>
<p class="tab">(FXa inhib)</p></td>
<td class="bg0-br"><p class="tab">20 mg qd (15 mg qd if CrCl 15–50) w/ pm meal</p></td>
<td class="bg0-b"><p class="tab">≈ ischemic stroke &amp; major bleeds, but ↓ fatal bleed incl ICH</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Apixaban</b></p>
<p class="tab">(FXa inhib)</p></td>
<td class="bg0-br"><p class="tab">5 mg bid (2.5 mg bid if ≥2 of: ≥80 y, ≤60 kg, Cr ≥1.5 mg/dL)</p></td>
<td class="bg0-b"><p class="tab">≈ ischemic stroke &amp; ↓ major bleed incl ICH,</p>
<p class="tab">11% ↓ death. In Pts felt not cand for warfarin, apixa 55% ↓ stroke w/o ↑ bleed vs ASA alone.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Edoxaban</b></p>
<p class="tab">(Fxa inhib)</p></td>
<td class="bg0-br"><p class="tab">60 mg qd if CrCl 51–95 (30 mg if CrCl 15–50)</p></td>
<td class="bg0-b"><p class="tab">≈ ischemic stroke &amp; ↓ major bleed incl ICH, 14% ↓ CV death. ↑ ischemic CVA if CrCl &gt;95.</p></td>
</tr>
<tr class="calibre12">
<td class="bg" colspan="3"><p class="tab">Onset w/in hrs. Reversal: idarucizumab for dabi; andexanet for FXa; 4F-PCC.</p></td>
</tr>
</table>
<p class="h2a"><b class="calibre4">Nonpharmacologic stroke prevent</b> <span class="s">(<i class="calibre3">JACC</i> 2015;66:1497)</span></p>
<p class="bl"><span class="sbl">•</span> If contraindic. to long-term OAC, consider perc. left atrial appendage (LAA) occlusion <span class="s1r">(<i class="calibre3">JACC</i> 2017;70:2964)</span>. Nb, ideally warfarin + ASA × 45 d → DAPT out to 6 mo → ASA.</p>
<p class="bl"><span class="sbl">•</span> Consider perc. epicardial LAA ligation or surgical resection if undergoing other card surg</p>
<p class="h2a"><b class="calibre4">Atrial flutter</b></p>
<p class="bl"><span class="sbl">•</span> Macroreentrant atrial loop. Typical involves cavotricuspid isthmus (if counterclockwise, flutter waves ⊖ in inf leads, if clockwise, ⊕). Atypical: other pathways related to prior scar.</p>
<p class="bl"><span class="sbl">•</span> Risk of stroke similar to that of AF, ∴ anticoagulate same as would for AF</p>
<p class="bl"><span class="sbl">•</span> Ablation of typical (cavotricuspid isthmus) AFL has 95% success rate</p>
<h2 class="ct"><a id="h16" class="calibre7"></a><a id="page_1-37" class="calibre7"></a><a href="part0002.html#rh20" class="calibre7">SYNCOPE</a></h2>
<p class="h2a"><b class="calibre4">Definition</b></p>
<p class="bl"><span class="sbl">•</span> Symptom of sudden transient loss of consciousness due to global cerebral hypoperfusion</p>
<p class="bl"><span class="sbl">•</span> If CPR or cardioversion required, then SCD and not syncope (different prognosis)</p>
<p class="bl"><span class="sbl">•</span> Presyncope = prodrome of light-headedness without LOC</p>
<p class="h2a"><b class="calibre4">Etiologies</b> <span class="s">(<i class="calibre3">JACC</i> 2017;70:e39; <i class="calibre3">EHJ</i> 2018;39:1883)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Neurocardiogenic</b> (a.k.a. vasovagal, ~25%): ↑ sympathetic tone → vigorous contraction of LV → LV mechanoreceptors trigger ↑ vagal tone (hyperactive Bezold-Jarisch reflex) → ↓ HR (cardioinhib.) and/or ↓ BP (vasodepressor). Cough, deglutition, defecation, &amp; micturition → ↑ vagal tone and thus can be precipitants. Carotid sinus hypersensitivity (exag vagal resp to carotid massage) is related disorder.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Orthostatic hypotension</b> (~10%)</p>
<p class="bl1">hypovolemia/diuretics, deconditioning; vasodilat. (esp. if combined w/ ⊖ chronotropes)</p>
<p class="bl1">autonomic neuropathy [1° = Parkinson’s, MSA/Shy-Drager, Lewy body dementia, POTS (dysautonomia in the young); 2° = DM, EtOH, amyloidosis, CKD] <span class="s1r">(<i class="calibre3">NEJM</i> 2008;358:615)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cardiovascular</b> (~20%, more likely in men than women)</p>
<p class="bl1"><i class="calibre3">Arrhythmia</i> (~15%): challenging to dx because often transient</p>
<p class="bl2">Bradyarrhythmias: SB, SSS, high-grade AV block, ⊖ chronotropes, PPM malfunction</p>
<p class="bl2">Tachyarrhythmias: VT, SVT (syncope rare unless structural heart disease or WPW)</p>
<p class="bl1"><i class="calibre3">Mechanical</i> (5%)</p>
<p class="bl2">Endocardial/Valvular: critical AS, MS, PS, prosthetic valve thrombosis, myxoma</p>
<p class="bl2">Myocardial: outflow obstruction from HCMP (or VT); Pericardial: tamponade</p>
<p class="bl2">Vascular: PE (in ~25% w/o alt dx; <i class="calibre3">NEJM</i> 2016;375:1524), PHT, AoD, ruptured AAA</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Neurologic</b> (~10%): vertebrobasil insuff, cerebrovasc dissection, SAH, TIA/CVA, migraine</p>
<p class="bl"><span class="sbl">•</span> Misc. causes of LOC (but not syncope): seizure, ↓ glc, hypoxia, narcolepsy, psychogenic</p>
<p class="h2a"><b class="calibre4">Workup (etiology cannot be determined in ~40% of cases)</b> <span class="s">(<i class="calibre3">jama</i> 2019;321:2448)</span></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">H&amp;P incl. orthostatic VS have highest yield and most cost effective</i> <span class="s1r">(<i class="calibre3">Archives</i> 2009;169:1299)</span></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">R/o life-threatening dx including: cardiac syncope, severe blood loss, PE, SAH</i></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">History</b> (from Pt and <i class="calibre3">witnesses</i> if available)</p>
<p class="bl1">activity and posture before the incident</p>
<p class="bl1">precipitating factors: exertion (AS, HCMP, PHT), positional ∆ (orthostatic HoTN), stressors such as sight of blood, pain, emotional distress, fatigue, prolonged standing, warm environment, N/V, cough/deglutition/micturition/defecation (neurocardiogenic), head turning or shaving (carotid sinus hypersens.); arm exercise (subclavian steal)</p>
<p class="bl1">sudden onset → cardiac; prodrome (eg, diaphoresis, nausea, blurry vision) → vasovagal</p>
<p class="bl1">associated sx: chest pain, palp., neurologic, postictal, bowel/bladder incontinence, (convulsive activity for &lt;10 sec may occur w/ transient cerebral HoTN &amp; mimic seizure)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">PMH:</b> prior syncope, previous cardiac or neurologic dis.; no CV disease at baseline → 5% cardiac, 25% vasovagal; CV disease → 20% cardiac, 10% vasovagal <span class="s1r">(<i class="calibre3">NEJM</i> 2002;347:878)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Medications that may act as precipitants</b></p>
<p class="bl1">vasodilators: α-blockers, nitrates, ACEI/ARB, CCB, hydralazine, phenothiazines, antidep.</p>
<p class="bl1">diuretics; ⊖ chronotropes (eg, βB and CCB)</p>
<p class="bl1">proarrhythmic or QT prolonging: class IA, IC or III antiarrhythmics (see “ECG”)</p>
<p class="bl1">psychoactive drugs: antipsychotics, TCA, barbiturates, benzodiazepines, EtOH</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Family history:</b> CMP, SCD, syncope (vasovagal may have genetic component)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Physical exam</b></p>
<p class="bl1"><b class="calibre4">VS incl. <i class="calibre3">orthostatics</i></b> (⊕ if supine → standing results in ≥20 mmHg ↓ SBP or ≥10 ↓ DBP or SBP &lt;90 mmHg w/in 3 min; POTS if ≥30 bpm ↑ HR w/in 10 min), BP in both arms</p>
<p class="bl1">Cardiac: HF (↑ JVP, displ. PMI, S<sub class="calibre8">3</sub>), murmurs, LVH (S<sub class="calibre8">4</sub>, LV heave), PHT (RV heave, ↑ P<sub class="calibre8">2</sub>)</p>
<p class="bl1">Vascular: ✔ for <i class="calibre3">asymmetric pulses</i>, carotid/vert/subclavian <i class="calibre3">bruits; carotid sinus massage</i> to ✔ for carotid hypersens (if no bruits): ⊕ if asystole &gt;3 sec or ↓ SBP &gt;50 mmHg</p>
<p class="bl1">Neurologic exam: focal findings, evidence of tongue biting; FOBT</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">ECG</b> (abnormal in ~50%, but only definitively identifies cause of syncope in &lt;10%)</p>
<p class="bl1">Conduction: SB, sinus pauses/sinus arrhythmia, AVB, BBB/IVCD</p>
<p class="bl1">Arrhythmia: ectopy, ↑ or ↓ QT, preexcitation (WPW), Brugada, ε wave (ARVC), SVT/VT</p>
<p class="bl1">Ischemic changes (new or old): atrial or ventricular hypertrophy</p>
<p class="bl"><span class="sbl">•</span> Lab: glc, Hb, HCG (pre-menop ♀), ? <small class="calibre40">D</small>-dimer, ? troponin/NT-proBNP (↓ yield w/o other s/s)</p>
<p class="h2a"><b class="calibre4">Other diagnostic studies</b> <span class="s">(consider based on results of H&amp;P and ECG)</span></p>
<p class="bl"><span class="sbl">•</span> Ambulatory ECG monitoring: if suspect arrhythmogenic syncope</p>
<p class="bl1">Holter monitoring (continuous ECG 24–72 h): useful if <i class="calibre3">frequent</i> events arrhythmia + sx (4%); asx but signif. arrhythmia (13%); sx but no arrhythmia (17%)</p>
<p class="bl1">Event recorder (activated by Pt to record rhythm strip): limited role in syncope because only useful if established prodrome (because must be Pt activated)</p>
<p class="bl1"><a id="page_1-38" class="calibre1"></a>External loop recorders (continuously saves rhythm, ∴ can be activated <i class="calibre3">after</i> an event): useful for episodes (including w/o prodrome) likely to occur w/in 1 mo; can be coupled w/ mobile cardiac telemetry than can be auto-triggered for specific rhythms</p>
<p class="bl1"><i class="calibre3">Implantable</i> loop recorders (SC; can record 2–3 y; can be triggered): useful if episodes &lt;1/mo; dx in 55% of cases; rec for recurrent syncope w/o prodrome</p>
<p class="bl"><span class="sbl">•</span> Echo: consider to r/o structural heart disease (eg, CMP [incl HCMP &amp; ARVC], valvular disease [incl AS, MS, MVP], myxoma, amyloid, PHT, ± anomalous coronaries)</p>
<p class="bl"><span class="sbl">•</span> ETT/CCTA/Cath: esp. w/ exertional syncope; r/o ischemia or catechol-induced arrhythmia</p>
<p class="bl"><span class="sbl">•</span> Electrophysiologic studies (EPS): consider in high-risk Pts in whom tachy or brady etiology is strongly suspected (eg, prior MI), but cannot be confirmed; avoid if ECG/Echo normal.</p>
<p class="bl1">50% abnl (inducible VT, conduction abnormalities) if heart disease, but ? significance</p>
<p class="bl1">3–20% abnl if abnl ECG; &lt;1% abnl if normal heart and normal ECG</p>
<p class="bl"><span class="sbl">•</span> Tilt table: debated utility due to poor Se/Sp/reproducibility; consider if suspected neurocardiogenic, orthostatic HoTN, POTS, or psychogenic, and initial eval unrevealing</p>
<p class="bl"><span class="sbl">•</span> Cardiac MRI: helpful to dx sarcoid or ARVC if suggestive ECG, echo (RV dysfxn) or ⊕ FHx</p>
<p class="bl"><span class="sbl">•</span> Neurologic studies (cerebrovascular studies, CT, MRI, EEG): if H&amp;P suggestive; low yield</p>
<p class="capf"><b class="calibre4">Figure 1-6</b> Approach to syncope</p>
<p class="center"><img src="../images/00032.jpeg" alt="" class="calibre2"/></p>
<p class="fn">(<i class="calibre3">Adapted from JACC</i> 2017;70:e39)</p>
<p class="h2a"><b class="calibre4">High-risk features</b> <span class="s">(admit w/ tele; <i class="calibre3">JACC</i> 2017;70:620; <i class="calibre3">EHJ</i> 2018;39:1883)</span></p>
<p class="bl"><span class="sbl">•</span> Age &gt;60 y, h/o CAD, HF/CMP, valvular or congenital heart dis., arrhythmias, FHx SCD</p>
<p class="bl"><span class="sbl">•</span> Syncope c/w cardiac cause (lack of prodrome, exertional, resultant trauma) or recurrent</p>
<p class="bl"><span class="sbl">•</span> Complaint of chest pain or dyspnea; abnl VS, cardiac, pulm, or neuro exam; low Hct</p>
<p class="bl"><span class="sbl">•</span> ECG suggesting conduction abnormality, arrhythmia, or ischemia; Pt w/ PPM/ICD</p>
<p class="bl"><span class="sbl">•</span> Canadian Syncope Risk Score <span class="s1r">(<i class="calibre3">CMAJ</i> 2016;188:e289)</span> stratifies from &lt;1% to &gt;20% risk of serious arrhythmias. If low-risk &amp; no arrhythmia in ED × 2 h, 0.2% risk over 30 d.</p>
<p class="h2a"><b class="calibre4">Treatment</b> <span class="s">(<i class="calibre3">EHJ</i> 2018;39:1883)</span></p>
<p class="bl"><span class="sbl">•</span> Arrhythmia, cardiac mechanical or neurologic syncope: treat underlying disorder, ? ICD if Brugada pattern, sarcoid, ARVC, early repol + syncope</p>
<p class="bl"><span class="sbl">•</span> Neurocardiogenic: consider fludrocortisone or midodrine <span class="s1r">(<i class="calibre3">JACC</i> 2016;68:1; <i class="calibre3">Neuro</i> 2014;83:1170)</span>; ? βB or SSRI <span class="s1r">(<i class="calibre3">Circ A&amp;E</i> 2012; 5:920)</span></p>
<p class="bl1">consider dual-chamber PPM if rec episodes + prolonged pauses <span class="s1r">(<i class="calibre3">Circ</i> 2012;125:2566)</span></p>
<p class="bl"><span class="sbl">•</span> Orthostatic: 2–3 L fluid &amp; 10 g Na per day; rise from supine to standing <i class="calibre3">slowly</i>, compression stockings; consider midodrine or fludrocortisone; ? atomoxetine <span class="s1r">(<i class="calibre3">HTN</i> 2014;64:1235)</span></p>
<p class="h2a"><b class="calibre4">Prognosis</b> <span class="s">(<i class="calibre3">Ann Emerg Med</i> 1997;29:459; <i class="calibre3">NEJM</i> 2002;347:878)</span></p>
<p class="bl"><span class="sbl">•</span> 22% overall recurrence rate if idiopathic, else 3% recurrence</p>
<p class="bl"><span class="sbl">•</span> Cardiac syncope has poor prognosis (20–40% 1-y SCD rate); vasovagal good prognosis</p>
<p class="bl"><span class="sbl">•</span> Unexplained syncope w/ 1.3-fold ↑ in mort., but noncardiac or unexplained syncope w/ nl</p>
<p class="bl1">ECG, no h/o VT, no HF, age &lt;45 → low recurrence rate and &lt;5% 1-y SCD rate</p>
<p class="bl"><span class="sbl">•</span> ✔ state driving laws and MD reporting requirements. Consider appropriateness of Pt involvement in exercise/sport, operating machinery, high-risk occupation (eg, pilot).</p>
<h2 class="ct"><a id="h17" class="calibre7"></a><a id="page_1-39" class="calibre7"></a><a href="part0002.html#rh21" class="calibre7">CARDIAC RHYTHM MANAGEMENT DEVICES</a></h2>
<p class="image1"><img src="../images/00033.jpeg" alt="" class="calibre2"/></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Common Pacing Modes</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">VVI</b></p></td>
<td class="bg0-b"><p class="tab">Ventricular pacing on demand w/ single lead in RV. Sensed ventricular beat</p>
<p class="tab">inhibits V pacing. Used in chronic AF with symptomatic bradycardia.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">DDD</b></p></td>
<td class="bg0-b"><p class="tab">A &amp; V sensing/pacing (RA &amp; RV leads). Native A beat inhib A pacing &amp; <i class="calibre3">triggers</i></p>
<p class="tab"><i class="calibre3">V pacing</i> → tracking of intrinsic atrial activity. Maintains AV synchrony, ↓ AF.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Mode Switch</b></p></td>
<td class="bg0-b"><p class="tab">In atrial tachyarrhythmia (eg, AF), PPM ∆s from DDD to nontracking mode (eg, VVI). Prevents PPM from pacing at max V rate in response to rapid atrial rate.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Magnet</b> over generator</p></td>
<td class="bg0-b"><p class="tab">PPM: fixed rate pacing (VOO/DOO). ICD: no shock, pacing preserved.</p>
<p class="tab">Indic: ✔ capture; surgery; inapprop PPM inhib/ICD shock, PM-mediated tachy</p></td>
</tr>
<tr class="calibre12">
<td class="bg" colspan="2">
<p class="tab"><i class="calibre3">Leadless</i> intracardiac PPM approved for single chamber RV pacing (<span class="tfont"><i class="calibre3">Circ</i> 2017;135:1458</span>); His bundle pacing ↓ death/HF/CRT upgrade vs RV pacing alone (<span class="tfont"><i class="calibre3">JACC</i> 2018;71:2319</span>).</p></td>
</tr>
</table>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre41"/>
<col class="calibre42"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Indications for Permanent Pacing</b> (<span class="tfont1"><i class="calibre3">Circ</i> 2008;117:350 &amp; 2012;126:1784</span>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">AV block</b></p></td>
<td class="bg0-b"><p class="tab">3° or type II 2° AVB a/w sx or w/ either HR &lt;40 or asystole ≥3 sec (≥5 if in AF) while awake; ? asx 3° or type II 2° AVB; bifasc or alter. L &amp; R BBB</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Sinus node</b></p></td>
<td class="bg0-b"><p class="tab">SB, pauses (SSS), chronotrop incompet a/w sx or ? if sx w/o clear assoc</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Tachy-arrhythmia</b></p></td>
<td class="bg0-b"><p class="tab">AF w/ SSS; sx recurrent SVT term. by pacing after failing drugs/ablation; Sustained pause-dependent VT; ? high-risk congenital long QT</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Syncope</b></p></td>
<td class="bg"><p class="tab">Carotid sinus hypersensitivity with asystole &gt;3 sec</p>
<p class="tab">? Neurocardiogenic syncope w/ prominent cardioinhib. response</p>
<p class="tab">? Syncope with bi- or trifascicular block and not likely 2° to other causes</p></td>
</tr>
</table>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre29"/>
<col class="calibre43"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">Pacemaker Complications</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Issue</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Manifestation</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Description &amp; etiologies</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Perforation</p></td>
<td class="bg0-br"><p class="tab">Effusion/tamp/pain</p></td>
<td class="bg0-b"><p class="tab">Typically acute, consider if HoTN</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Failure to pace</p></td>
<td class="bg0-br"><p class="tab">Bradycardia</p></td>
<td class="bg0-b"><p class="tab">↓ Battery, lead fx/dislodgment, ↑ pacing threshold due to tissue rxn/injury; oversense → inapprop. inhib</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Failure to sense</p></td>
<td class="bg0-br"><p class="tab">Inapprop. pacing</p></td>
<td class="bg0-b"><p class="tab">Lead dislodgment or sensing threshold too high</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">PM-mediated tachycardia</p></td>
<td class="bg0-br"><p class="tab">WCT at device upper rate</p></td>
<td class="bg0-b"><p class="tab">Seen w/ DDD. V → A retrograde conduction; sensed by A lead → triggers V pacing → etc.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">PM syndrome</p></td>
<td class="bg0-r"><p class="tab">Palpit, HF</p></td>
<td class="bg"><p class="tab">Seen w/ VVI, due to loss of AV synchrony</p></td>
</tr>
</table>
<p class="h2a"><b class="calibre4">Cardiac resynch therapy</b> (CRT)/Biventricular (BiV) pacing <span class="s">(<i class="calibre3">JACC</i> 2013;61:e6)</span></p>
<p class="bl"><span class="sbl">•</span> 3-lead pacemaker (RA, RV, coronary sinus to LV); R &gt; S in V<sub class="calibre8">1</sub> suggests approp LV capture</p>
<p class="bl"><span class="sbl">•</span> Synch LV fxn (↑ CO/EF, ↓ adv remodeling); ↓ HF sx &amp; hosp, ↑ survival <span class="s1r">(<i class="calibre3">NEJM</i> 2010;363:2385)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Indications:</b> LVEF ≤35% + NYHA II–IV despite med Rx + SR + LBBB ≥150 ms (also reasonable if LBBB ≥120 ms, any non-LBBB ≥150 ms, or &gt;40% V-pacing); mort. benefit w/ CRT-D only if LBBB (&amp; QRS ≥130ms) <span class="s1r">(<i class="calibre3">NEJM</i> 2014;370:1694)</span></p>
<p class="bl1">? benefit in NYHA I–III, EF ≤50% w/ PPM indication for AVB <span class="s1r">(<i class="calibre3">NEJM</i> 2013;368:1585)</span></p>
<p class="h2a"><b class="calibre4">Implantable cardiac defibrillator (ICD)</b> <span class="s">(<i class="calibre3">JACC</i> 2013;61:e6; <i class="calibre3">Circ</i> 2015;132:1613)</span></p>
<p class="bl"><span class="sbl">•</span> RV lead: defib &amp; pacing (± antitachycardia pacing [ATP] = burst pacing &gt; VT rate to stop VT); ± RA lead for dual-chamber PPM. Subcut-ICD (consider if young), but ∅ pace/ATP.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pt selection</b> <span class="s1r">(<i class="calibre3">JACC</i> 2008;51:e1; <i class="calibre3">Circ</i> 2012;126:1784)</span></p>
<p class="bl1">2° prev: survivors of VT/VF arrest w/o revers cause; asx sustained VT + struct. heart dis.</p>
<p class="bl1">1° prevention: LVEF ≤30% &amp; post-MI <i class="calibre3">or</i> LVEF ≤35% &amp; NYHA II–III (wait: ≥40 d if post-MI, ≥90 d for niCMP) <i class="calibre3">or</i> LVEF ≤40% &amp; inducible VT/VF; <i class="calibre3">life expectancy must be</i> &gt;<i class="calibre3">1 y;</i></p>
<p class="bl2">More recently, for niCMP ICD ↓ SCD but not overall mortality <span class="s1r">(<i class="calibre3">NEJM</i> 2016;375:1221)</span>;</p>
<p class="bl2">Consider if unexplained syncope + DCM, or if HCM, ARVC, Brugada, sarcoid, LQTS, Chagas, or congenital heart disease if risk for SCD;</p>
<p class="bl2">Pts w/ recent MI: wearable vest ? ↓ death <span class="s1r">(<i class="calibre3">NEJM</i> 2018;379:1205)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Risks:</b> inapprop shock in ~15–20% at 3 y (commonly d/t misclassified SVT); infxn; lead fx</p>
<p class="bl"><span class="sbl">•</span> ICD discharge: ✔ device to see if approp; r/o ischemia; 6-mo driving ban (✔ state law)</p>
<p class="bl"><span class="sbl">•</span> MRI: older systems may be OK <span class="s1r">(<i class="calibre3">NEJM</i> 2017;377:2555)</span>; may need to reprogram prior to MRI</p>
<p class="h2a"><b class="calibre4">Device infection</b> <span class="s">(<i class="calibre3">JAMA</i> 2012;307:1727; <i class="calibre3">NEJM</i> 2012;367:842 &amp; 2019;380:1895)</span></p>
<p class="bl"><span class="sbl">•</span> Presents as <i class="calibre3">pocket infection</i> (warmth, erythema, tenderness) and/or <i class="calibre3">sepsis w</i>/ <i class="calibre3">bacteremia</i></p>
<p class="bl"><span class="sbl">•</span> ~2% over 5 y; if <i class="calibre3">S. aureus</i> bacteremia, infxn in ≥35%; antibacterial envelope ↓ risk</p>
<p class="bl"><span class="sbl">•</span> TTE/TEE used to help visualize complic. (eg, vegetation), but even ⊖ TEE does not r/o</p>
<p class="bl"><span class="sbl">•</span> Rx: abx; system removal if pocket infxn or GPC bacteremia; ∅ routine abx prior to inv. proc.</p>
<h2 class="ct"><a id="h18" class="calibre7"></a><a id="page_1-40" class="calibre7"></a><a href="part0002.html#rh22" class="calibre7">CARDIAC RISK ASSESSMENT FOR NONCARDIAC SURGERY</a></h2>
<p class="cst"><i class="calibre3">Goal: characterize risk of Pt &amp; procedure</i> → <i class="calibre3">appropriate testing (ie, results will</i> ∆ <i class="calibre3">management) and interventions (ie, reasonable probability of</i> ↓ <i class="calibre3">risk of MACE)</i></p>
<p class="h2a"><b class="calibre4">Preoperative evaluation</b> <span class="s">(<i class="calibre3">NEJM</i> 2015;373:2258)</span></p>
<p class="capf"><b class="calibre4">Figure 1-7</b> Approach to preop CV eval for non-CV surgery (modified from <i class="calibre3">Circ</i> 2014;130:e278)</p>
<p class="image"><img src="../images/00034.jpeg" alt="" class="calibre2"/></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre43"/>
<col class="calibre29"/>
<col class="calibre33"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">Noninvasive Testing Result</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">High Risk</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Intermediate Risk</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Low Risk</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4"><i class="calibre3">Ischemia at</i></b> &lt;<b class="calibre4"><i class="calibre3">4 METs</i></b> <i class="calibre3">manifested</i> by ≥1 <i class="calibre3">of:</i></p>
<p class="bull-t"><span class="sbull-t">•</span> Horiz/down ST ↓ ≥1 mm or STE</p> 
<p class="bull-t"><span class="sbull-t">•</span> ≥5 abnl leads or ischemic ECG ∆s lasting &gt;3 min after exertion</p> 
<p class="bull-t"><span class="sbull-t">•</span> SBP ↓ 10 mmHg or typical angina</p></td>
<td class="bg0-r"><p class="tab"><b class="calibre4"><i class="calibre3">Ischemia at</i> 4–6 <i class="calibre3">METs</i></b></p>
<p class="tab"><i class="calibre3">manifested by</i> ≥1 <i class="calibre3">of:</i></p>
<p class="bull-t"><span class="sbull-t">•</span> Horiz/down ST ↓ ≥1 mm</p> 
<p class="bull-t"><span class="sbull-t">•</span> 3–4 abnl leads</p> 
<p class="bull-t"><span class="sbull-t">•</span> 1–3 min after exertion</p></td>
<td class="bg"><p class="tab"><b class="calibre4"><i class="calibre3">No ischemia or</i></b></p>
<p class="tab"><b class="calibre4"><i class="calibre3">at</i></b> &gt;<b class="calibre4">7 METs w/</b></p>
<p class="bull-t"><span class="sbull-t">•</span> ST ↓ ≥1 mm or</p> 
<p class="bull-t"><span class="sbull-t">•</span> 1–2 abnl leads</p></td>
</tr>
</table>
<p class="h2a"><b class="calibre4">Additional preoperative testing</b> <span class="s">(<i class="calibre3">Circ</i> 2014;130:e278)</span></p>
<p class="bl"><span class="sbl">•</span> ECG if known cardiac disease and possibly reasonable in all, except if low-risk surgery</p>
<p class="bl"><span class="sbl">•</span> TTE if any of following &amp; prior TTE &gt;12 mo ago or prior to ∆ in sx: dyspnea of unknown origin; hx of HF w/ ↑ dyspnea; suspect (eg, murmur) or known ≥ moderate valvular dis.</p>
<p class="h2a"><b class="calibre4">Coronary artery disease</b></p>
<p class="bl"><span class="sbl">•</span> If possible, wait ~60 d after MI in the absence of revascularization before elective surgery</p>
<p class="bl"><span class="sbl">•</span> Coronary revasc guided by standard indications. Has not been shown to ∆ risk of death or postop MI when done prior to elective vasc. surgery <span class="s1r">(<i class="calibre3">NEJM</i> 2004;351:2795)</span>.</p>
<p class="h2a"><b class="calibre4">Heart failure</b> <span class="s">(<i class="calibre3">JACC</i> 2014;64:e77)</span></p>
<p class="bl"><span class="sbl">•</span> Decompensated HF should be optimally Rx’d prior to elective surgery</p>
<p class="bl"><span class="sbl">•</span> 30-d CV event rate: symptomatic HF &gt; asx HFrEF &gt; asx HFpEF &gt; no HF</p>
<p class="h2a"><b class="calibre4">Valvular heart disease</b></p>
<p class="bl"><span class="sbl">•</span> If meet criteria for valve intervention, do so before elective surgery (postpone if necessary)</p>
<p class="bl"><span class="sbl">•</span> If severe valve disease and surgery urgent, intra- &amp; postoperative hemodynamic monitoring reasonable (espec for AS, because at ↑ risk even if sx not severe; be careful to maintain preload, avoid hypotension, and watch for atrial fibrillation)</p>
<p class="h2a"><a id="page_1-41" class="calibre1"></a><b class="calibre4">Cardiac implantable electronic devices</b></p>
<p class="bl"><span class="sbl">•</span> Discuss w/ surgical team need for device (eg, complete heart block) &amp; consequences if interference w/ fxn, and likelihood of electromagnetic interference</p>
<p class="bl"><span class="sbl">•</span> Consider reprogramming, magnet use, etc. as needed</p>
<p class="h2a"><b class="calibre4">Pre- &amp; perioperative pharmacologic management</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">ASA:</b> continue in Pts w/ existing indication. Initiation prior to surgery does not ↓ 30-d ischemic events and ↑ bleeding <span class="s1r">(<i class="calibre3">NEJM</i> 2014;370:1494)</span>, but Pts w/ recent stents excluded.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Dual antiplatelet therapy:</b> delay elective surg 14 d after balloon angioplasty, 30 d after BMS and ideally 6 mo (min 3 mo) after DES <span class="s1r">(<i class="calibre3">JACC</i> 2016; 68:1082)</span> unless risk of bleeding &gt; risk of stent thrombosis or ACS. If must discontinue P2Y<sub class="calibre8">12</sub> inh, continue ASA and restart P2Y<sub class="calibre8">12</sub> inh ASAP; can consider IV cangrelor if high-risk <span class="s1r">(<i class="calibre3">JAMA</i> 2012;307:265)</span>.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">β-blockers</b> <span class="s1r">(<i class="calibre3">JAMA</i> 2015;313:2486)</span></p>
<p class="bl1">Continue βB in Pts on them chronically. Do not stop βB abruptly postop (may cause reflex sympathetic activation). Use IV if Pt unable to take PO.</p>
<p class="bl1">Reasonable to initiate if intermed- or high-risk ⊕ stress test, or RCRI ≥3, espec if vasc surgery. Initiate ≥1 wk prior to surgery (<i class="calibre3">not day of</i>), use low-dose, short-acting βB, and titrate to achieve HR and BP goal (? HR ~55–65). Avoid bradycardia and HoTN.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Statins:</b> ↓ ischemia &amp; CV events in Pts undergoing vascular surg <span class="s1r">(<i class="calibre3">NEJM</i> 2009;361:980)</span>. Consider if risk factors &amp; non–low-risk surgery and in all Pts undergoing vascular surgery.</p>
<p class="bl"><span class="sbl">•</span> ACEI/ARB: holding 24 h preop to ↓ intraop HoTN <span class="s1r">(<i class="calibre3">Anes</i> 2017;126:16)</span>. Restart ASAP.</p>
<p class="bl"><span class="sbl">•</span> Amiodarone: ↓ incidence of postop AF if started prior to surgery <span class="s1r">(<i class="calibre3">NEJM</i> 1997;337:1785)</span></p>
<p class="h2a"><b class="calibre4">Postoperative monitoring</b></p>
<p class="bl"><span class="sbl">•</span> ECG if known CAD or high-risk surgery. Consider if &gt;1 risk factor for CAD.</p>
<p class="bl"><span class="sbl">•</span> Routine troponin prognostic <span class="s1r">(<i class="calibre3">JAMA</i> 2017;317:1642)</span> but ✔ only if sx/ECG ∆s suggestive of ACS</p>
<h2 class="ct"><a id="h19" class="calibre7"></a><a href="part0002.html#rh23" class="calibre7">PERIPHERAL ARTERY DISEASE (PAD)</a></h2>
<p class="h2a"><b class="calibre4">Clinical features</b> <span class="s">(<i class="calibre3">NEJM</i> 2016;374:861)</span></p>
<p class="bl"><span class="sbl">•</span> Prev. ↑ w/ age: &lt;1% if &lt;40 y, ~15% if ≥70 y; risk factors incl. <b class="calibre4">smoking</b>, <b class="calibre4">DM</b>, HTN, chol</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Claudication</b> (ache/cramp, often in calves) precip by walking and relieved by stopping (vs. spinal stenosis, qv); Leriche synd = claudic., ↓ or ∅ fem pulses, &amp; erectile dysfxn</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Critical limb ischemia (CLI): rest pain</b> (↑ w/ elevation b/c ↓ perfusion), <b class="calibre4">ulcer</b> (typically at pressure foci, often dry; in contrast, venous ulcers are more often at medial malleolus, wet, and with hemosiderin deposition) or <b class="calibre4">gangrene</b>, due to PAD, and &gt;2-wk duration (implies chronicity vs. acute limb ischemia; see below)</p>
<p class="h2a"><b class="calibre4">Diagnosis</b> <span class="s">(<i class="calibre3">Circ</i> 2016;135:e686)</span></p>
<p class="bl"><span class="sbl">•</span> ↓ peripheral pulses, bruits; signs of chronic PAD: hair loss, skin atrophy, nail hypertrophy</p>
<p class="bl"><span class="sbl">•</span> Ankle:brachial index (ABI): nl 1–1.4; borderline 0.91–0.99; abnl ≤0.90; if &gt;1.4, non-dx possibly due to calcified noncompressible vessel → ✔ PVR, TBI (toe-brachial index). If ABI abnl → segmental ABI w/ PVR to localize disease. If ⊕ sx but nl ABI, ✔ for ↓ lower extrem BP after exercise (≥20% ↓ in ABI w/ exercise or ≥30 mmHg ↓ in ankle pressure).</p>
<p class="bl"><span class="sbl">•</span> Duplex arterial U/S; CTA w/ distal run-off; MRA or angio if dx in ? or possible intervention</p>
<p class="h2a"><b class="calibre4">Treatment</b> <span class="s">(<i class="calibre3">JACC</i> 2013;61:1555; <i class="calibre3">JAMA</i> 2013;309:453 &amp; 2015;314:1936)</span></p>
<p class="bl"><span class="sbl">•</span> Risk factor modif. Screen for CAD/AAA. Structured exercise program <span class="s1r">(<i class="calibre3">JAMA</i> 2013;310:57)</span>.</p>
<p class="bl"><span class="sbl">•</span> If sx or if asx with ABI ≤0.90, ASA, clopi, or ticag to ↓ D/MI/stroke <span class="s1r">(<i class="calibre3">NEJM</i> 2017; 376:32)</span> More intensive antiplt Rx ↓ both MACE &amp; limb ischemic events <span class="s1r">(<i class="calibre3">JACC</i> 2016;67:2719)</span> Adding riva 2.5 mg bid to ASA ↓ MACE &amp; death but ↑ bleeding <span class="s1r">(<i class="calibre3">NEJM</i> 2017;377:1319)</span></p>
<p class="bl"><span class="sbl">•</span> Statins &amp; PCSK9i ↓ MACE &amp; limb ischemic events <span class="s1r">(<i class="calibre3">Circ</i> 2018;137:338)</span>. Cilostazol (if no HF).</p>
<p class="bl"><span class="sbl">•</span> Endovascular (angioplasty vs. stent) or surgical revasc if limiting/refractory sx or CLI</p>
<p class="h2a"><b class="calibre4">Acute limb ischemia (ALI)</b> <span class="s">(<i class="calibre3">Circ</i> 2016;135:e686)</span></p>
<p class="bl"><span class="sbl">•</span> Sudden decrement in limb perfusion (ie, acutely cold &amp; painful) that threatens viability</p>
<p class="bl"><span class="sbl">•</span> Etiologies: embolism &gt; acute thrombosis (eg, athero, APS, HITT), trauma to artery</p>
<p class="bl"><span class="sbl">•</span> Clinical manifestations (<b class="calibre4">6 Ps</b>): pain (distal to proximal, ↑ in severity), poikilothermia, pallor, pulselessness, paresthesias, paralysis</p>
<p class="bl"><span class="sbl">•</span> Testing: pulse &amp; neuro exam; arterial &amp; venous Doppler; angiography, CTA or MRA</p>
<p class="bl"><span class="sbl">•</span> Urgent consultation w/ vascular medicine and/or vascular surgery</p>
<p class="image1"><img src="../images/00035.jpeg" alt="" class="calibre2"/></p>
<h2 class="ct"><a id="page_1-42" class="calibre7"></a>NOTES<a id="page_1-43" class="calibre7"></a></h2>


  </div>

  
  <div class="calibreToc">
    <h2><a href="../../k34gmbu8.html">Table of contents
</a></h2>
    <div>
  <ul>
    <li>
      <a href="part0000.html#0-74951b69f9a94472af57c47504abb1f1">Title Page</a>
    </li>
    <li>
      <a href="part0001.html#UGI0-74951b69f9a94472af57c47504abb1f1">Copyright Page</a>
    </li>
    <li>
      <a href="part0002.html#1T140-74951b69f9a94472af57c47504abb1f1">Contents</a>
    </li>
    <li>
      <a href="part0003.html#2RHM0-74951b69f9a94472af57c47504abb1f1">Contributing Authors</a>
    </li>
    <li>
      <a href="part0004.html#3Q280-74951b69f9a94472af57c47504abb1f1">Foreword</a>
    </li>
    <li>
      <a href="part0005.html#4OIQ0-74951b69f9a94472af57c47504abb1f1">Preface</a>
    </li>
    <li>
      <a href="part0006.html#5N3C0-74951b69f9a94472af57c47504abb1f1">Cardiology</a>
      <ul>
        <li>
          <a href="part0006.html#h1">Electrocardiography</a>
        </li>
        <li>
          <a href="part0006.html#h2">Chest Pain</a>
        </li>
        <li>
          <a href="part0006.html#h3">Noninvasive Evaluation of CAD</a>
        </li>
        <li>
          <a href="part0006.html#h4">Coronary Angiography and Revascularization</a>
        </li>
        <li>
          <a href="part0006.html#h5">Acute Coronary Syndromes</a>
        </li>
        <li>
          <a href="part0006.html#h6">PA Catheter and Tailored Therapy</a>
        </li>
        <li>
          <a href="part0006.html#h7">Heart Failure</a>
        </li>
        <li>
          <a href="part0006.html#h8">Cardiomyopathies</a>
        </li>
        <li>
          <a href="part0006.html#h9">Valvular Heart Disease</a>
        </li>
        <li>
          <a href="part0006.html#h10">Pericardial Disease</a>
        </li>
        <li>
          <a href="part0006.html#h11">Hypertension</a>
        </li>
        <li>
          <a href="part0006.html#h12">Aortic Aneurysms</a>
        </li>
        <li>
          <a href="part0006.html#h13">Acute Aortic Syndromes</a>
        </li>
        <li>
          <a href="part0006.html#h14">Arrhythmias</a>
        </li>
        <li>
          <a href="part0006.html#h15">Atrial Fibrillation</a>
        </li>
        <li>
          <a href="part0006.html#h16">Syncope</a>
        </li>
        <li>
          <a href="part0006.html#h17">Cardiac Rhythm Management Devices</a>
        </li>
        <li>
          <a href="part0006.html#h18">Cardiac Risk Assessment for Noncardiac Surgery</a>
        </li>
        <li>
          <a href="part0006.html#h19">Peripheral Artery Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0007.html#6LJU0-74951b69f9a94472af57c47504abb1f1">Pulmonary</a>
      <ul>
        <li>
          <a href="part0007.html#h20">Dyspnea</a>
        </li>
        <li>
          <a href="part0007.html#h21">Pulmonary Function Tests</a>
        </li>
        <li>
          <a href="part0007.html#h22">Asthma</a>
        </li>
        <li>
          <a href="part0007.html#h23">Anaphylaxis</a>
        </li>
        <li>
          <a href="part0007.html#h24">Chronic Obstructive Pulmonary Disease</a>
        </li>
        <li>
          <a href="part0007.html#h25">Solitary Pulmonary Nodule</a>
        </li>
        <li>
          <a href="part0007.html#h26">Hemoptysis</a>
        </li>
        <li>
          <a href="part0007.html#h27">Bronchiectasis</a>
        </li>
        <li>
          <a href="part0007.html#h28">Cystic Fibrosis</a>
        </li>
        <li>
          <a href="part0007.html#h29">Interstitial Lung Disease</a>
        </li>
        <li>
          <a href="part0007.html#h30">Pleural Effusion</a>
        </li>
        <li>
          <a href="part0007.html#h31">Venous Thromboembolism</a>
        </li>
        <li>
          <a href="part0007.html#h32">Pulmonary Hypertension</a>
        </li>
        <li>
          <a href="part0007.html#h33">Respiratory Failure</a>
        </li>
        <li>
          <a href="part0007.html#h34">Mechanical Ventilation</a>
        </li>
        <li>
          <a href="part0007.html#h35">Acute Respiratory Distress Syndrome</a>
        </li>
        <li>
          <a href="part0007.html#h36">Sepsis and Shock</a>
        </li>
        <li>
          <a href="part0007.html#h37">Toxicology</a>
        </li>
        <li>
          <a href="part0007.html#h38">Lung Transplant</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0008.html#7K4G0-74951b69f9a94472af57c47504abb1f1">Gastroenterology</a>
      <ul>
        <li>
          <a href="part0008.html#h39">Esophageal and Gastric Disorders</a>
        </li>
        <li>
          <a href="part0008.html#h40">Gastrointestinal Bleeding</a>
        </li>
        <li>
          <a href="part0008.html#h41">Diarrhea</a>
        </li>
        <li>
          <a href="part0008.html#h42">Dysmotility &amp; Nutrition</a>
        </li>
        <li>
          <a href="part0008.html#h43">Disorders of the Colon</a>
        </li>
        <li>
          <a href="part0008.html#h44">Inflammatory Bowel Disease</a>
        </li>
        <li>
          <a href="part0008.html#h45">Intestinal Ischemia</a>
        </li>
        <li>
          <a href="part0008.html#h46">Pancreatitis</a>
        </li>
        <li>
          <a href="part0008.html#h47">Abnormal Liver Tests</a>
        </li>
        <li>
          <a href="part0008.html#h48">Hepatitis</a>
        </li>
        <li>
          <a href="part0008.html#h49">Acute Liver Failure</a>
        </li>
        <li>
          <a href="part0008.html#h50">Cirrhosis</a>
        </li>
        <li>
          <a href="part0008.html#h51">Hepatic Vascular Disease</a>
        </li>
        <li>
          <a href="part0008.html#h52">Ascites</a>
        </li>
        <li>
          <a href="part0008.html#h53">Biliary Tract Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0009.html#8IL20-74951b69f9a94472af57c47504abb1f1">Nephrology</a>
      <ul>
        <li>
          <a href="part0009.html#h54">Acid-Base Disturbances</a>
        </li>
        <li>
          <a href="part0009.html#h55">Sodium and Water Homeostasis</a>
        </li>
        <li>
          <a href="part0009.html#h56">Potassium Homeostasis</a>
        </li>
        <li>
          <a href="part0009.html#h57">Renal Failure</a>
        </li>
        <li>
          <a href="part0009.html#h58">Glomerular Disease</a>
        </li>
        <li>
          <a href="part0009.html#h59">Urinalysis</a>
        </li>
        <li>
          <a href="part0009.html#h60">Nephrolithiasis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0010.html#9H5K0-74951b69f9a94472af57c47504abb1f1">Hematology-Oncology</a>
      <ul>
        <li>
          <a href="part0010.html#h61">Anemia</a>
        </li>
        <li>
          <a href="part0010.html#h62">Disorders of Hemostasis</a>
        </li>
        <li>
          <a href="part0010.html#h63">Platelet Disorders</a>
        </li>
        <li>
          <a href="part0010.html#h64">Coagulopathies</a>
        </li>
        <li>
          <a href="part0010.html#h65">Hypercoagulable States</a>
        </li>
        <li>
          <a href="part0010.html#h66">Disorders of Leukocytes</a>
        </li>
        <li>
          <a href="part0010.html#h67">Transfusion Therapy</a>
        </li>
        <li>
          <a href="part0010.html#h68">Myelodysplastic Syndromes</a>
        </li>
        <li>
          <a href="part0010.html#h69">Myeloproliferative Neoplasms</a>
        </li>
        <li>
          <a href="part0010.html#h70">Leukemia</a>
        </li>
        <li>
          <a href="part0010.html#h71">Lymphoma</a>
        </li>
        <li>
          <a href="part0010.html#h72">Plasma Cell Dyscrasias</a>
        </li>
        <li>
          <a href="part0010.html#h73">Hematopoietic Stem Cell Transplantation</a>
        </li>
        <li>
          <a href="part0010.html#h74">Lung Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h75">Breast Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h76">Prostate Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h77">Colorectal Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h78">Pancreatic Tumors</a>
        </li>
        <li>
          <a href="part0010.html#h79">Hepatocellular Carcinoma (HCC)</a>
        </li>
        <li>
          <a href="part0010.html#h80">Oncologic Emergencies</a>
        </li>
        <li>
          <a href="part0010.html#h81">Chemotherapy &amp; Immunotherapy Side Effects</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0011.html#AFM60-74951b69f9a94472af57c47504abb1f1">Infectious Diseases</a>
      <ul>
        <li>
          <a href="part0011.html#h82">Pneumonia</a>
        </li>
        <li>
          <a href="part0011.html#h83">Fungal Infections</a>
        </li>
        <li>
          <a href="part0011.html#h84">Infections in Immunosuppressed Hosts</a>
        </li>
        <li>
          <a href="part0011.html#h85">Urinary Tract Infections</a>
        </li>
        <li>
          <a href="part0011.html#h86">Soft Tissue and Bone Infections</a>
        </li>
        <li>
          <a href="part0011.html#h87">Infections of the Nervous System</a>
        </li>
        <li>
          <a href="part0011.html#h88">Bacteremia &amp; Endocarditis</a>
        </li>
        <li>
          <a href="part0011.html#h89">Tuberculosis</a>
        </li>
        <li>
          <a href="part0011.html#h90">HIV/AIDS</a>
        </li>
        <li>
          <a href="part0011.html#h91">Tick-Borne Diseases</a>
        </li>
        <li>
          <a href="part0011.html#h92">Fever Syndromes</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0012.html#BE6O0-74951b69f9a94472af57c47504abb1f1">Endocrinology</a>
      <ul>
        <li>
          <a href="part0012.html#h93">Pituitary Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h94">Thyroid Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h95">Adrenal Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h96">Calcium Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h97">Diabetes Mellitus</a>
        </li>
        <li>
          <a href="part0012.html#h98">Lipid Disorders</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0013.html#CCNA0-74951b69f9a94472af57c47504abb1f1">Rheumatology</a>
      <ul>
        <li>
          <a href="part0013.html#h99">Approach to Rheumatic Disease</a>
        </li>
        <li>
          <a href="part0013.html#h100">Rheumatoid Arthritis</a>
        </li>
        <li>
          <a href="part0013.html#h101">Adult-Onset Still’s Disease &amp; Relapsing Polychondritis</a>
        </li>
        <li>
          <a href="part0013.html#h102">Crystal Deposition Arthritides</a>
        </li>
        <li>
          <a href="part0013.html#h103">Seronegative Spondyloarthritis</a>
        </li>
        <li>
          <a href="part0013.html#h104">Infectious Arthritis &amp; Bursitis</a>
        </li>
        <li>
          <a href="part0013.html#h105">Connective Tissue Diseases</a>
        </li>
        <li>
          <a href="part0013.html#h106">Systemic Lupus Erythematosus</a>
        </li>
        <li>
          <a href="part0013.html#h107">Vasculitis</a>
        </li>
        <li>
          <a href="part0013.html#h108">IgG4-Related Disease</a>
        </li>
        <li>
          <a href="part0013.html#h109">Cryoglobulinemia</a>
        </li>
        <li>
          <a href="part0013.html#h110">Amyloidosis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0014.html#DB7S0-74951b69f9a94472af57c47504abb1f1">Neurology</a>
      <ul>
        <li>
          <a href="part0014.html#h111">Change in Mental Status</a>
        </li>
        <li>
          <a href="part0014.html#h112">Seizures</a>
        </li>
        <li>
          <a href="part0014.html#h113">Alcohol Withdrawal</a>
        </li>
        <li>
          <a href="part0014.html#h114">Dizziness</a>
        </li>
        <li>
          <a href="part0014.html#h115">Stroke</a>
        </li>
        <li>
          <a href="part0014.html#h116">Weakness &amp; Neuromuscular Dysfunction</a>
        </li>
        <li>
          <a href="part0014.html#h117">Headache</a>
        </li>
        <li>
          <a href="part0014.html#h118">Back and Spinal Cord Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0015.html#E9OE0-74951b69f9a94472af57c47504abb1f1">Consults</a>
      <ul>
        <li>
          <a href="part0015.html#h119">Surgical Issues</a>
        </li>
        <li>
          <a href="part0015.html#h120">Ob/Gyn Issues</a>
        </li>
        <li>
          <a href="part0015.html#h121">Ophthalmic Issues</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0016.html#F8900-74951b69f9a94472af57c47504abb1f1">Appendix</a>
      <ul>
        <li>
          <a href="part0016.html#h122">ICU Medications &amp; Treatment of Hypotension/Shock</a>
        </li>
        <li>
          <a href="part0016.html#h123">Antibiotics</a>
        </li>
        <li>
          <a href="part0016.html#h124">Formulae and Quick Reference</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0017.html#G6PI0-74951b69f9a94472af57c47504abb1f1">Abbreviations</a>
    </li>
    <li>
      <a href="part0018.html#H5A40-74951b69f9a94472af57c47504abb1f1">Index</a>
    </li>
    <li>
      <a href="part0019.html#I3QM0-74951b69f9a94472af57c47504abb1f1">Photo Inserts</a>
      <ul>
        <li>
          <a href="part0019.html#h125">Radiology</a>
        </li>
        <li>
          <a href="part0019.html#h126">Echocardiography &amp; Coronary Angiography</a>
        </li>
        <li>
          <a href="part0019.html#h127">Peripheral Blood Smears &amp; Leukemias</a>
        </li>
        <li>
          <a href="part0019.html#h128">Urinalysis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0022.html#KVCC0-74951b69f9a94472af57c47504abb1f1">ACLS</a>
    </li>
  </ul>
</div>


  </div>
  

  <div class="calibreEbNav">
    
      <a href="part0005.html" class="calibreAPrev">previous page
</a>
    

    <a href="../../k34gmbu8.html" class="calibreAHome">start
</a>

    
      <a href="part0007.html" class="calibreANext">next page
</a>
    
  </div>

</div>

</body>
</html>
